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Abstract

Antidepressant drugs (ADDs) are one of the most widely prescribed drug classes in the world,
administered to over 10% of the population for the treatment of major depressive and
anxiety-related disorders. Similarly, approximately 10% of pregnant women are prescribed
ADDs for the treatment of depression. Whilst various classes of ADDs exist, selective
serotonin reuptake inhibitors (SSRIs) are the most widely prescribed to pregnant women (in
80% of cases). SSRIs such as Fluoxetine bind to the serotonin transporter (SERT) blocking the
reabsorption of serotonin by the presynaptic neuron resulting in increased serotonin levels at
the synapse. The antidepressant properties of SSRIs are thought to be mediated largely
through downstream mechanisms such as increases in brain derived neurotrophic factor
(BDNF) and subsequent increases in neuroplasticity and neurogenesis related processes in
the prefrontal cortex (PFC) and hippocampus (HPC). The serotonergic system and
downstream signaling pathways such as that associated with brain derived neurotrophic
(BDNF), are also critical for normal neurodevelopment where they play a key role in
neurodevelopmental processes. Furthermore, the serotonergic system regulates the
development and maturation of the brain’s primary excitatory neurotransmitter system, the
glutamatergic system. This raises concerns about exposure of the developing foetus and
newborns to SSRIs as it has been shown that SSRIs administered during pregnancy cross the
placenta and are also excreted in breast milk. This concern is accentuated by studies
demonstrating associations between abnormal development of the serotonergic, BDNF and
glutamatergic systems and several psychiatric and behavioural disorders. Recent clinical
studies have suggested that maternal SSRI use is associated with increased risk for
neurodevelopmental and mood disorders such as Autism Spectrum Disorder (ASD), Attention
Deficit Hyperactivity Disorder (ADHD) and depression in exposed offspring. Conversely,
several studies have reported no significant association between maternal SSRI use and
offspring risk for any neurodevelopmental or psychiatric abnormalities or disorders.
Furthermore, there is an inherent difficulty in discerning the effects of maternal SSRI use on
offspring from that of the innate maternal depression or mood disorder, given that they
generally occur together in the clinic. In addition, untreated maternal mood disorders such as
depression have themselves been associated with increased risk for neurodevelopmental and
15

psychiatric disorders in offspring. Determining the effects of maternal SSRI treatment on
offspring behavior in rodent models of innate depression and understanding the
neurobiological changes is important to determine the clinical risk associated with maternal
SSRI use in the context of the underlying maternal psychopathology. Thus, the aim of this
thesis was to investigate the effects of maternal SSRI (Fluoxetine) treatment on offspring
behavior and neurobiology relevant to neurodevelopmental and psychiatric disorders.
Specifically, by comparing the effects of maternal SSRI treatment in a rodent model of innate
depression (Wistar-Kyoto (WKY)) to that of a standard laboratory rat strain (Sprague-Dawley
(SD)), we aimed to test the hypotheses that maternal depressive phenotypes (which model
depressive disorders) could influence the effects of SSRI exposure on offspring neurobiology,
related behavior, and ultimately risk for neurodevelopmental disorders in the clinic. As a
secondary aim, we sought to determine the neurobiological profile of the WKY rat compared
to a control strain, to test the hypothesis that alterations in underlying neurobiology
contribute to the strain’s depressive-like phenotype, as it does in the clinic.

To investigate the effects of perinatal fluoxetine exposure on offspring in a clinically relevant
model of depression, we treated pregnant SD and WKY dams with fluoxetine hydrochloride
(10mg/kg/day) or vehicle (tap water), throughout the gestational period and a further two
weeks of the lactation period (5 weeks in total). The last day of treatment corresponded to
postnatal day 14 in offspring. At postnatal day 35 (adolescence) male and female offspring
underwent a series of behavioural tests to measure primarily emotionality-related
behaviours, using the open field test (OFT), elevated plus maze (EPM) and forced swim test
(FST). Rats were euthanized 48 hours following the last behavioural test, the prefrontal cortex
and hippocampus were dissected for immunoblot analysis of glutamatergic and neurotrophic
markers, and/or prepared for immunohistochemistry analysis of neuron specific nuclear
protein (NeuN), a marker of neuronal maturation. An additional cohort of male offspring were
euthanized at postnatal day 14 (corresponding to birth in humans), and the prefrontal cortex
and hippocampus also collected for immunoblot analysis of glutamatergic markers.

In chapters 2 and 3 we aimed to investigate the effects of perinatal fluoxetine exposure on
adolescent male (chapter 2) and female (chapter 3) behaviour, as well as glutamatergic
signaling relevant to neurodevelopmental and psychiatric disorders. We found that perinatal
16

fluoxetine exposure increased anxiety-like behaviours and forced swim immobility in males
of both strains. In females however, fluoxetine exposure increased anxiety-like parameters
only, and only in SD offspring. Furthermore, perinatal fluoxetine exposure produced a similar
sex-specific effect on glutamatergic markers with males showing deficits in cortical NMDA
receptor subunits NR1 and NR2A, as well as the key scaffolding protein PSD-95, in both the
prefrontal cortex and ventral hippocampus, in both strains. In females, perinatal fluoxetine
exposure had much more restricted effects, reducing hippocampal PSD-95 only. These
chapters additionally characterized the glutamatergic pathology in the WKY rat model of
depression; adolescent WKY rats at baseline displayed deficits in cortical NMDA receptor
subunits NR1, NR2A and NR2B, and PSD-95 in both male and female rats. However, in WKY
females, further deficits in NR2A, NR2B and PSD-95 were observed in the ventral
hippocampus. Collectively, findings from chapter 2 and 3 suggest that perinatal fluoxetine
exposure influences offspring behaviour and relevant glutamatergic markers in a sex- and
strain-specific manner. Furthermore, in a rodent model of depression, deficits in NMDA
receptor signaling exist, particularly in females, and could contribute to the strain’s
depressive-like phenotype.

Building on previous findings from chapter 3, in chapter 4 we investigated the effects of
perinatal fluoxetine exposure on BDNF-TrkB neurotrophic signaling and NeuN+, a marker of
neuronal maturation, in female adolescent offspring. Specifically, in chapter 3 we found that
perinatal fluoxetine exposure reduced PSD-95 in both strains. Previous works have
demonstrated that PSD-95, which is often used as an indicator of the overall glutamatergic
synapses, is linked to the activity of BDNF-TrkB signaling. Furthermore, BDNF can directly
influence the survivability of neurons through neuroprotective processes. Therefore, we
hypothesized that reductions in PSD-95 caused by perinatal fluoxetine exposure could be
indicative of reductions in mature neurons. As a secondary aim, we sought to investigate the
neurotrophic profile and neuronal cell counts in female adolescent WKY rats at baseline to
determine whether changes in these parameters contribute to the strain’s depressivephenotype. Accordingly, we found that WKY offspring exhibited cortical and hippocampal
deficits in NeuN+ cells; perinatal fluoxetine exposure ameliorated cortical, but not
hippocampal, deficits. In SD offspring, fluoxetine exposure induced deficits in NeuN+ cells in
both brain regions, similar to levels observed in WKY at baseline. Perinatal fluoxetine
17

exposure had strain independent effects on BDNF-TrkB signaling, by increasing BDNF, and
reducing proBDNF, in the hippocampus. Findings from chapter 4 suggest that perinatal
fluoxetine exposure could ameliorate deficits in neuronal number present in a rodent model
of depression, but cause alterations in BDNF-TrkB signaling in exposed offspring
independently.

In chapter 5 we investigated the effects of perinatal fluoxetine exposure on male offspring at
postnatal day 14 to determine whether the glutamatergic changes observed at adolescence
(chapter 2) were present early in development. This thesis has shown that perinatal fluoxetine
exposure produces alterations in NMDA receptor signaling in SD, but not WKY, male offspring
at this early developmental time period. Specifically, fluoxetine exposure increased NMDA
receptor subunits NR2A and NR2B in SD but had negligible effects on WKY rats. These findings
suggest that in a rodent model of depression the effects of perinatal fluoxetine exposure on
the glutamatergic system are attenuated or at least delayed. Findings from chapter 5 provide
novel insight into the effects of perinatal fluoxetine exposure on the developmental trajectory
of glutamatergic receptors in the context of the underlying maternal psychopathology.

Collectively this thesis has provided novel insights into the effects of perinatal fluoxetine
exposure in the context of the underlying maternal psychopathology. Specifically, this thesis
provides evidence that fluoxetine exposure can alter emotionality-related behaviours in
adolescent offspring, as well as glutamatergic, neurotrophic and neuronal markers, in a strain
and/or sex-specific manner. We have shown that while perinatal fluoxetine exposure can
have negative outcomes on some of many of these parameters, in female offspring, perinatal
fluoxetine exposure could have beneficial effects in a rodent model of depression, by
ameliorating deficits in neuronal numbers. Finally, this thesis provides evidence of robust
glutamatergic dysfunction and reductions in cortical and hippocampal neuronal numbers in
the WKY strain, providing further evidence to support its use as a rodent model of
endogenous depression. This thesis highlights the fact that maternal depressive phenotypes,
such as that modelled with the WKY strain, and offspring age and sex, can significantly
influence the effects of perinatal SSRI exposure. Accordingly, these factors should be
considered in the design of future studies. Ultimately, ADDs play a critical role in in minimizing
risk associated with untreated maternal MDD. Future studies investigating ways to minimize
18

the effects of SSRI exposure on offspring, will be critical to ensuring healthy pregnancies and
offspring development.
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Chapter 1

1.1 Introduction
Antidepressant drugs (ADDs) are currently one of the most widely prescribed drug classes
worldwide, administered to over 10% of the population for the treatment of clinical
depression and anxiety-related disorders (Moore et al., 2009; Olfson and Marcus, 2009).
Similarly, 8-10% of pregnant women are prescribed ADDs for the treatment of depression
(Cooper et al., 2007; Huybrechts et al., 2013a). With the overall incidence of depression
significantly rising over the last several decades, this value may continue to increase
(Huybrechts et al., 2013a; Kessler, 2003). While various classes of ADDs exist, selective
serotonin reuptake inhibitors (SSRIs) are the most widely prescribed to pregnant women (in
~80% of cases) (Huybrechts et al., 2013a; Mitchell et al., 2011a) and have been considered
moderately safe for antenatal use (Oberlander et al., 2009a). However, recent analyses
indicate that maternal use of SSRIs, particularly paroxetine, is associated with greater risk of
structural neuroteratogenic effects (Reefhuis et al., 2015).

SSRIs, such as fluoxetine,

sertraline, and citalopram (the most commonly prescribed SSRIs during pregnancy; Patil et
al., 2011) bind to the serotonin transporter (SERT), blocking the reabsorption of serotonin by
the presynaptic neuron and increasing serotonin levels in the synaptic cleft (Hiemke and
Härtter, 2000a) (Figure 1.1). While SSRIs cause acute elevations in serotonin concentrations,
the antidepressant properties of SSRIs are largely thought to be elicited by downstream
mechanisms, such as increases in brain derived neurotrophic factor (BDNF) and subsequent
neurogenesis, particularly in the prefrontal cortex (PFC) and hippocampus (Martinowich and
Lu, 2007). The serotonergic system and other downstream effectors, such as BDNF, are also
critical for normal neurodevelopment. This raises concerns about exposure of the developing
foetus and newborns to SSRIs as it has been shown that SSRIs administered during pregnancy
cross the placenta (up to ~70% of maternal levels) (Heikkinen et al., 2002a) and are excreted
in breast milk (Hendrick et al., 2001a; Kim et al., 2006). This concern is accentuated by studies
demonstrating associations between abnormal neurodevelopment of the serotonergic

21

system and several psychiatric and behavioural disorders, such as Autism Spectrum Disorder
(ASD) (Hranilovic et al., 2007; Mulder et al., 2004; Schain and Freedman, 1961), AttentionDeficit Hyperactivity Disorder (ADHD) (Banerjee et al., 2006; Oades et al., 2002; Retz et al.,
2008), anxiety and depression (Caspi et al., 2003; Olivier et al., 2011) and schizophrenia
(Bleich et al., 1988; Ikeda et al., 2005).

Figure 1.1 Selective serotonin reuptake inhibitors (SSRIs) block the serotonergic transporter (SERT), which
inhibits the reuptake of serotonin, raising synaptic serotonin concentrations that causes prolonged and
exaggerated serotonin receptor activation. Serotonin exerts its effects via a myriad of g-protein coupled
receptors (5HTR1-2, 4-7) and ionotropic receptor (5HTR3) subclasses. (a) Serotonin-containing vesicles fuse with
the pre-synaptic membrane; (b) spilling their contents into the synaptic cleft. (c) SERT removes serotonin from
the synaptic cleft, modulating the action of serotonin on its receptors. (d) SSRIs bind to SERT and inhibit removal
of serotonin from the cleft. (e) Activation of presynaptic and (f) (g) postsynaptic serotonin receptors exerts
varying inhibitory and excitatory effects depending on the subclass and location and regulates synaptic
transmission and associated signaling cascades.

1.1.1 Development of the Serotonergic System

The serotonergic system plays an important role in early brain development and is critical to
a range of processes, including neuronal proliferation, migration, differentiation and
synaptogenesis (Vitalis and Parnavelas, 2003; Whitaker-Azmitia, 2001). Serotonergic neurons
and receptors appear in the human brain by gestational week 5 (Figure 1.2); it is one of the
earliest monoaminergic systems generated during development (Gaspar et al., 2003a; Lambe
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et al., 2011; Sundström et al., 1993; Whitaker-Azmitia, 2001). By gestational week 15,
serotonin cell bodies are in their typical organisation in the raphe nuclei, comprised of nine
distinct cell groups spanning from the medulla oblongata through to the midbrain. The caudal
division of cell bodies (B1-B5) project serotonergic fibres to the spinal cord, whilst the rostral
division (B6-B9) provides the major ascending serotonergic fibres to areas throughout the
forebrain, including the cerebral cortex, hippocampus and basal ganglia, and account for 85%
of all serotonergic neurons (Glover and Clinton, 2016; Hornung, 2003; Törk, 1990) (Sodhi and
Sanders-Bush, 2004a). Serotonin signals through 7 receptor families, 5-HT1-7, most of which
are G-protein coupled, except the ionotropic 5HT3 receptor subtype (Figure 1). The action of
serotonin in the synaptic cleft is terminated by its reuptake by presynaptic SERT and
subsequent metabolism by monoamine oxidase A (MAO-A) to 5-hydroxyindoleacetic acid (5HIAA).

In the human brain, SERT expression begins in parallel with the emergence of serotonergic
neurons; SERT positive fibres originating from the raphe nucleus reach the telencephalon at
gestational week 8, the subplate at gestational week 10 and the cortical plate at gestational
week 13 (Verney et al., 2002). A similar neurodevelopmental pattern has been demonstrated
in rodents (Figure 1.2); SERT expression arises in the serotonergic neurons of the raphe nuclei
at mid-gestation (embryonic day 13) (Hansson et al., 1998; Rubenstein, 1998) and serotonin
fibers project into the telencephalon by embryonic day 17, passing through the septal areas
and spreading throughout the cerebral cortex (Sodhi and Sanders-Bush, 2004a).
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Figure 1.2. Schematic of SERT expression in rodents and humans from early gestation to adulthood. (a) In
rodents, SERT expression follows a similar neurodevelopmental pattern as humans, beginning in the raphe
neurons at Embryonic Day (ED) 13 then extending to non-serotonergic neurons at ED17; SERT expression on
non-serotonergic neurons ceases in the rat brain by postnatal day (PN)12. (b) In humans, SERT expression arises
in raphe neurons corresponding with the development of the serotonergic system at gestational week (GW) 5,
and remains through to adulthood. At ~GW12, SERT expression arises in non-serotonergic thalamocortical
neurons. Whether transient SERT expression occurs in other non-serotonergic neurons in humans, similar to the
rodent brain, remains to be determined. Figure adapted from Homberg et al., (2009).

While SERT is largely expressed on serotonergic neurons throughout neurodevelopment and
maturity, it is also transiently expressed on non-serotonergic neurons. In the rodent brain,
SERT expression has been shown to appear on non-serotonergic neurons, including
glutamatergic neurons of thalamocortical pathways, pyramidal neurons in the prefrontal
cortex and hippocampus (Chen et al., 2016, 2015), and also projection neurons of the
somatosensory and corticolimbic systems, from approximately embryonic day 17 (Homberg
et al., 2010; Narboux-Nême et al., 2008). Developmental SERT expression on nonserotonergic neurons in the rodent brain ceases in the first two weeks of postnatal life
(equivalent to birth in humans (Semple et al., 2013), and is localized to serotonergic neurons
in the mature brain (Narboux-Nême et al., 2008). Likewise in the human brain, an
anatomically distinct set of non-serotonergic thalamocortical axons (i.e. internal capsule and
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corona radiata) have been observed to transiently express SERT between gestational weeks
12 and 14 (Verney et al., 2002). Whether this transient expression of SERT on nonserotonergic corticolimbic and somatosensory neurons also occurs in the human brain has
not yet been determined.
The presence of SERT on non-serotonergic neurons and their ability to transiently capture
serotonin during this early time period alludes to the possible involvement of serotonin in key
neurodevelopmental processes of non-serotonergic systems. Studies have shown that
serotonin plays a key role in the development of the neocortex by modulating the migration
of cortical neurons (Riccio et al., 2011), and the formation of dendritic spines and branches,
as well as dendritic length, in the hippocampus and cerebral cortex (Sodhi and Sanders-Bush,
2004a; Vitalis and Parnavelas, 2003). During telencephalic development, monoaminergic
afferents and SERT-expressing thalamocortical axons are in close proximity along the internal
capsule. These SERT-expressing thalamocortical axons have been shown to take up serotonin,
and have been implicated in the migration and proliferation of developing glutamatergic
neurons, potentially through subsequent serotonin release (Edgar and Price, 2001; Vitalis and
Parnavelas, 2003; Whitworth et al., 2002). Aberrant glutamatergic signalling, in particular via
ionotropic

N-Methyl-D-Aspartate

(NMDA)

and

α-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid (AMPA) receptors, and group 1 metabotropic receptors (mGluRs), has
been linked to several neurodevelopmental, mood and psychiatric disorders including autism,
ADHD, schizophrenia, MDD and anxiety (Deschwanden et al., 2011; Hashimoto, 2010; Javitt,
2004; Lakhan et al., 2013; Matosin and Newell, 2013; Musazzi et al., 2012; Rojas, 2014; Yuan
et al., 2015). In addition, serotonin has been shown to modulate the response of developing
thalamocortical axons to guidance cues, such as Netrin-1, via the serotonin receptor
(5HTR1B/1D) (Bonnin et al., 2007). The serotonin 5HT1A receptor is highly expressed in the
telencephalic proliferative zone in early development, where it modulates cell division and
proliferation (Hillion et al., 1994; Lidow and Rakic, 1995; Varrault et al., 1992; Vitalis and
Parnavelas, 2003). Recently, studies have shown that serotonin influences the speed and
trajectory of migrating GABAergic cortical interneurons via activation of 5HT3A receptors
(Murthy et al., 2014), and also encourages the differentiation of early progenitor cells into
glutamatergic neurons in the developing cerebral cortex (Lavdas et al., 1997). Taken together,
these findings clearly implicate the serotonergic system as a key regulator of
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neurodevelopment.

Considering the critical role of the serotonergic system in neurodevelopment, it is feasible
that manipulation of the serotonergic system during early development has the potential to
cause broader disruptions in brain structure and circuitry and lead to associated disturbances
in behaviour. Indeed, increased levels of serotonin during early development, modelled
utilizing SERT-knockout mice, was found to cause abnormal development of thalamocortical
axons and underdevelopment of the somatosensory cortical barrels (Gaspar et al., 2003a;
Persico et al., 2001), as well as increases in anxiety- and depressive-like behaviours (Ansorge
et al., 2004). Behavioural and biological alterations in other serotonergic system knockout
models have also been reported with mutants showing increased (5HT1A receptor knockout)
and decreased (5HT2C and 5A receptor knockout) anxiety levels, reductions in GABAA receptor
binding and hippocampal neurogenesis (5HT1A receptor knockout), as well as increased
aggression in monoamine oxidase A (the enzyme responsible for 5HT degradation) knockout
mice (for review see Gaspar et al., 2003). Therefore, altering the normal function of the
serotonergic system can have broad implications on behavioural and biological phenotypes.

1.1.2 The behavioural and biological effects of maternal SSRI treatment on exposed
offspring: evidence from human studies

Considering the significant neurodevelopmental role that the serotonergic system plays and
the widespread expression of SERT during gestation, manipulation to the serotonergic system
could have major implications for human neurodevelopment and associated disorders. SSRIs
administered during pregnancy are transferred across the placenta, resulting in prenatal SSRI
exposure to the foetus; however, the extent and consequences of this exposure on the
developing brain are unclear (Hendrick et al., 2001a; Kim et al., 2006). Studies examining SSRI
concentrations in foetal cord blood from treated mothers have reported concentrations of at
least 50% compared to maternal levels (for review see Ewing et al., 2015). Additionally, two
enzymes responsible for the metabolism of SSRIs in humans, cytochrome P450 2C and 2D6
(CYP2C and CYP2D6), are low or undetectable in the foetal liver but increase progressively
during early life (Hines and McCarver, 2002; Sadler et al., 2016). Therefore, the foetus and
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neonate may be particularly sensitive to maternal SSRI exposure due to an inability to
eliminate drugs through metabolism by the liver (Hiemke and Härtter, 2000a; Kim et al.,
2006).

Several studies observing birth outcomes of infants exposed to SSRIs in-utero (as early as the
1st trimester and throughout pregnancy) have identified an increased risk for preterm delivery
(Davis et al., 2007; Huang et al., 2014; Maschi et al., 2008; Reis and Källén, 2010), low Apgar
scores (Casper et al., 2011, 2003; Jensen et al., 2013; Källén, 2004), increased risk for low birth
weight (Huang et al., 2014; Oberlander et al., 2006; Reis and Källén, 2010), frequent intensive
care unit admissions (Casper et al., 2011; Galbally et al., 2009), neonatal abstinence syndrome
(i.e. effects of withdrawal caused by the cessation of SSRI exposure) (Levinson-Castiel et al.,
2006; Nordeng et al., 2001) and risk for cardiac defects (Källén and Otterblad Olausson, 2007;
Kornum et al., 2010; Pedersen et al., 2009). Whilst other studies report no significant
association between prenatal SSRI exposure and cardiovascular anomalies (Davis et al., 2007)
and pre-term birth (Hendrick et al., 2003), a recent study by Reefhuis et al., (2015), suggested
that the potential teratogenicity of SSRIs was drug-specific. Using a Bayesian analysis
approach, combining results from independent published studies together with data from a
multicentre population-based case-control study of birth defects, the authors concluded that
only fluoxetine and paroxetine were associated with increased risk of cardiac defects, while
paroxetine alone was associated with an increased risk for anencephaly and atrial septal
defects (Reefhuis et al., 2015).

While traditional assessments of drug safety during pregnancy have focused on structural or
teratogenic defects to exposed offspring, more recent research has focused on the possible
long-term effects on brain function, behaviour and the development of neurodevelopmental
disorders. Several studies have examined the effects of maternal antidepressant drug
treatment on offspring behaviour and risk of neurodevelopmental and psychiatric disorders,
with a primary focus on ADHD and ASD (Table 1.1). These studies exhibit an apparent division
into longitudinal studies that track the development of offspring from antidepressant-treated
mothers and studies that track the familial history of offspring with ADHD and ASD. While the
results of these studies are varied, there is evidence to suggest a possible association between
maternal antidepressant drug use and ASD and/or ADHD and their associated behaviours in
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exposed offspring. Five out of nine retrospective studies reported significant increases in the
risk of ASD following prenatal exposure to antidepressant (primarily SSRI) treatment
(Boukhris et al., 2016; Croen et al., 2011; Gidaya et al., 2014; Harrington et al., 2014; King,
2017). Of these studies, three found that maternal SSRI treatment was associated with a 2fold increased risk in the development of ASD in offspring (Croen et al., 2011; Harrington et
al., 2014; King, 2017), with a three-fold increase in risk observed when exposure occurred in
the first trimester (Croen et al., 2011; Harrington et al., 2014). Moreover, Croen et al., (2011)
found no increase in the risk of ASD in offspring of mothers with a history of depression or
any other health disorder in absence of prenatal SSRI treatment, suggesting that SSRI
exposure plays an influential role (Croen et al., 2011). Conversely, another study reported
that maternal history of depression was associated with a greater risk for ASD in offspring,
with an even greater risk observed when combined with maternal SSRI treatment (Rai et al.,
2013). In addition, Viktorin et al., (2017) found that the relative risk for ASD in SSRI-exposed
offspring is negligible when adjusted for maternal history of depression or anxiety. While
these studies are somewhat conflicting, SSRI treatment could be an indicator of maternal
depressive symptom severity that could also contribute to the greater risk of ASD reported in
these studies. Interestingly, one study reported that SSRI exposure prior to, but not during
pregnancy, increased the risk for ASD in offspring (Clements et al., 2015), further suggesting
that the observed risk for ASD as the result of prenatal SSRI exposure is possibly confounded
by severity of maternal mental illness. Unfortunately, the measure in severity of maternal
mental illness in these studies was based on measures such as frequency of past hospital
admissions, which may be insufficient to truly capture symptom severity differences between
participants. Nonetheless, Croen et al (2011) did report an increase in risk of ASD in offspring
exposed to SSRIs in pregnancy, despite taking into consideration maternal mental health
symptom severity and history (Croen et al., 2011) suggesting that symptom severity and
history alone may not influence the risks.

Of the retrospective studies that investigated cases of ADHD, two reported a significantly
increased risk associated with SSRI exposure and this behavioural disorder (Clements et al.,
2015; Figueroa, 2010). One study reported that SSRI treatment during, but not prior to
pregnancy was associated with an increased risk for ADHD in offspring (Clements et al., 2015),
suggesting that exposure plays an influential role. In comparison to these findings, another
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study reported an increased risk of ADHD in children of women exposed to SSRIs postnatally
only, proposing greater emphasis on the influence that maternal mood disorders play during
pregnancy; however, the influence of SSRI-exposure through breast milk on offspring cannot
be ruled out (Figueroa, 2010). Differences in sample sizes, ages and methodology may have
contributed to the conflicting findings. For example Clements et al., (2015) recruited data
from cases of ADHD (n= 2,243) in offspring aged 2-19 years, then identified those exposed to
maternal SSRIs (n= 62), whilst Figueroa et al., (2010) recruited data from pregnancies with
SSRI exposure (n= 916) and aligned with cases of ADHD (n= 23) in offspring aged 0-5 years.

Collectively, with the exception of Malm et al., (2016), who reported an increased risk for
depression in adolescent offspring exposed prenatally to SSRIs, the retrospective studies
largely neglect the assessment of symptoms specific to anxiety and depressive disorders or
later adolescent ages, and focus instead on ASD, ADHD and the juvenile ages, making it
difficult to posit the potential longer term effects of maternal SSRI exposure. In addition,
though the majority of the retrospective studies indicate that maternal SSRI exposure may
increase the risk for developmental disorders in offspring, it is obvious that the exposure
period that confers the greatest risk is much deliberated.

While retrospective studies provide the opportunity for large sample sizes and relative ease
in data collection, they are limited by their inability to confirm SSRI use/compliance or
symptom severity of maternal mood disorders during pregnancies. In comparison, despite
lower samples sizes, longitudinal studies have the added benefit of examining more specific
subject behaviours and measures of neurodevelopment and associated disorders. Of the ten
published longitudinal studies, five reported no significant effects of SSRI exposure on
behavioural parameters, as measured using the Bayley Scales of Infant and Toddler
Development Instrument (BSID) administered by trained clinicians (Austin et al., 2013; Casper
et al., 2003; Galbally et al., 2011) and the Child Behaviour Checklist (CBCL), a subjective,
observational questionnaire completed by subject parents or caregivers (Misri et al., 2006;
Nulman et al., 2012). The BSID assesses motor, language and cognitive development of infants
and toddlers aged 0-3.5, whilst the CBCL aims to measure problem behaviour in children
characterized by internalizing, such as withdrawal and anxiety, and/or externalizing, such as
delinquent or aggressive behaviours (Nøvik, 1999). These studies include small sample sizes
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(n=13-35) that may have limited statistical power to detect any associations. Conversely, five
studies with larger sample sizes (n=28-5,531) have reported significant associations between
maternal SSRI exposure and behavioural disturbances in offspring, including autistic traits,
anxiety and externalizing behaviours. These studies were conducted in cohorts of slightly
older children (up to 6 years of age) assessed using the CBCL (Hanley et al., 2015; Hermansen
et al., 2016; Marroun et al., 2014; Oberlander et al., 2010) and BSID (Hanley et al., 2013). The
question of whether the conflicting nature of these findings is due to the different
methodology employed, or other factors such as sample size and age of subjects, needs
further investigation. Furthermore, it must be acknowledged that several longitudinal studies
lack effective comparison groups that enable separation of the effects of SSRI exposure from
the effects of maternal depression (Austin et al., 2013; Galbally et al., 2011; Hanley et al.,
2013; Misri et al., 2006; Oberlander et al., 2010). In addition, the longitudinal studies only
examine the juvenile years and as such emotional disturbances, such as depression and
anxiety, that commonly emerge during adolescent years, were not measured (Paus et al.,
2008). Therefore, further studies examining later time periods would help provide a complete
spectrum of potential neurobehavioural alterations associated with developmental SSRI
exposure.
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Table 1.1: Effects of maternal SSRI exposure on offspring neurodevelopmental disorders: evidence from human studies.
Study
Antidepressants
Participants (n) with or
Age of
Findings
without symptomology of
offspring
Major Depressive Disorder
studied
(+/- MDD)
Longitudinal Studies
Austin et al.,
SSRIs
n = 35 treated/exposed
17-24
Nil significant effects of in-utero SSRI exposure on
(2013)
(Fluoxetine, Sertraline,
+ MDD
months
motor, language or cognitive development – assessed
Citalopram, Escitalopram,
using the Bayley Scales of Infant and Toddler
Paroxetine, Fluvoxamine)
n = 23 controls untreated
Development instrument (BSID-III).
- MDD
SNRI
(venlafaxine)
TCA
(Dothiepin)
Casper et al., SSRIs
n = 31 treated/exposed
6-40
Nil significant effects of in-utero SSRI exposure on
(2003)
(Fluoxetine, Sertraline,
+ MDD
months
infant neurodevelopmental outcomes measuring
Paroxetine, Fluvoxamine)
motor, language and cognitive development - assessed
n = 13 controls untreated
using BSID-II.
+ MDD

Misri et al.,
(2006)

SSRIs
(Fluoxetine, Sertraline,
Paroxetine)

n = 22 treated/exposed
+ MDD
n = 14 controls untreated
-MDD

4-5 years

Nil significant differences between groups in
internalizing behaviours, based on parental/teacher
self-report using the Child Behaviour Checklist (CBCL)
(which is designed to screen for psychological
disorders and associated behaviours, including anxiety,
depression, social interaction, aggressiveness,
attention and cognition)(Mazefsky et al., 2011)
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Oberlander et SSRIs (fluoxetine, paroxetine,
al., (2010)
sertraline, venlafaxine,
Citalopram)

n = 33 treated/exposed
+ MDD

3 years

Children exposed to SSRIs and maternal depressed
mood had significantly increased internalizing
behaviours reported using the CBCL.

19-35
months

Children exposed to SSRIs scored lower on motor
subscales, particularly fine motor and gross motor,
using the BSID-II. Nil significant effects on infant
language and cognitive development.

5-6 years

Children exposed to SSRIs had significantly increased
internalizing and externalizing behaviour measured
by the CBCL.

n = 42 controls untreated
- MDD
Galbally et
al., (2011)

SSRIs
(sertraline, venlafaxine,
citalopram)

Hermansen
et al., (2016)

SSRIs (Fluoxetine, Paroxetine,
Sertraline, Escitalopram and
citalopram)
SNRI (Venlafaxine)
Mirtazapine

Hanley et al.,
(2015)

SSRIs
(Fluoxetine, Paroxetine,
Sertraline, Venlafaxine,
Citalopram)

El Marroun et
al., (2014)

SSRI
(paroxetine, fluoxetine,
sertraline, fluvoxamine and
citalopram)

n = 22 treated/exposed
+ MDD
n = 19 controls untreated
- MDD
n = 28 treated/exposed
+ MDD
n = 42 controls untreated
+ MDD
n = 33 controls untreated
- MDD

n = 44 treated/exposed
+ MDD
n = 66 controls untreated, of
which n = 10 +MDD
n = 69 treated/exposed
+ MDD
n = 376 controls untreated
+ MDD
n = 5,531 controls untreated
- MDD

3 – 6 years Children exposed had significantly increased anxiety
and internalizing behaviours at 3 and 6 years of age,
measured using the CBCL.

1.5-6
years

Prenatal SSRI exposed offspring showed higher risk
for autistic traits and development of pervasive
developmental problems compared to those exposed
to maternal depression only – measured by the CBCL
and the Social Responsiveness Scale, which focuses
specifically on dimensions that relate to that of autism
spectrum disorders, such as social cognition,
communication and autistic mannerism (Constantino
et al., 2003).
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Hanley et al.,
(2013)

SSRIs
(paroxetine, fluoxetine,
sertraline, venlafaxine,
citalopram)

Nulman et al., SSRIs
(2012)
(sertraline, paroxetine,
citalopram, fluoxetine,
fluvoxamine).
SNRIs
(venlafaxine)

n = 31 treated/exposed
+ MDD
n = 52 controls untreated
- MDD

10 months Children exposed to SSRIs scored significantly lower
on gross motor, social-emotional and adaptive
behaviour using the BSID-III, and after controlling for
MDD.

n = 62 treated/exposed (SSRI)
+ MDD

3-6 years

n = 62 treated/exposed (SNRI)
+ MDD

IQs of children exposed to venlafaxine and SSRIs
were significantly lower compared to children of
mothers with untreated MDD and controls with no
history of MDD or ADD treatment.
Nil significant differences in cognitive or behavioural
abnormalities of exposed groups assessed using the
Child Behaviour Checklist.

n = 54 controls untreated
+ MDD
n = 62 controls untreated
- MDD
Retrospective Studies
Hviid et al.,
SSRIs (fluoxetine, sertraline,
(2013)
paroxetine, citalopram,
escitalopram, fluvoxamine)

n = 6,068 SSRI exposed of
which
n= 835 mothers + MDD
n= 52 offspring + ASD

0 – 10
years

SSRI use during pregnancy was not associated with an
altered risk of ASD.

n = 620,807 control of which
2647 mothers + MDD
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Viktorin et
al., (2017)

SSRIs, SNRI, TCA

n = 179,007 children, of which
n = 1641 + ASD
n = 3982 ADD exposed

7-8 years

Increased relative risk of ASD in offspring exposed to
the SSRIs citalopram and escitalopram (1.71), however
relative risk was reduced (1.07) when adjusted for
history of depression or anxiety.

King, (2017)

SSRIs

n = 2532 exposed to SSRIs, of
which
n = 31 + ASD

6 years

Use of SSRIs during second and/or third trimester
was significant associated with an increased risk of
ASD (adjusted hazard ratio 2.17). The risk was
persistent even after accounting for maternal history
of depression (adjusted hazard ratio 1.75)

5-9 years

Prenatal exposure to SSRIs was not associated with a
significantly altered risk for ASD in offspring.

0 – 11
years

SSRI use was associated with increased risk of ASD in
offspring, when exposed in the second and/or third
trimester only (HR 1.87), after accounting for
confounders.

Sorensen et
al., (2013)

SSRIs, SNRI, TCA

n = 140 732 children not
exposed to ADD, of which
n = 1008 + ASD
n = 8,833 ADD exposed, of
which
n= 1,756 mothers + MDD
n= 104 + ASD
Of those exposed to ADD;
n = 7,506 SSRI exposed
n = 673 SNRI exposed
n = 642 TCA exposed

Boukhris et
al., (2016)

SSRIs, SNRIs, TCA, Monoamine
Oxidase Inhibitors (MAOI)

n = 646,782 controls, of which;
n= 4,324 mothers + MDD
n= 5,333 + ASD
n = 4724 ADD exposed, of
which;
n = 46 + ASD
n = 3290 mothers + MDD
n = 140,732 controls, of which;
n = 1008 + ASD
n = 14,651 mothers + MDD
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Brown et al.,
(2017)

SSRIs

n = 2837 pregnancies ADD
exposed, of which;
n = 1176 + Bipolar or MDD
n = 2364 other
depressive/anxiety disorder

4 – 12
years

In-utero SSRI exposure was not associated with
increased risk of ASD in offspring.

n = 58 offspring +ASD
n = 33069 pregnancies without
ADD exposure, of which;
n = 3175 + Bipolar or MDD
n = 13589 other
depressive/anxiety disorder
n = 335 offspring +ASD
Figueroa
(2010)

SSRIs, Bupropion, TCA

n = 1030 ADD exposed, of
which;
n = 28 +ADHD
n = 3532 children of mothers
+MDD, of which;
n = 88 +ADHD
n = 29, 329 children of mothers
–MDD, of which;
n = 239 +ADHD

Brandlistuen
et al., (2015)

SSRIs, TCA, Other

n = 141 ADD exposed, of which;
n = 90 +MDD
n = 20,039 not exposed, of
which;
n = 3831 +MDD

0 – 5 years Significant increase in ADHD in offspring exposed to
SSRIs postnatally, and not before/during pregnancy
(OR 2.04).
Significant increase in ADHD in offspring exposed to
Bupropion during pregnancy, and not before/after
(OR 3.63).

0-3 years

Significant increase in anxiety symptoms in offspring
exposed to ADDs (r=0.64, p<0.05 regression analysis)
after adjusting for MDD during pregnancy, MDD
history, smoking, alcohol and co-medication.
Measured using the CBCL.
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Clements et
al., (2015)

Antidepressants (categorized by
their 5-HT transporter affinity –
High: fluoxetine, paroxetine,
duloxetine, sertraline,
escitalopram.
Moderate: citalopram,
fluvoxamine, venlafaxine.
Low: nefazodone, bupropion,
mirtazapine).

Croen et al.,
(2011)

SSRI, TCA and DAA (dual action
ADD)

n = 1,377 ASD, of which
n= 128 ASD subjects had a
mother with history of + MDD

2-19 years

ADD exposure during but not prior to pregnancy was
associated with ADHD (OR 1.69), after adjusting for
MDD
ADD use prior to pregnancy but not during was
associated with ASD (OR 1.91), after adjusting for
MDD

12 to 16
years

Two-Fold increased risk of ASD associated with SSRI
exposure during the year prior to delivery (OR 2.2)
(including before and during pregnancy), with the
strongest effect associated with treatment in first
trimester (OR 3.8).

n= 4,022 controls, of which
n= 225 subjects had mother +
MDD
n = 2,243 ADHD, of which
n= 184 subjects had mother +
MDD
n = 5,631 controls, of which
n= 214 subjects had mother +
MDD
n = 298 ASD, of which 10
mothers + MDD

n = 1,507 controls, of which 44
mothers + MDD

Gidaya et al.,
(2014)

SSRIs (fluoxetine, citalopram,
paroxetine, sertraline,
fluvoxamine, escitalopram).

n = 5,215 ASD, of which;
n = 76 SSRI exposed
n= 55 mothers + MDD

8-17 years

No increase in risk of ASD in children of mothers with a
history of mental health treatment and no SSRI use.
In utero exposure to SSRIs increased risk for ASD (OR
1.8), after adjusting for maternal depression and any
SSRI indication.

n = 52,150 controls
Of which;
n = 365 SSRI exposed
n = 347 mothers + MDD
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Harrington et
al., (2014)

SSRIs (fluoxetine, sertraline,
paroxetine, citalopram,
escitalopram)

n = 492 ASD, of which 122
mothers + MDD

2 to 5
years

SSRI use associated with greater risk of ASD (OR
2.91), with strongest association occurring with firsttrimester exposure (OR 3.22) and developmental
delay in boys (OR 3.39) (authors report invalid sample
size for girls)

0 – 14
years

SSRI exposure was associated with increased rates of
depression in early adolescence (HR 1.78) but not
with ASD or ADHD.

0-17 years

Maternal history of depression was associated with a
higher risk of ASD in offspring (OR 1.49). Of the
subsample with available data on ADD exposure, this

n = 154 developmental delay,
of which 40 mothers + MDD
n = 320 controls, of which 67
mothers + MDD
Malm et al.,
(2016)

Rai et al.,
(2013)

SSRIs (fluoxetine, sertraline,
paroxetine, citalopram,
escitalopram, fluvoxamine)

SSRI, TCA

n = 15,729 SSRI exposed, of
which;
n = 60 + ASD
n = 160 + ADHD
n = 60 + Depression
n = 65 + Anxiety
n = 9,651 maternal psychiatric
disorder, no SSRI, of which;
n = 79 + ASD
n = 137 + ADHD
n = 30 + Depression
n = 39 + Anxiety
n = 31,394 controls, nil SSRI
exposure, nil maternal
psychiatric disorders, of which;
n = 100 + ASD
n = 124 + ADHD
n = 30 + Depression
n = 62 + Anxiety
n = 4,429 ASD, of which 44
mothers + MDD
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association was limited to women reporting ADD use
during pregnancy.

n = 43,277 control, of which
272 mothers + MDD
Abbreviations: ADD = Antidepressant Drug; ADHD = Attention Deficit Hyperactivity Disorder; ASD = Autism Spectrum Disorders; BSID = Bayley Scales of
Infant and Toddler Development instrument; HR = Hazards Ratio; MDD = Major Depressive Disorder; OR = Odds Ratio; SNRI = Serotonin and Norepinephrine
Reuptake Inhibitors; SSRI = Selective Serotonin Reuptake Inhibitors; TCA = Tricyclic Antidepressants.

38

While there has been minimal investigation of the neuro-biological consequences of foetal
SSRI exposure, the limited studies that have been conducted (Bellissima et al., 2015; Davidson
et al., 2009; Laine et al., 2003; Oberlander et al., 2008; Pawluski et al., 2012, 2009; Podrebarac
et al., 2017) have focused primarily on aspects of the hypothalamic-pituitary-adrenal (HPA)
axis and neurotransmitter metabolites in cord blood samples, with an absence of studies
focusing on longer term changes. One study reported significantly decreased serotonin and
its main metabolite, 5HIAA, by as much as 67% in the cord blood of SSRI exposed infants
compared to controls (Laine et al., 2003), providing evidence that SSRIs may not necessarily
increase foetal serotonin as it does in the adult brain. However, given that sources of foetal
serotonin are dynamic and switch progressively during development from exogenous
(placental) to endogenous (foetal raphe neurons) sources (Bonnin et al., 2011; caution needs
to be taken when interpreting levels of serotonin in cord blood. Furthermore, another study
reported a reduction in the dopamine metabolite, homovanillic acid (HVA), and a borderline
reduction in cord blood noradrenaline (Laine et al., 2003), suggesting that SSRI exposure can
influence neurotransmission systems beyond serotonin. The serotonergic system is a key
regulator of the HPA axis and corticotropin releasing hormone (CRH) release is mediated by
serotonergic transmission (Heisler et al., 2007b, 2007a). Accordingly, SSRI exposed infants
have exhibited significantly decreased levels of cortisol in cord blood (Davidson et al., 2009)
and in salivary samples at three months of age (Oberlander et al., 2008).

Recent studies have investigated other potential markers of neurobiological alterations
caused by maternal SSRI exposure in human samples (Table 1.2). One recent study has shown
that antenatal SSRI exposure is associated with alterations in white and gray matter
microstructural growth and development, even after controlling for factors related to illness,
prematurity and maternal history (Podrebarac et al., 2017). S100 calcium-binding protein β
(S100β) is an astroglial-derived neurotrophic factor used as a marker of CNS cellular damage
when detected at elevated biological concentrations (Kleindienst et al., 2007). One study
reported significantly increased S100β levels in maternal blood, amniotic fluid, cord blood and
neonatal peripheral blood throughout pregnancy, at birth and 24hours postnatal following
maternal treatment with the SSRI paroxetine compared to untreated controls (Bellissima et
al., 2015). In addition, infants showing major neurological symptoms (i.e. hypotonia and
seizures) at postnatal day 7 exhibited the highest blood S100β levels (Bellissima et al., 2015).
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Separating these findings in SSRI-treated mothers from the effects of innate maternal
depression are difficult given that no control group for maternal depression was used
(Bellissima et al., 2015), particularly when other studies suggest that untreated depressed
subjects display higher levels of S100β (Arolt et al., 2003; Grabe et al., 2001). On the other
hand, another study reported decreased S100β levels in cord blood following SSRI exposure,
even after controlling for maternal mood disorder, but reported significantly higher maternal
S100β levels in SSRI treated subjects compared with non-treated (Pawluski et al., 2009). The
conflicting findings regarding neonatal S100β levels between these two studies may be
attributed to the specific SSRIs tested with Pawluski et al., (2009) collectively examining a
range of SSRIs, whereas Bellissima et al., (2015) included data from those mothers treated
with paroxetine only.

Finally, although levels of biological markers taken from blood provide some insight into the
potential peripheral neurochemical perturbations occurring as the result of SSRI exposure,
there is no guarantee that these peripheral measures accurately reflect changes in the brain.
Further studies investigating the long-term effects of SSRI exposure on central
neurotransmitter systems and their metabolites are required to elucidate the potential for
these drugs to manipulate the developing brain. This last point is compounded given the
purported role of the serotonergic system in the development of other systems, including
glutamate and GABA (refer to section 1.1.2) and its relationship with neurotrophic markers
such as BDNF, and their role in neurogenesis.
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Table 1.2: Effects of maternal antidepressant administration on biological measures in offspring: Evidence from human studies
Study

Antidepressants

Participants (n)

Measurements Taken

Main Findings

Bellissima et al.
(2015)

SSRI
(Paroxetine n = 75)

n = 75 SSRI exposed + MDD or
other mood disorders

S100β protein
concentrations assessed
in maternal blood,
amniotic fluid, cord blood
and neonatal peripheral
blood.

• Significant increase in S100β levels in
maternal blood, amniotic fluid, and arterial and
venous cord blood at all time points.

n = 231 controls untreated
- MDD or other mood disorders

Samples taken at:
-16-20, 27-30 and 35-40
weeks pregnancy
(maternal blood).

Davidson et al.
(2009)

SSRIs
(paroxetine n = 8,
fluoxetine n = 7,
citalopram n = 6)

n = 21 exposed (details of
maternal mood disorders
unknown)
n = 20 control untreated
- MDD or other mood disorders

- Birth (amniotic fluid)
- 24 hours postnatal
(arterial and venous cord
blood).
Birth (cord blood)
- cortisol
- Thyroid Stimulating
Hormone (TSH)
- Insulin-like growth factor
(IGF-1)
- Dehydroepiandrosterone
(DHEA)
Placenta

% Difference in median S100β levels
16-20 weeks (+233%)
27-30 weeks (+220%)
35-40 weeks (+157%)
Birth (+1425%)
24 hours (+829%)

• Significant decrease (-31%) in cord blood
cortisol levels in the SSRI exposed group.
• Significant increase (+31%) in cord blood TSH
levels in SSRI exposed group.
• Significantly lower (-70%) IGF-I level in infants
exposed to citalopram only.
• Significantly elevated (+100%) level of
placental (IGF-1R) in SSRI exposed group.
• Nil significant difference in DHEA and 5HIAA
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- IGF-1 receptor (IGF-1R)
Urine (newborn)
- 5-HIAA

Podrebarac et
al., (2017)

SSRIs

n = 177, of which
n = 14 exposed to SSRIs

Diffusion tensor and
magnetic resonance
spectroscopic imaging

In SSRI-exposed neonates
• Significantly increased fractional anisotropy,
and decreased mean, axial and radial
diffusivity in superior white matter.
• Significantly decreased fractional anisotropy
in the basal ganglia and thalamus.
• Significantly decreased N-acetylaspartate to
choline ration, and increased lactate to
choline ratio.

Laine et al.
(2003)

SSRIs
(n=20 Fluoxetine;
n=20 Citalopram)

n = 20 SSRI exposed (n=10 +
MDD; n=10 + panic disorder)
n = 20 control untreated
- MDD or other mood disorders

Oberlander et
al. (2008)

SSRIs

n = 31 SSRI exposed (maternal
mood disorder history not
stated)

Birth (cord blood)
- 5-HT
- 5-HIAA
- Homovanillic Acid (HVA)
(dopamine metabolite)
- Noradrenaline
- Prolactin

• Significantly decreased cord 5-HT (-67%), 5HIAA (-18%) and HVA (-23%), serum prolactin
(-29%) in the SSRI exposed infants compared
to control.
• Borderline significant decrease (-46%; p=0.05)
cord Noradrenaline in SSRI exposed.

Cortisol collected at 3
months’ age (saliva) at
three daily time points,
before, during, and after
an information processing

• No significant differences in saliva cortisol
levels between infants during the time points
associated with the information processing task.
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n = 45 control untreated
- MDD or other mood disorders

Pawluski et al.
(2009)

Pawluski et al.,
(2012)

SSRIs
paroxetine n =14,
fluoxetine n = 6,
sertraline n = 6,
citalopram n = 4

n = 36 exposed + MDD or other
mood disorders

SSRIs

36 Weeks (n)
n = 47 control untreated - MDD
or other mood disorders

task.
An additional measure of
cortisol was taken the
next day in the
afternoon/evening.
Birth (cord blood)
- S100β pg/ml

• Evening cortisol was significantly lower (-65%)
in SSRI exposed infants compared to control.

• Prenatal SSRI exposure significantly lowered (16%) neonatal serum S100β levels compared to
controls.

n = 17 controls untreated
- MDD or other mood disorders

n = 29 exposed + MDD or other
mood disorders
Neonate (n)
n = 40 control untreated - MDD
or other mood disorders

Serum at 36 weeks and
neonates (cord blood)
- Cortisol-binding globulin
(CBG)
- Cortisol

• Significant increases in serum CBG (+33%) of
neonates exposed to SSRIs after vaginal
delivery.
• No significant differences in levels of other
measured parameters.

Saliva (infants 3month
old)
- cortisol

n = 25 exposed + MDD or other
mood disorders
Abbreviations: SSRIs = selective serotonin reuptake inhibitors, IGF-I = insulin-like growth factor, IGF-IR = insulin-like growth factor receptor, TSH = thyroid
stimulating hormone, 5-HT = 5-hydroxytryptamine, 5-HIAA = 5-hydroxyindoleacetic acid, HVA = homovanillic acid, DHPG = dihydroxyphenylglycine, S100β =
S100 calcium-binding protein B.
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1.1.3 Considerations for Human Studies
Human studies are invaluable to clarify the risks associated with maternal SSRI exposure; yet
they are confounded by the underlying maternal psychopathology and maternal stress or
adversities. Furthermore, human studies often omit or report difficulties measuring the
severity of maternal mood disorders, which may be phenotypically masked due to SSRI
treatment, and could represent a considerable influence over the observed effects of SSRI
exposure on offspring. As iterated by Petersen et al., (2014), SSRI use may be a marker of
severity of underlying mental illness and that may confound the interpretation of these
clinical findings. Therefore, careful consideration must be given to the interpretation of
clinical studies and their implications for the broader population, especially when inherent
difficulties in separating the effects of maternal SSRI exposure from confounding factors, such
as maternal depression, are often overlooked.

Maternal mood disorders and adversity themselves are factors associated with a greater risk
for obstetric complications, impaired pre- and post-natal care and the development of
psychopathologies in children (Ashman et al., 2002; Davalos et al., 2012; Glover, 2014;
Hammen and Brennan, 2003; Nulman et al., 2002; O’Connor et al., 2002). Systematic reviews
have shown that untreated maternal depression is associated with increased markers of
infant morbidity, including preterm birth, low birth weight, childhood emotional and
behavioural problems and poor cognitive development (Davalos et al., 2012; Gentile, 2015;
Steer et al., 1992). Studies have also noted neurobehavioural consequences of untreated
maternal depression or maternal adversity on children, with some showing an increased risk
for internalizing behaviours (Ashman et al., 2002), decreased cognitive and language
development (Nulman et al., 2002), developmental delay (Deave et al., 2008) and an
increased risk for depression, anxiety, ADHD and ASD symptomology (Glover, 2014; Hammen
and Brennan, 2003; O’Connor et al., 2003, 2002; Rice et al., 2010; Rodriguez and Bohlin, 2005;
Ronald et al., 2011; Van den Bergh and Marcoen, 2004). Untreated maternal depression can
also have indirect effects on the offspring through means of unhealthy maternal behaviours,
for example studies have found a significant association with pregnant women suffering from
depression and cigarette, alcohol and cocaine use in some people (Zuckerman et al., 1989);
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all well-known to detrimentally affect pregnancy outcomes (Cnattingius, 2004; Eyler et al.,
1998; Ornoy and Ergaz, 2010). Finally, prenatal depression remains one of the strongest risk
factors for postnatal depression (Robertson et al., 2004); a disorder linked to developmental
problems and increased risk of depression in children (Murray et al., 2011; Talge et al., 2007).
Severe untreated depression, can also result in suicide, which is a major cause of maternal
death (Oates, 2003). Therefore, SSRIs continue to be critically important to the health and
well-being of mothers with depression and accordingly, current clinical guidelines from the
American Psychiatric Association advise against the discontinuation of SSRI use in pregnancy
(though switching from paroxetine may be advised in some instances), particularly if the
chance of psychopathological relapse is high (Yonkers et al., 2009). Despite reports of
increased risk associated with third trimester SSRI exposure and teratogenic effects or
neonatal abstinence syndrome, tapering of SSRI dosage has also been recommended over
discontinuation (Yonkers et al., 2009). Finally, although some clinical studies report ~2-3x fold
increases in risks for neurodevelopmental disorders in offspring exposed to SSRIs (Boukhris
et al., 2016; Clements et al., 2015; Croen et al., 2011; Gidaya et al., 2014; Harrington et al.,
2014), the fact remains that the overall incidence/prevalence of these disorders in the
population is relatively low (incident rate of 38.6 per 100,000 and prevalence of 6 per 1000
for ASD (Jensen et al., 2014; Newschaffer et al., 2007); and incidence rate of 9.9 per 100,000
and prevalence of 1 per 1000 for ADHD (Holden et al., 2013)). The low incidence of
behavioural disorders in the general population warrants careful consideration in light of the
consequences associated with untreated maternal depression and the risks this pathology
poses for the health and wellbeing of the mother and child. Ultimately, this is clearly an area
that requires further research with an emphasis on discerning the effects of maternal SSRI
treatment from maternal psychopathology on the neurodevelopment and risk for associated
disorders in offspring.
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1.1.4 The behavioural and biological effects of maternal SSRI treatment on exposed
offspring: Evidence from animal studies

Given the inherent difficulties in assessing the effects of developmental SSRI exposure in
humans, researchers have turned to animal models to gain a deeper understanding of the
effects of maternal SSRI treatment on exposed offspring. To begin translation of the findings
from animal models to the clinic, emphasis needs to be placed on the timeline of SSRIexposure, and the equivalent neurodevelopmental milestones reached compared to humans.
In humans, the blood brain barrier is established at 23-32 weeks gestation, whilst gliogenesis,
synaptogenesis and myelination contribute to the peak brain growth occurring at 36-40
weeks gestation (reviewed in Semple et al., (2013)). In rodents, these same milestones are
reached at PN1 – 3 and PN7 – 10, respectively (Semple et al., 2013). Indeed, it has been
estimated based on neurodevelopmental comparisons that rodent PN7-14 is equivalent to
birth in humans (Clancy et al., 2007). Typically, rodent studies are divided into those that
deliver SSRIs to dams during gestation (+/- lactation) and others that deliver SSRIs directly to
pups in the early postnatal period. Despite wide variance in other methodological
considerations, including drug dosage, administration method and treatment duration, it is
clear that SSRI exposure in rodent models can alter neurodevelopment in ways that impact
behavioural characteristics of offspring, including increases in anxiety- and depressive-like
behaviours, as well as abnormalities in social interaction and exploratory behaviours (Table
1.3). With the exception of a few studies (Boulle et al., 2016a, 2016b; Gemmel et al., 2019,
2017; Glover et al., 2015; Kiryanova et al., 2016; Rayen et al., 2011), the current body of
animal literature, does not assess the effects of SSRIs in a depression or anxiety model.
Furthermore, of those that do, the majority implement environmental models of pregestational/gestational stress to induce depressive maternal phenotypes. Although these
models are invaluable, there is little investigation using endogenous models of depression.
Considering depression and anxiety are associated with altered serotonergic development in
their own right (Nulman et al., 2012), modelling SSRI exposure in a model of depression or
anxiety that mimics the underlying serotonergic pathology may influence the effects of SSRIs
on the serotonergic system.

Of the 16 studies assessing maternally administered SSRIs, 14 report significant increases in
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anxiety- or depressive-like behaviour and/or deficits in cognition and social-related
behaviours in offspring ranging in age from PN8 to PN140 (Table 1.3). Specifically, seven of
these studies demonstrated an increase in anxiety-like behaviours following doses ranging
from 0.3 – 25mg/kg Fluoxetine (Bairy et al., 2006; Boulle et al., 2016b; Lisboa et al., 2007;
Noorlander et al., 2008; Olivier et al., 2011; Smit-Rigter et al., 2012) and 10mg/kg citalopram
(Sprowles et al., 2016), with exposure durations from GD0 to PN21. Six studies reported
increases in depressive-like behaviour measured by the forced swim test, shock escape test
and novelty-supressed feeding test (Boulle et al., 2016a; Glover et al., 2015; Lisboa et al.,
2007; Noorlander et al., 2008; Rayen et al., 2011; Sprowles et al., 2016). Conversely, six
studies found either no differences (Glover et al., 2015; Rayen et al., 2011), or decreases in
anxiety-like behaviour (Francis-Oliveira et al., 2013; Kiryanova et al., 2016; McAllister et al.,
2012), and no changes (Francis-Oliveira et al., 2013; Olivier et al., 2011) or decreases in
depressive-like behaviour (Francis-Oliveira et al., 2013; McAllister et al., 2012). In addition,
five studies assessed cognition, with one noting significant deficits in the passive avoidance
test (Bairy et al., 2006), and another reporting reduced performance in the Morris water maze
in SSRI-exposed offspring; the latter study also reported increased prepulse inhibition
(Sprowles et al., 2016). On the contrary, other studies reported no changes (Kiryanova et al.,
2016; McAllister et al., 2012; Olivier et al., 2011), or increases in cognition (spatial memory)
in the Morris water maze (Bairy et al., 2006). The differences in findings may be attributable
to differences in drug dosages, subject sex and behavioural test protocols (Table 1.3). For
example, one study reported a decrease in ambulation during the open field test in males
only, but not females, and an increase in immobility time in the forced swim test specifically
in females, following maternal fluoxetine exposure (Lisboa et al., 2007). Another study
reported negligible alterations in the behaviour of female rodents exposed to a high dose of
fluoxetine (McAllister et al., 2012), excluding males from the study. Finally, recent studies
investigating ultrasonic vocalizations (USVs), social interaction and play behaviour have
reported sex- and age-specific alterations in response to perinatal fluoxetine exposure
(Gemmel et al., 2019, 2017; Houwing et al., 2019). Specifically, Gemmel et al., (2017, 2019)
reported that perinatal fluoxetine exposure (5mg/kg/day) reduced time spent grooming
novel conspecifics in adolescent males and increases aggression in both sexes at adolescence
(Gemmel et al., 2017). Conversely, perinatal fluoxetine exposure increases social play in adult
male, and social investigation in adult female offspring (Gemmel et al., 2019), collectively
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suggesting that males may be more vulnerable to the effects of perinatal fluoxetine exposure
on social interaction at early ages, but both sexes are equally affected in adulthood. A recent
study has shown that perinatal fluoxetine exposure can even influence behaviour as early as
postnatal day 6, with exposed offspring exhibiting reduced durations of separation protest
USVs, regardless of sex (Houwing et al., 2019). Ultimately these studies suggest that in models
of maternal depression, perinatal SSRI exposure can influence offspring behaviour in an age,
sex and treatment-specific manner. Further studies are required to assess the dose effects of
SSRI exposure on offspring behaviour of both sexes, across development.

Studies examining the effects of postnatal SSRI exposure (ranging from PN0 – PN21) on
offspring behaviour provided the greatest consistency in findings (Table 1.3). All studies
reported significant increases in anxiety-like behaviour evident through decreases in
exploration and/or increases in anxiogenic parameters in the open field test, elevated plus
maze, light-dark test, novelty-induced hypophagia and novelty-suppressed feeding tests
(Ansorge et al., 2008, 2004; Karpova et al., 2009; Lee, 2009; Lee and Lee, 2012; RodriguezPorcel et al., 2011; Zheng et al., 2011). Three studies assessed the effects of postnatal
exposure on offspring depressive-like behaviour. Of those, two reported increases in learned
helplessness in the shock escape test (Ansorge et al., 2008, 2004) and one reported decreased
immobility time in the forced swim test (Karpova et al., 2009). The conflicting findings of the
three latter studies are likely to be attributable to the different behavioural tests used to
measure depressive-like behaviour, given that the drug dose and administration methods
were similar. Indeed, although the forced swim test has been validated as an effective
measure of antidepressant efficacy and depressive-like behaviour in rodents (Slattery and
Cryan, 2012), others have suggested that in some cases immobility behaviour may resemble
a survival mechanism rather than behavioural despair (Nishimura et al., 1988). Despite the
relative consistency in findings of these studies exposing offspring to SSRIs postnatally,
translation of the results must be taken with caution. In the clinical scenario, SSRIs are
transferred via the mother in utero or through breast milk, which has been shown to influence
the pharmacokinetics of SSRIs (Heikkinen et al., 2002a; Velasquez and Bonnin, 2016).
Therefore, directly exposing offspring to SSRIs postnatally could have an exaggerated
influence on their behaviour and neurobiology. Nonetheless, these consistent findings
suggest that the first 14 days of postnatal development in rodents, (third trimester in humans
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(Clancy et al., 2007)), a period marked by peak brain growth (Semple et al., 2013), represents
a time period perhaps more vulnerable to the effects of developmental SSRI exposure.

As previously mentioned, the majority of animal studies assess the effects of developmental
SSRI exposure in naïve rodents. A limited number assess the effects in models of maternal
depression (Boulle et al., 2016a, 2016b; Gemmel et al., 2019, 2017; Glover et al., 2015;
Kiryanova et al., 2016; Rayen et al., 2011), which arguably represents the clinical scenario
more closely.

Several studies have modelled SSRI exposure in dams exposed to

environmental stress (as a model of maternal depression) through restraint, intense light
exposure, confinement or other stressors (Table 1.3) (Boulle et al., 2016b, 2016a; Gemmel et
al., 2019, 2017; Kiryanova et al., 2016; Rayen et al., 2011). Of those studies, two reported
increased depressive-like behaviour in the forced swim test in SSRI-exposed offspring of
maternally stressed dams (Boulle et al., 2016a; Rayen et al., 2011). Boulle et al., (2016a)
reported an increase in immobility in the forced swim test in fluoxetine exposed female (but
not male; Boulle et al., (2016b)) offspring regardless of maternal stress, whilst Rayen et al.,
(2011) reported increased immobility time in fluoxetine-exposed offspring of maternally
stressed dams only. Another reported that SSRI-exposed offspring born of dams subjected to
stress have decreased anxiety-like behaviour compared to SSRI-exposed offspring born of
dams naïve to stress (Boulle et al., 2016b). Similarly, Kiryanova et al., (2016) reported a
reduction in anxiety-like behaviour in male offspring of maternally stressed dams exposed to
fluoxetine, suggesting that exposure could be beneficial in ameliorating the effects of
maternal mood on offspring, at least in relation to anxiety-related behaviour. In line with this
finding Gemmel et al., (2017) demonstrated that perinatal fluoxetine exposure prevented the
negative influence that pre-gestational stress had on pre-adolescent play behaviour,
supporting the notion that exposure can ameliorate or prevent effects of stress. In
comparison to these studies, another study investigated the effects of maternal SSRI exposure
in selectively bred rats to determine whether innate disturbances in emotional behaviour
altered susceptibility (or resistance) to the effects of paroxetine treatment in offspring (Glover
et al., 2015). Using selectively bred Sprague-Dawley rats that exhibited decreased anxiety-like
behaviour (high responders) or increased anxiety-like behaviour (low responders), Glover et
al., (2015) showed significantly greater immobility times (depressive-like behaviour) in the
forced swim test in offspring of paroxetine-treated low responder dams, but no other
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differences in any parameters of the open field test, forced swim test and elevated plus maze
(Glover et al., 2015). Taken together these findings suggest that the effects of developmental
SSRI exposure can differ substantially in models of maternal adversity and depression (which
appears to reflect the findings observed in the clinic). Furthermore, animal studies have
highlighted an influence of sex on the effects of SSRI exposure in offspring that warrants
further investigation.
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Table 1.3: Effects of maternal antidepressant administration on biological measures in exposed offspring: evidence from animal studies.
Study
Species, Strain, Drug Dose, Route and
(Shaded studies
Duration
indicates those
implementing
models of maternal
depression/adversit
y).
Prenatal/maternal exposure

Test and age performed

Main Findings:
(SSRI-exposed offspring compared to control unless
otherwise stated. Percentages given are approximations)

Bairy et al., (2006)

PN8-49 (pre-adolescence
to adolescence)
Negative Geotaxis (NG)
Open Field Test (OFT)
Rotarod Test (RT)
Morris Water Maze
(MWM)
Elevated Plus Maze (EPM)
Passive Avoidance (PA)

NG – Flx 8mg/kg increased time to turn 180o at PN10
(+20%) and PN12 (+53%).
Flx 12mg/kg decreased time to turn 180o at PN10 (-6%) an
increased time at PN12 (+44%)

Species/Strain
Wistar Rats (n= 16 offspring/group)
Dose
Fluoxetine 8 and 12mg/kg
Route and Duration
GD6 – GD20 Oral (dissolved in water)

OFT – Increased central, peripheral and total crossings at
PN18 (Flx 8mg/kg: +320%, +127% and +133%. Flx
12mg/kg: +136%, +110% and +110%). Decreased central,
peripheral and total crossings at PN35 (Flx 8mg/kg: -52%, 15% and -20%. Flx 12mg/kg: -38%, -23% and -25%). No
differences on PN56.
RT – Increased retention time at PN22 (Flx 12mg/kg:
+350%) and PN49 (Flx 8 and 12mg/kg: +70%)
MWM – Flx 8mg/kg: Decrease in time to escape at PN24 (29%). Flx 12mg/kg decrease time to escape at PN24 and
PN29 (-32% and -50%).
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Glover et al., (2015)

Lisboa et al., (2007)

Species/Strain
Sprague-Dawley Rats (high responders
and low responders, n= 24
offspring/group)
Dose
Paroxetine 10mg/kg
Route and Duration
7 days prior to mating – PN21 Oral
(dissolved in water)
Species/Strain
Swiss Mice (n= 9-17 offspring/group)
Dose
Fluoxetine 7.5mg/kg
Route and Duration
GD0 – PN21 Gavage

PN75 (Adult)
Locomotor response to
novelty (LRN)
EPM
Forced Swim Test (FST)

PN30-40 (Adolescence)
and PN70 (Adult)
OFT
EPM
FST
Intruder-resistant test (IRT)
Hot plate test (HPT)

PA – Flx 12mg/kg: increase in latency to enter dark
compartment (+96%)
EPM – No significant differences
Summary – SSRI exposure caused a transient delay in
motor development, favourable effect on cognition and
learning at higher doses and decreased exploratory
behaviour at adolescence.
FST – exposed low-responders had increased immobility
compare to vehicle low-responders (+50%).
LRN and EPM – no differences
Summary – SSRI exposure exacerbated low-responder’s
depressive-like behaviour but had no effect on high
responders.

Male:
OFT – Decreased ambulation at PN40 (-16%)
IRT – Increased latency to first attack (+65%)
EPM, FST and HPT – no differences
Summary – Males: SSRI exposure induced decreased
exploratory behaviour at adolescence and decreased
reactivity/impulsivity in adults.
Female:
FST – Increased immobility both PN30 (+41%) and PN70
(+22%)
OFT, EPM and HPT – no differences
Summary - Females: SSRI exposure increased depressivelike behaviour at both adolescence and adulthood.
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Kiryanova et al.,
(2016)

Olivier et al., (2011)

Species/Strain
C57BL/6 Mice (n= 16-17
offspring/group)
Dose
Fluoxetine 25mg/kg
Route and Duration
GD15 to PN12 Oral (dissolved in
drinking water)
Stress (maternal depression model)
Combination of restricted access to
food, continuous lighting, cage tilt,
foreign object in cage, paired housing
of dams, soiled cage, irregular tones,
restraint and white noise from GD4 –
GD18.
Species/Strain
Wistar Rats (n= 7-16 offspring/group)
Dose
Fluoxetine 12mg/kg
Route and Duration
GD11 – PN1 Gavage

PN56 (Adult)
OFT
EPM
Passive Avoidance Test
(PAT)
MWM
Prepulse Inhibition (PPI)
IRT
Social Behaviour (SB)

EPM – Increase time in open arms in both stressed and
non-stressed offspring (+96%).
IRT – Increase in time spent (+223%) engaged in
aggressive behaviour.

PN28-35 (Adolescence)
and PN65 (Adult)
Novelty Suppressed
Feeding (NSF)
OFT
EPM
Conditioned Place Aversion
(CPA)
EPM – After Stress (EPMS)
FST
Sucrose Preference Test
(SPT)
Adolescent Social Play
(ASP)
Adult Social Play (AdSP)

NSF – increased latency to start eating (+110%)
CPA – increased freezing time in the shock compartment
(+5%)
EPMS – decreased time spent in open arms (-45%)
AdSP – decreased amount of pinning behaviour (-46%)
OFT, EPM, FST, SPT, ASP and SeB – no difference
Summary – SSRI exposure caused increases in anxiety-like
behaviour. No effect on depressive-like behaviour was
observed.

OFT, PAT, MWM and PPI – no difference
Summary – SSRI exposure caused decreases in anxiety and
increases in aggression in adulthood, largely independent
of maternal stress.
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Noorlander et al.,
(2008)

McAllister et al.,
(2012)

(Houwing et al.,
2019)

Species/Strain
C57BL/6 Mice (n= 5-13
offspring/group)
Dose
Fluoxetine 0.3, 0.6 or 0.8mg/kg
Fluvoxamine 4.2mg/kg
Route and Duration
GD8 – 18 Intraperitoneal (IP)
Species/Strain
C57BL/6 Mice (n= 16-17
offspring/group)
Dose
Fluoxetine 25mg/kg
Route and Duration
GD15 – PN12 Oral (dissolved in
drinking water)

P20 (pre-adolescence) and
PN90 (adult)
EPM
OFT
NSF

EPM – increased duration in closed arms at both PN20
(Flx: +23%, Flv: 14%)
OFT – decreased distance travelled in the centre arena at
adulthood (Flx: -56%)
NSF – increased latency to feed at adulthood (Flx: +240%)
Summary – SSRI exposure caused increases in anxiety-like
and depressive-like behaviour

PN73 – 83 (adult)
EPM
OFT
Horizontal Ladder (HL)
FST
MWM
PPI
Fear Conditioning (FC)

EPM – reduced time spent in closed arms (-21%)
FST – longer latency to first bout of immobility (+25%)
OFT, HL, MWM, PPI and FC – no difference

Species/Strain
SERT knock out rats
SERT+/+, SERT+/-, and SERT-/-

Ultrasonic vocalizations
(USVs) at PN6

USV – lowered the duration of USVs after separation from
mother and littermates, regardless of sex

Juvenile play behaviour
(PN28-35)

Play behaviour – reduced pouncing frequency and chasing
duration in both male and females

Social Interaction (PN7077)

Social interaction – adult offspring heterozygous for SERT
showed reduced social exploration toward a conspecific,
regardless of FLX exposure

Dose
Fluoxetine 10mg/kg/day
Route and Duration
GD0 – PN21 Oral gavage to dams
Pups subjected to maternal separation
from PN2 – PN15 for 6hrs daily.
Gemmel et al.,
(2017)

Species/Strain
Sprague-Dawley Dams
(n= 10-16/group)

Summary – SSRI exposure caused decreases in anxietyand depressive-like behaviours.

Summary – SSRI exposure causes alterations in USV, and
reductions in juvenile play behaviour, regardless of sex
Play behaviour test (preadolescent PN22-25)

Play Behaviour pre-adolescent – perinatal fluoxetine
prevents the negative influence that pre-gestational stress
has on pre-adolescent play behaviour.
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Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX

Social interaction test
(adolescent PN27)

Social Interaction – perinatal fluoxetine reduces time
spent grooming novel conspecifics in males, but not
females. Perinatal fluoxetine exposure increases
aggressive interactions in both sexes
Exposure to pre-gestational stress increases time spent
grooming novel social partner in females.

Dose
Fluoxetine (5mg/kg)

Summary – SSRI exposure reduces social interaction in
males but not females and prevents the effects of pregestational stress on pre-adolescent play behaviour.

Route and Duration
Orally to dams in wafer biscuit GD10 –
PN21
Females subjected to chronic
unpredictable stress for three weeks
prior to breeding, 0-2 stressors per
day (damp bedding, food deprivation,
5 min of forced swim, restraint under
bright light for 1hr, and cage rotation
for 12 hours.
(Gemmel et al.,
2019)

Species/Strain
Sprague-Dawley Dams
(n= 8-16/group)
Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX

Social interaction (adult
offspring)

Social Interaction – perinatal fluoxetine exposure
increased social play in adult male offspring. In females,
perinatal fluoxetine exposure increased social
investigation and time spent interacting with novel
partner(s)
Pre-gestational stress reduced social investigation, and
time spent interacting with novel partner(s) in males only.

Dose
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Fluoxetine (5mg/kg)

Summary – SSRI exposure increases social play in adult
male offspring and increases social investigation in female
offspring.

Route and Duration
Orally to dams in wafer biscuit GD10 –
PN21
Females subjected to chronic
unpredictable stress for three weeks
prior to breeding, 0-2 stressors per
day (damp bedding, food deprivation,
5 min of forced swim, restraint under
bright light for 1hr, and cage rotation
for 12 hours.
Boulle et al., (2016a)
Boulle et al., (2016b)

Rayen et al., (2011)

Species/Strain
Sprague-Dawley Rats (n= 13-16
offspring/group)
Dose
Fluoxetine 5mg/kg
Route and Duration
PN1 – PN21 Osmotic Minipumps
Stress (maternal depression model)
Restraint 3x daily under bright light for
45 minutes from GD15 – GD21.

PN140 (adult)
OFT
Elevated Zero Maze (EZM)
FST

Male:
OFT – Fluoxetine exposure decreased centre crossing in
naïve offspring compared to maternally stressed offspring
(-50%).
FST – decreased escape driven behaviour in maternally
stressed offspring regardless of treatment (-12%).
EZM – no differences
Summary – In male offspring SSRI exposure in
combination with maternal stress decreased anxiety-like
behaviour.
Female:
FST – increased immobility (+100%)
OFT and EZM – no differences
Summary - In females, SSRI exposure increased
depressive-like behaviour regardless of maternal stress.

Species/Strain
Sprague-Dawley Rats (n= 9-11
offspring/group)

PN32 (adolescence)
OFT
FST

FST – Increased immobility in offspring born of maternally
stressed dams (+150%).
OFT – no difference
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Dose
Fluoxetine 5mg/kg
Route and Duration
PN1 – PN21 Osmotic Minipumps
Stress (maternal depression model)
Restraint 3x daily under bright light for
45 minutes from GD15 – GD20.

Summary – SSRI exposure reversed the decrease in
depressive-like behaviour observed in unexposed
maternally stressed offspring.

Francis-Olivier et al.,
(2013)

Species/Strain
Wistar Rat
Dose
Fluoxetine 5mg/kg
Route and Duration
GD0 – PN21 Gavage

PN35 (adolescence) and
PN75 (adult)
SPT
NSF

NSF – decreased latency to feed at adolescence (-30%)
SPT – no difference
Summary – SSRI exposure caused decreases in anxiety-like
and depressive like-behaviour in offspring at adolescence.

Smit-Rigter et al.,
(2012)

Species/Strain
C57BL/6 Mice (n/group not specified)
Dose
Fluoxetine 0.6mg/kg
Route and Duration
GD8 – GD18 IP

Unknown age of testing
NSF

NSF – Increased latency to feed (+66%)
Summary – SSRI exposure caused increases in anxiety-like
and depressive like-behaviour in offspring.

PN60 (adult)
Straight Channel Swimming
(SCS)
Cincinnati Water Maze
(CWM)
MWM
OFT
EZM

MWM – Increased latency to reach platform (+40)
OFT –decreased centre crossing (-66%, females only)
MB – increased burying of marbles (+140%)
PPI – increased response amplitudes (day 1, +280%; day 2,
+110%)
FST – decreased latency to first bout of immobility (-100%)
SCS, CWM, EZM and SB – no difference

Prenatal/maternal exposure and postnatal/pup exposure
Sprowles et al.,
Species/Strain
(2016b)
Sprague-Dawley Rats (n= 9-23
offspring/group)
Dose
Citalopram 10mg/kg
Route and Duration (Dams)
GD6 – GD21 2x daily Subcutaneous
Injection (SC)
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Route and Duration (Offspring)
PN1 – PN20 2x daily SC

Postnatal/pup exposure
Lee and Lee (2012)
Species/Strain
Wistar Rats (n= 14-15/group)
Dose
Fluoxetine 20mg/kg
Route and Duration
PN0 – PN4 SC

Marble Burying (MB)
PPI
SB
FST

Summary – SSRI exposed offspring had alterations in
cognition and increased anxiety- and depressive-like
behaviour.

PN30 (adolescence)
OFT
EPM
RT

OFT – decreased locomotor activity (-23%)
RT – decreased latency to fall (-44%)
EPM – no difference
Summary – SSRI exposed offspring had increased anxietylike behaviour, evident through decreased exploratory
behaviour and impaired motor function.
OFT – decreased distance travelled (-40%), reduced total
ambulatory time (-38%) and vertical activity (-75%)
EPM – decreased entries into both arms (-30%)
NSF – increased latency to feed in (+/-) mice only (+130%)
SE – Increased latency to escape (+150%)
Summary – SSRI exposure increased anxiety- and
depressive-like behaviour evident through reduced
exploratory behaviours, increased latency to feed, and
increased latency to escape in SERT (+/+) and (+/-)
offspring. Had no effect on SERT (-/-) offspring.
OFT – reduced ambulatory time (-18 to -30%)
EPM – reduced entries into either arms (-10 to -22%)
NSF – increased latency to feed (+60 to +45%)
NIH – increased latency to drink (+83 to +100%)
SE – increased latency to escape (+25 to +38%)
Summary – SSRI exposed had increased anxiety- and
depressive-like behaviour and reduced exploratory
behaviour.

Ansorge et al.,
(2004)

Species/Strain
SERT Knockout Mice (+/+)( +/-)(-/-)
(n= 13-27/group)
Dose
Fluoxetine 10mg/kg
Route and Duration
PN4 – PN21 IP

PN84 (adult)
OFT
EPM

Ansorge et al.,
(2008)

Species/Strain
SERT Knockout Mice (+/+)( +/-)
(n= 32-65/group)
Dose
Fluoxetine 10mg/kg
Desipramine 10mg/kg
Citalopram 10mg/kg
Clomipramine 20mg/kg

PN84 (adult)
OFT
EPM
NSF
Novelty Induced
Hypophagia (NIH)
Shock Escape (SE)
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Route and Duration
PN4 – PN21 IP
Zheng et al., (2011)

Species/Strain
GFP-transgenic mice and wild-type
C57 mice. (n/group not specified)
Dose
Fluoxetine (10mg/kg)
Fluvoxamine (10mg/kg)
Route and Duration
PN4 – PN21 IP

PN91 (adult)
OFT

OFT – decreased distance travelled (-37%)
Summary – SSRI exposure increased anxiety-like
behaviour evident through decreased exploratory
behaviour.

Karpova et al.,
(2009)

Species/Strain
C57BL/6 Mice (n= 9-12/group)
Dose
Fluoxetine (10mg/kg)
Route and Duration
PN4 – PN21 IP

PN110 (adult)
Light-Dark Test (LDT)
OFT
FST

Lee, (2009)

Species/Strain
Wistar Rats (n = 12 – 15/group)
Dose
Fluoxetine (10mg/kg)
Route and Duration
PN0 – PN6 SC

PN30 – 35 (adolescence)
HPT
Gap-Crossing Test (GCT)
OFT

Rodriguez-Porcel et
al., (2011)

Species/Strain
Long Evans Rats (n = 12 – 22/group)
Dose
Fluoxetine (5mg/kg)
Citalopram (10mg/kg)
Bupropion (15mg/kg)

PN25 – 39 (adolescence)
Locomotor Tone (LT)
Novel Object Approach
(NOA)
Juvenile Play (JP)
PN89 – 184 (adult)
Object-Conspecific

LDT – reduction in rearing (-42%) and increased immobility
(+11%)
OFT – reduced rearing (-30%) increased immobility in
central arena (+42%)
FST – decreased immobility time (-38%)
Summary – SSRI-exposed offspring had increased anxietylike behaviour but reduced depressive-like behaviour.
HPT – increased latency to first licking (+110%)
GCT – decreased crossable gap distance (-36%)
OFT – decreased total (-20%) and central (-37%)
ambulation and decreased rearing (-19%)
Summary – SSRI-exposed offspring exhibited greater pain
thresholds. Impaired environmental perception (gapcrossing test) and increased anxiety-like behaviour.
Adolescence (PN25-39)
LT – increased immobility in response to tone (+180%)
NOA – reduced time spent investigating the novel object (33%) in males
JP – reduced pinning (-82 to -98%) in males and boxing in
both male (-71 to -80%) and females (-71%).
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Route and Duration
PN8 – PN21 2x daily SC

Preference (OCP)
SB

Adult (PN89-184)
OCP – reduced time spent investigating conspecific subject
(-58%)
SB – disrupted mounting behaviour
Summary – SSRI-exposure increased anxiety-like
behaviour and impaired social and sexual behaviour in
offspring.
Abbreviations: Flx = Fluoxetine; Flv = Fluvoxamine; GD = Gestational Day; PN = Postnatal Day; NG = Negative Geotaxis; OFT = Open Field Test; RT =
Rotarod Test; MWM = Morris Water Maze; EPM = Elevated Plus Maze; PA = Passive Avoidance Test; LRN = Locomotor Response to Novelty; FST = Forced
Swim Test; IRT = Intruder Resistant Test; HPT = Hot Plate Test; PAT = Passive Avoidance Test; PPI = Prepulse Inhibition Test; SB = Social Behaviour; NSF =
Novelty-Suppressed Feeding; CPA = Conditioned Place Aversion; EPMS = Elevated Plus Maze after Stress; SPT = Sucrose Preference Test; ASP = Adolescent
Social Play; AdSP = Adult Social Play; SeB = Sexual Behaivour; IP = Intraperitoneal; SC = Subcutaneous; HL = Horizontal Ladder; FC = Fear Conditioning; EZM
= Elevated Zero Maze; CWM = Cincinnati Water Maze; MB = Marble Burying Test; SCS = Straight Channel Swimming; NIH = Novelty Induced Hypophagia;
SE = Shock Escape Test; LDT = Light-Dark Test; GCT = Gap-Crossing Test; LT = Locomotor Tone; NOA = Novel Object Approach; JP = Juvenile Play; OCP =
Object Conspecific Recognition
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There is mounting evidence from human and animal studies to suggest neurobehavioural
alterations in offspring exposed to SSRIs (Tables 1.1 and 1.3). Understanding the biological
foundations of such exposure might help elucidate causative mechanisms underlying
behavioural alterations and increased risk profiles and assists in the development of
appropriate preventative strategies.

As SSRIs bind to and inhibit SERT, resulting in increased synaptic levels of serotonin, it is
reasonable to hypothesise that SSRI exposure could lead to altered development of aspects
of the serotonin system. Several studies have focused on the effect of developmental SSRI
exposure on the developmental expression of SERT. Specifically, it was reported that SERT
densities at adolescence (PN28) were significantly increased in the hippocampus, amygdala
and lateral hypothalamus, decreased in the dorsomedial hypothalamus and substantia nigra,
and unchanged in the raphe nuclei, of fluoxetine-exposed rodent offspring (Cabrera-Vera and
Battaglia, 1998). The findings indicated brain region specific changes and a particular
vulnerability of the limbic system (Cabrera-Vera and Battaglia, 1998). Interestingly, the same
study noted no significant differences in SERT densities between exposed and control groups
at adulthood (PN70), suggesting that the effects of developmental SSRI exposure on SERT are
transient in nature and become negligible in later life (Cabrera-Vera and Battaglia, 1998). On
the contrary another study reported reductions in SERT expression in the raphe nucleus that
persisted during adolescence (PN20) and adulthood (PN90) following exposure to fluoxetine
(Noorlander et al., 2008). The same study also reported increases in anxiety- and depressivelike behaviour at both PN20 and PN90 in offspring exposed to SSRIs in-utero, providing a
potential behavioural translation to the alterations in SERT expression (Noorlander et al.,
2008). Another study assessing serotonergic neurons in the raphe nucleus of offspring at
PN56 reported marked reductions in neuronal number and axonal terminals as a result of SSRI
exposure (Silva et al., 2010). The contrast in findings in the raphe nucleus between these
studies (Cabrera-Vera and Battaglia, 1998 and Noorlander et al., 2008) may be attributed to
the use of different species (rat vs. mouse) as well as different drug doses and administration
methods (10mg/kg s.c. vs. 0.8mg/kg i.p. fluoxetine). Interestingly, a high maternal fluoxetine
dosage did not produce longer lasting changes in SERT expression in the brain of offspring
(Cabrera-Vera and Battaglia, 1998), which seems paradoxical but may allude to a greater
influence of the drug administration method used in these studies. Accordingly, unlike
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subcutaneous, the pharmacokinetics of intraperitoneal injections parallels those
administered orally given that they are absorbed through the mesenteric vessels and undergo
first pass metabolism by the liver (Turner et al., 2011), and could result in a greater ratio of
active metabolite to parent drug.

Taken together, it may be suggested that SERT expression is altered through a) decreased
serotoninergic neurons at their origin (raphe nucleus) and hence decreased SERT expression,
and/or b) alterations in serotonergic afferents to areas including the hippocampus and the
subsequent altered expression of SERT, or c) the down/up-regulation of SERT in response to
increased extracellular serotonin. Surprisingly, given the effect of SSRIs on the serotonergic
system, there have been no studies to-date that have assessed the potential alterations to
serotonergic receptors or associated signaling. Considering that SERT knock-out (KO) rodents
have shown reduced 5HT1A receptor binding in the raphe, hypothalamus, amygdala and
septum (Li et al., 2000), and increased 5HT2A/2C receptor binding in the hypothalamus and
amygdala (Li et al., 2003), this is clearly an area that warrants further investigation.

Given the neurotrophic role of serotonin during neurodevelopment (Gaspar et al., 2003a),
animal studies have also focused on the effects of developmental SSRI exposure on dendritic
and neuronal mapping, and markers of neurogenesis, growth and development in offspring
(Table 1.4). All studies report significant cellular alterations to some extent with varying SSRI
exposure duration, dosage and exposure time points (Lee, 2009; Lee and Lee, 2012; Silva et
al., 2010; Smit-Rigter et al., 2012; Swerts et al., 2010; Zheng et al., 2011). Exposing embryos
to SSRIs during gestation induced significant morphological alterations, such as a decrease in
neuronal number in the foetal frontal lobe at GD21 following 10mg/kg fluoxetine treatment
on GD9, 10 and 11 (Swerts et al., 2010). This study provides clear evidence of neuronal
alterations in exposed offspring; however, examination of any potentially permanent
alterations from birth to adulthood is required. Another study assessed pyramidal neuronal
complexity (quantified by measuring dendritic branching and length) throughout adolescence
to adulthood and reported a significant reduction in complexity following administration of
0.6mg/kg/day fluoxetine to dams during GD8 – GD18 (Smit-Rigter et al., 2012). The study
provided evidence to suggest alterations caused by SSRI exposure persist to adulthood.
As discussed previously, a limited number of animal studies assess the effects of
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developmental SSRI exposure in clinically relevant models. Several recent studies have
assessed the effects of SSRI exposure on the neurobiology of offspring using a model of
maternal adversity by subjecting dams to stress (Boulle et al., 2016b, 2016a; Gemmel et al.,
2019, 2018, 2017, 2016; Rayen et al., 2011) or injections of corticosterone (Gobinath et al.,
2017). Although slightly varied in methodology, these studies collectively show significant
influences

of SSRI exposure in animal models of stress (Table 1.4). One study reported a

decrease in hippocampal neurogenesis and proliferation, and increase in depressive-like
behaviour in adolescent offspring exposed to maternal stress (Rayen et al., 2011). The same
study noted that these findings were corrected when the offspring were also exposed to
maternal SSRI treatment (Rayen et al., 2011), suggesting that SSRI-exposure has the potential
to reverse the negative effects of maternal depression on offspring, at least in relation to
hippocampal neurogenesis. In the same vein, Gemmel et al., (2018) reported that perinatal
fluoxetine exposure prevents the attenuating effects of pre-gestational stress on serotonin
and serotonin turnover in the prefrontal cortex of pre-adolescent offspring, particularly in
females. This finding adds further evidence that perinatal SSRI-exposure, but also offspring
sex, can influence the negative effects of maternal stress on offspring. It has been widely
suggested that the anti-depressive characteristics of SSRIs occurs via downstream
mechanisms by increasing BDNF expression and subsequent neurogenesis (Martinowich and
Lu, 2007). In contrast to this notion, one study assessing SSRI-exposure during development
showed reduced levels of hippocampal BDNF mRNA expression in male and female offspring
(Boulle et al., 2016a, 2016b). However, when examined in a model of maternal adversity, it
was shown that the SSRI exposure corrected an observable increase in hippocampal BDNF
induced by maternal stress in female offspring; while in the males, exposure to maternal
stress alone or in combination with fluoxetine caused no effect (Boulle et al., 2016b).
Furthermore, another study has recently shown that perinatal fluoxetine exposure increases
doublecortin, a marker of immature neurons, in the dentate gyrus of adult females (Gemmel
et al., 2019). Work by the same laboratory has also demonstrated that exposure to pregestational stress reduces hippocampal neurogenesis and synaptophysin density, a marker of
presynaptic vesicles, in the dentate gyrus of pre-adolescent males, but not females (Gemmel
et a., 2017). In agreeance with this finding, a recent study modelling postpartum depression
and SSRI treatment using daily concomitant corticosterone and fluoxetine injections also
found that males were more susceptible to the deleterious effects of stress with
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corticosterone exposure reducing hippocampal doublecortin levels at pre-adolescence
(Gobinath et al., 2017). The study also reported that fluoxetine exposure decreased
doublecortin in the hippocampus of pre-adolescent females, but not males, irrespective of
corticosterone exposure (Gobinath et al., 2017). Collectively these studies suggest that
females may be more vulnerable to the effects of developmental SSRI exposure in early ages,
whilst males are more susceptible to the effects of maternal depression and/or adversity
alone. Ultimately, these sex-specific findings highlight the need for a greater focus on
assessing the influence of sex on SSRI exposure and outcomes of maternal adversity.
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Table 1.4: Effects of maternal antidepressant administration on biological measures in exposed offspring: evidence from animal studies.
Study (Shaded studies Species, Strain, Drug Dose, Route and Duration
indicates those
implementing models
of maternal
depression/adversity).
Prenatal/maternal exposure
Fornaro et al., (2007)
Species/Strain
Sprague-Dawley rat dams. (n=9 to 11/group)
Dose
Fluoxetine (10mg/kg)

Analyses

Main Findings

Serotonin concentrations in
Placenta and foetal lungs

• Prenatal FLX exposure significantly reduced
(-38%) placental tissue serotonin content. Did
not alter lung serotonin content.

Rat foetuses were collected
via caesarean section on
GD21

Route and Duration
Oral gavage daily to dams from GD11 to GD21

Gemmel et al., (2017)

Species/Strain
Sprague-Dawley Dams
(n= 10-16/group)
Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX

Pre-adolescent rats
Blood Samples
- Corticosterone
- Corticosterone binding
globulin capacity
Brain Samples for
monoamines using HPLC-ED
- 5HT, 5HTIAA, DA and HVA
- 5HIAA/5HT and HVA/DA

• Perinatal FLX exposure increased serum
corticosteroid binding globulin, hippocampal
5HT levels, and synaptophysin in the dentate
gyrus
• Pre-gestational stress resulted in decreased
hippocampal neurogenesis and
synaptophysin density in the dentate gyrus of
pre-adolescent males, but not females

Dose
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Fluoxetine (5mg/kg)
Route and Duration
Orally to dams in wafer biscuit GD10 – PN21
Females subjected to chronic unpredictable
stress (damp bedding, food deprivation, 5 min
of forced swim, restraint under bright light for
1hr, and cage rotation for 12 hours.
(Gemmel et al., 2018)

Species/Strain
Sprague-Dawley Dams
(n= 6-16/group)
Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX
Dose
Fluoxetine (5mg/kg)

Immunohistochemistry
- PSD-95
- Synaptophysin
- Glucocorticoid Receptor
(GR)
- Doublecortin (DCX)

Pre-adolescent and adult
Brain Samples for
monoamines using HPLC-ED
- 5HT, 5HTIAA, DA, DOPAC
and HVA
- 5HIAA/5HT, HVA/DA,
DOPAC/DA

• perinatal fluoxetine exposure prevented the
attenuating effects of pre-gestational stress
on 5HT and 5HT turnover in the PFC of preadolescent offspring, particularly in females
• Pre-gestational stress reduces synaptic
markers, PSD-95 and synaptophysin,
particularly in males.

Immunohistochemistry
- PSD-95
- Synaptophysin
- Glucocorticoid Receptor
(GR)

Route and Duration
Orally to dams in wafer biscuit GD10 – PN21
Females subjected to chronic unpredictable
stress for three weeks prior to breeding, 0-2
stressors per day (damp bedding, food
deprivation, 5 min of forced swim, restraint
under bright light for 1hr, and cage rotation for
12 hours.
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(Gemmel et al., 2019)

Species/Strain
Sprague-Dawley Dams
(n= 8-16/group)
Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX
Dose
Fluoxetine (5mg/kg)

Adult rats
Blood Samples
- corticosterone
- estradiol
- testosterone
Immunohistochemistry
- PSD-95
- Synaptophysin
- Glucocorticoid Receptor
(GR)
- Doublecortin (DCX)

• perinatal fluoxetine exposure decreased GR
density in the hippocampal CA3 region of
male offspring, and increased GR density in
the dentate gyrus of females
• perinatal fluoxetine exposure increased
DCX+ cells in the dentate gyrus of females,
but reduced PSD-95 in the hippocampal CA2
region in both sexes.
• In the dentate gyrus, exposure to pregestational stress reduced DCX+ cells in males,
and GR density in females

Route and Duration
Orally to dams in wafer biscuit GD10 – PN21
Females subjected to chronic unpredictable
stress for three weeks prior to breeding, 0-2
stressors per day (damp bedding, food
deprivation, 5 min of forced swim, restraint
under bright light for 1hr, and cage rotation for
12 hours.
Noorlander et al.,
(2008)

Species/Strain
Mice (C57BI/6-JIco) (n= 3-6/group)
Dose
Fluoxetine (0.3, 0.6 or 0.8mg/kg).

Dorsal raphe nucleus
examined via
autoradiography for SERT
binding (PN20 and PN90)

• Significant decreases at PN20 (-40%) and
PN90 (-53%) in SERT binding in the raphe
nucleus after prenatal exposure to FLX
compared to controls (dose-dependent
exposure).

Route and Duration
I.P. injection daily to dams from GD8 to GD18.
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(Gobinath et al.,
2017)

Species/Strain
Sprague-Dawley Dams
Groups
Oil + Saline
Oil + FLX
CORT + Saline
CORT + FLX

Pre-adolescent, adolescent
and adult offspring
- DCX
immunohistochemistry

• Postnatal fluoxetine exposure decreased
DCX density in the dorsal hippocampus of preadolescent female, but not male offspring.
• Postnatal fluoxetine prevented the increase
in density of DCX+ cells from adolescence to
adulthood in dorsal hippocampus of females
• Postnatal cortisol exposure reduced density
of DCX+ cells in pre-adolescent males, and
increased density in dorsal hippocampus of
both adolescent male and females

Dose
Fluoxetine (10mg/kg/day).
Corticosterone (40mg/kg/day)
Route and Duration
S.C. injection daily to dams from PN2 to PN24.
Cabrera-Vera &
Battaglia (1998)

Species/Strain
Sprague-Dawley Dams
(n= 7/group)
Dose
Fluoxetine (10mg/kg)
Route and Duration
S.C. injection daily to dams from GD13 to GD20

PN28 and PN70
Cortex, hippocampus,
septum, amygdala, basal
ganglia and raphe nucleus –
autoradiography for SERT
binding.

PN28 Following prenatal FLX exposure
• Significant increases in SERT densities in the
CA2 and CA3 areas of the hippocampus (+47%
and +38% respectively).
• Significant increases in SERT densities in
basolateral (+32%) and medial (+44%)
amygdaloid nuclei and lateral hypothalamus
(+21%) of offspring compared to controls.
• Significant reductions in SERT densities in
dorsomedial hypothalamus (-21%) and
substantia nigra (-19%)
•Nil significant differences in SERT densities in
raphe nucleus
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PN70 Following prenatal FLX exposure
• nil significant differences in SERT densities in
any examined brain regions compared to
control
Female offspring
study
Boulle et al., (2016a)

Male offspring study
Boulle et al., (2015b)

Species/Strain
Sprague-Dawley Dams
(n= 7/group)
Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX
Dose
Fluoxetine (5mg/kg)
Route and Duration
Osmotic minipumps from PN1 to PN21.

Offspring (PN168)
Hippocampus
- Quantitative reverse
transcriptase PCR (qRT-PCR),
analyses of genes associated
with BDNF/TrKB signalling
pathway
- Chromatin
immunoprecipitation (ChIP),
quantification of fragments
of promoter regions of
target genes in BDNF/TrKB
signalling pathway

Dose
Fluoxetine (98.5µg/kg)

• Significant negative correlation (r = -0.33, p
= 0.02) between hippocampal BDNF exon IV
mRNA levels and immobility in the forced
swim test.
Male
• Significant decreases in BDNF IV (-20%) and
TrKB (-40%) mRNA expression in the
hippocampus of FLX-exposed offspring.
• Significant decreases in hippocampal BDNF
mRNA (-20%) expression of prenatally
stressed subjects regardless of treatment.

Stress (exposure to confinement and bright
light for 45min) induced on GD15-20 to
assigned dams, occurring 3x daily and 2x on
GD21.
Morrison et al., (2004) Species/Strain
Sheep ewe (n=7-8/group)

Female
• Significant decreases in hippocampal BDNF
exon IV mRNA levels in FLX-exposed offspring
(-10% non-stressed group; -20% stressed
group)

Foetal blood (sampled daily
during infusion period, 8
days).
- ACTH
- Cortisol
- FLX

• Significant increase (+115%) in FLX exposed
foetal plasma cortisol concentrations on
infusion day(s) 6, 7 and 8.
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Rayen et al., (2011)

Route and Duration
Polyvinyl catheters to dam for 8 days,
commencement ranged from GD118 – 122 ±4-5
days.
Species/Strain
Sprague-Dawley (n=9-11/group)
Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX

• Significant increase (+102%) foetal plasma
ACTH concentrations on infusion day 7 in FLX
exposed
Immunohistochemistry
(PN42)
- Hippocampus and dentate
gyrus number of
proliferating cells and
immature neurons.

• FLX exposure significantly reversed the
decrease in hippocampal cell proliferation
and hippocampal neurogenesis in prenatally
stressed offspring to levels comparable to
control.

Offspring brains collected to
determine complexity of
dendritic tree of layer 2/3
pyramidal neurons in the
somatosensory cortex at
three ages (PN6-9, PN60 and
PN>365).

• Significant reduction (~50%) in complexity
of 2/3 pyramidal neurons of fluoxetine
exposed animals. Reduction in complexity was
evident at all life stages (PN6-9, PN60,
PN>365)

Dose
Fluoxetine (5mg/kg)
Route and Duration
Osmotic minipumps from PN1 to PN21.
Stress (exposure to confinement and bright
light for 45min) induced on GD15-20 to
assigned dams, occurring 3x daily and 2x on
GD21.
Smit-Rigter et al.,
(2012)

Species/Strain
Mice (C57/BL6J)
Dose
Fluoxetine (0.6mg/kg)
Route and Duration
I.P. injections to dams from GD8 – GD18.

Complexity of dendritic tree
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Swerts et al., (2010)

Species/Strain
Wistar Rats
Dose
Fluoxetine or Imipramine (10mg/kg)
Route and Duration
I.P. injections to dam on GD9, GD10 and GD11

Postnatal/pup exposure
Silva et al., (2010)
Species/Strain
Wistar Rat pups (n=5/group)
Dose
Fluoxetine (10mg/kg)
Route and Duration
S.C. injections daily to pups from PN1 to PN21

was quantified using the
Dendritic Complexity Index
(DCI), which takes into
consideration dendritic
branching and dendritic
length.
Dams euthanized GD21, and
foetuses extracted.
Foetal brains collected and
analysed via optical
microscope for visual
quantification of frontal lobe
nerve cell bodies.

2 months of age (~PN56)
subject brains collected for
morphometric analysis of
5HT neurons in the dorsal
(DR) and median (MnR)
raphne nuclei, and
hippocampal dentate gyrus
(DG).
Morphometric parameters
of serotonergic neurons
- Perimeter (PER)

• Significant decreases in the number of
frontal lobe neurons in FLX (-6%) and IMIP (23%) exposed offspring compared to control

• Significant reduction in neuron number of
the DR (-26%), and reduced 5HT terminals (63%) in the DG of FLX exposed compared to
vehicles.
• Significant reduction in all morphometric
parameters of serotonergic neurons.
DR
- Perikaryal area (-18%), Dmax (-9.6%), Dmin (17%), Perikaryal perimeter (-9.6%).
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Lee (2009)

Lee & Lee (2011)

Species/Strain
Wistar Rat Pups (n=36 to 42/group)

MnR
- Perikaryal area (-23%), Dmax (-13%), Dmin (10%), Dmed (-14%) Perikaryal perimeter (13.5%).

PN7 and PN35

• Significant reduction (-51%) in number of
terminal tips of Thalamocortical afferent
arbors

Dose
Fluoxetine (10mg/kg)

Dil Labelling of
Thalamocortical Afferents
(somatosensory cortex)

Route and Duration
S.C. injections daily to pups from PN0 to PN6.

Golgi-Cox impregnation
(somatosensory cortex)

Species/Strain
Wistar Rat Pups (n=7 to 9/group)
Dose
Fluoxetine (20mg/kg)
Dose and Duration
S.C. injections daily to pups from PN0 to PN4

Zheng et al., (2011)

- Maximum, minimum and
median diameters (Dmax,
Dmin and Dmed).

Species/Strain
Male GFP-Transgenic mice or wild-type C57
mice
Dose
Fluoxetine or Fluvoxamine (10mg/kg)

PN35
Immunochemistry
- cerebellum (Purkinje cells)
Golgi-Cox Impregnation
- Striatum (dendritic
structure)
- Layer 5 pyramidal neurons
of primary motor cortex
Confocal imaging of
hippocampus neuronal
development – spinal
densities of CA1 neurons
were assessed at PN22
(adolescence) and PN90
(adult) stages.

• Significant reduction in dendritic field (27%), shorter dendritic length (-20%) and
fewer terminal endings (-20%) in FLX exposed
compared to vehicle.
• Significant reduction in dendritic spines of
the 2nd (-43%), 3rd (-42%) and 4th (-40%)
dendritic orders.
•Significant reduction in bifurcation nodes (25%), terminals (-25%) and dendritic length (38%) of medium spiny striatal neurons and
Layer 5 pyramidal M1 neurons.
• No significant differences in Purkinje cell
density and soma size between treatment
groups
• Significant reduction (-10%) in spine density
of basal dendrites at PN22 of SSRI exposed
groups
• Significant reduction (-16%) in spine density
of apical dendrites at PN22 of those exposed
to fluvoxamine
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Route and Duration
I.P. injections daily to pups from PN4 to PN21

• Significant increase (+15%) in spine density
of basal dendrites at PN90 of SSRI exposed
groups

• Significant increase (+13%) in spine density
of apical dendrites at PN90 of those exposed
to fluoxetine.
Abbreviations: FLX = fluoxetine, DA = dopamine, NE = norephinephrine, 5-HT = 5-hydroxytryptamine receptors, DOPAC = 3,4-dihydroxyphenylacetic acid,
5-HIAA = 5-hydroxyindoleacetic acid, HVA = homovanillic acid, s.c. = subcutaneously, SERT = serotonin transporter, GD = gestational day, PCo2 = partial
pressure of carbon dioxide, PO2 = partial pressure of oxygen, ACTH = adrenocorticotropic hormone, i.p. = intraperitoneal, CBG = corticosteroid binding
capacity, GR = glucocorticoid receptor, GRIP1 = glucocorticoid receptor interacting protein, MR = mineralcorticoid, DCX = doublecortin, IMIP = imipramine.
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1.1.5 Considerations for Animal Studies

Animal studies, whilst being a step away from the clinic, have begun to address the
question of whether the reported adverse effects of maternal SSRI treatment on
offspring are the result of SSRI exposure or a response to innate maternal depression
and/or adversity. However, limitations and challenges arise when translating preclinical
findings to the clinical scenario. Animal studies have been useful in the assessment of
the molecular effects of SSRI exposure on offspring; however, they have largely focused
on the serotonergic system and neuronal topography, with evidence suggesting that
SSRI exposure can produce alterations to serotonergic (Raphe) neuronal number, SERT
densities and neuronal/dendritic mapping in offspring (see Table 1.4). Further
examination of other neurotransmitter systems implicated in the neurobiology and
pathology of various developmental neuropsychiatric disorders is required. Human
studies have suggested an increased risk of ADHD, ASD and depression in SSRI-exposed
offspring; disorders which are characterized by gross alterations in glutamatergic and
neurotrophic signalling (Brambilla et al., 2003; Castrén and Rantamäki, 2010; Coghlan et
al., 2012; Dölen et al., 2007; Duman et al., 2000; Dwivedi et al., 2003; Hashemi et al.,
2016; Hashimoto, 2010; Homberg et al., 2014; Kim et al., 1982; Knable et al., 2004;
Küçükibrahimoğlu et al., 2009; Lin and Sibille, 2013; Mitani et al., 2006; Sanacora et al.,
2012). Indeed, the purported increased risk of inducing developmental disorders
associated with maternal SSRI exposure could be related to the perturbed development
of a range of systems, not only serotonin itself. Investigation of other neurotransmitter
and neurotrophic systems would provide valuable insight into broader alterations
caused by maternal SSRI exposure and form a basis for future studies. In addition, with
the exception of studies that model maternal depression using environmental stressors,
most studies administer SSRIs to healthy dams, which does not represent the clinical
scenario. Indeed, the very presence of maternal depression, a disorder characterized by
an underlying serotonergic pathology, could influence the effects of maternal SSRI
exposure on offspring. One current animal model of depression, the Wistar-Kyoto rat
(WKY), exhibits serotonergic and behavioural abnormalities similar to human depressive
disorder (Arango et al., 2001; Lemos et al., 2011; Paré, 1994; Pare and Tejani-Butt, 1996;
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Quan-Bui et al., 1984; Scholl et al., 2010; Sullivan et al., 2006; Zhang et al., 2005) and
could provide an invaluable tool for investigating the effects of SSRI exposure in a more
clinically relevant setting. For example, the WKY exhibits increased anxiety- and
depressive-like behaviour, decreased basal serotonin and 5HIAA concentrations,
decreased SERT density in hippocampal and cortical brain regions, decreased 5HT 1a
receptor density and a reduction in the serotonin rate limiting enzyme, tryptophan
hydroxylase; all of which have been reported in clinical cases of MDD (Arango et al.,
2001; Lemos et al., 2011; Paré, 1994; Pare and Tejani-Butt, 1996; Quan-Bui et al., 1984;
Scholl et al., 2010; Sullivan et al., 2006; Zhang et al., 2005). Acknowledging that MDD is
not characterised by abnormalities in the serotonergic system alone, these serotonergic
alterations in both clinical cases of MDD and the WKY rat could underpin significant
differences in response to SSRI exposure compared to the response observed in
otherwise healthy subjects and control animals respectively. Furthermore, the few
animal studies modelling maternal adversity have shown that maternal SSRI treatment
differentially affects offspring neurodevelopment and behaviour compared to subjects
born of dams absent of adversity (Boulle et al., 2016a, 2016b; Gemmel et al., 2019, 2018,
2017; Kiryanova et al., 2016; Rayen et al., 2011). Overall, further research utilising
appropriate models of depression or adversity are required in order to determine the
effects of maternal SSRI exposure on offspring in a clinically relevant setting.

1.1.6 The Wistar-Kyoto: A rat model of endogenous depression
The WKY rat strain has long been established as a model of depression. Initially
developed from the Wistar strain as a normotensive control for the spontaneously
hypertensive rat in 1963 (Okamoto and Aoki, 1963), the WKY displayed increased
behavioural abnormalities compared to other strains (Wistar, Fisher 344, Lewis and
Sprague-Dawley) likened to symptoms seen in clinical MDD (Armario et al., 1995; LópezRubalcava and Lucki, 2000; Nam et al., 2014; Pare and Tejani-Butt, 1996; Rittenhouse et
al., 2002). The WKY strain has since been assessed in a wide range of neurobehavioral
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test batteries where it has displayed exaggerated stress responses, increased
anhedonia, learned helplessness, novelty-induced hypophagia, neophobia, decreased
locomotor activity and increased anxiety- and depressive-like behaviours in the elevated
plus maze, open field test, forced swim test, defensive burying test, passive-avoidance
test, novelty-suppressed feeding and sucrose preference test (Burke et al., 2016, 2016;
López-Rubalcava and Lucki, 2000; Millard et al., 2019; Nam et al., 2014; Pare and TejaniButt, 1996; Rittenhouse et al., 2002; Will et al., 2003). Furthermore, altered emotional
behaviours in the WKY strain have been detected as early as postnatal day 10 (Braw et
al., 2008). Ultrasonic vocalisations produced by infant offspring during maternal
separation were attenuated in WKYs compared to Wistars (Braw et al., 2008). The
abnormal rates of ‘separation-protest’ vocalisations were also accompanied by a
reluctance for WKY offspring to seek proximity to their dams (Braw et al., 2008). The
WKY strain also shows some resistance to the effects of cross-fostering. Specifically,
WKY offspring, cross fostered with Sprague-Dawley and Spontaneously Hypertensive
Rat dams retain their anxiety- and depressive-like behaviours (Howells et al., 2009),
suggesting that maternal behaviour may not be driving the depressive-like phenotype in
the offspring. Ultimately, preclinical evidence has shown that the WKY strain displays
robust depressive-like behavioural phenotypes like that observed in clinical cases of
MDD. Furthermore, phenotypes present in the WKY strain are detected at an early age
and largely persist despite maternal behaviour. Preclinical models of depression, such
as the WKY strain, are therefore useful to investigate the neurobiology of major
depressive disorder, and to test novel treatment strategies.

Investigations into the neurobiology underlying the depressive-like phenotype of the
WKY strain has focused largely on the serotonergic system and the HPA axis, with some
emerging research on neurotrophic and neuroinflammatory markers (Gormley et al.,
2016; Kin et al., 2017; Lemos et al., 2011; Scholl et al., 2010; Will et al., 2003). However,
alterations to the glutamatergic system have more recently been implicated in the
pathophysiology of major depressive disorder (Autry et al., 2011; Berman et al., 2000;
Sanacora et al., 2012, 2008), with the ‘glutamate hypothesis’ of MDD becoming an
increasingly investigated theorem (Musazzi et al., 2012). Recently this hypothesis has
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evolved to suggest that the glutamate system is the key mediator of neuropsychiatric
pathophysiology, and potentially, that the therapeutic effects of antidepressant drugs
are all derived from their final influence on the glutamatergic system (Sanacora et al.,
2008), which could provide an alternate therapeutic target for treatment resistant
depression. Indeed, one fundamental observation contributing to this hypothesis is the
fact that SSRIs have a delayed onset of therapeutic effect. This effect is thought to occur
due to serotonin’s influence on downstream mechanisms such as growth factors
including BDNF which in turn, alter the morphology of glutamatergic neurons
(Martinowich and Lu, 2007). The NMDA receptor antagonist Ketamine, which targets
the glutamatergic system directly by blocking NMDA receptors, upregulating
postsynaptic AMPA receptors and increasing BDNF transcription, possesses rapid
antidepressant effects (Zanos and Gould, 2018; Zhou et al., 2012). Accordingly, evidence
from a growing body of clinical and preclinical literature provides further evidence of
glutamatergic dysfunction underlying MDD, shifting the focus from a solely
monoaminergic based disorder. Based on clinical observations of the use of Ketamine in
MDD (Zanos and Gould, 2018), it is plausible to suggest that an underlying alteration in
glutamatergic function or signaling may also be contributing to the behavioural
phenotypes observed in the WKY strain. Ultimately, the WKY strain presents itself as a
robust tool for dissecting the neurobiology of novel glutamatergic ADDs, and the
pathophysiology underlying MDD.

1.1.7 Summary
In summary, the current body of evidence suggests that maternal SSRI treatment may
cause perturbations to the neurobiology, behaviour and ultimately risk for
neurodevelopmental disorders in exposed offspring. However, conflicting findings do
persist and the evidence summarized here regarding the safety of SSRI use during
pregnancy or whilst breast feeding is far from conclusive. Evidence from human studies
suggest that SSRI exposure during neurodevelopment may be associated with an
increased risk for neurodevelopmental disorders, such as ADHD and ASD, and mood
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disorders including depression; however, these studies are often confounded by the
presence of the underlying maternal psychopathology. Difficulties in quantifying or
accounting for the symptom severity of the maternal psychopathology are often
inherent to clinical studies, and since SSRI treatment could be phenotypically masking
symptoms, the findings warrant careful consideration. Furthermore, given that
untreated maternal depression and adversity themselves are associated with an
increased risk for neurodevelopmental disorders; maternal SSRI use could in fact be a
marker of symptom severity of the underlying mood disorder, which itself contributes
to the reported risk. Contrary to this notion, preclinical studies have reported alterations
in behaviour and neurobiology in offspring as the result of developmental SSRI-exposure
in otherwise healthy animals, suggesting that SSRI exposure can cause long lasting
perturbations to neurodevelopment, irrespective of the innate maternal mood disorder.
In the clinic, SSRI treatment and an underlying mood disorder occur in combination and
it may be that the underlying mood disorder confers a degree of resistance (or
exacerbation), or at least influences the effects of SSRI-exposure on offspring. The
pervading question that remains unanswered is: if SSRI use does increase the risk of
neurodevelopmental disorders in offspring, which of the two factors - the underlying
maternal psychopathology or the SSRI treatment – has a greater influence on this risk.
Further research utilizing models of depression is required in order to clarify the answer
to this question in a manner that truly discerns the effects of SSRI-exposure from the
innate maternal mood disorder on offspring neurodevelopment and risk for associated
disorders. Considering the number of women prescribed ADDs during pregnancy,
further research into this area is warranted.
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Aims and Hypotheses
1.1.8 General Aim:
Aim 1: To investigate the effects of perinatal antidepressant treatment (fluoxetine) on
male and female offspring behavior and neurobiology relevant to neurodevelopmental
and neuropsychiatric disorders and determine how these effects differ between a
standard laboratory rodent strain (SD) and a rodent model of innate depression (WKY).

Aim 2: The glutamatergic and neurotrophic profile of the WKY rat has not been
thoroughly investigated despite the observation that these systems are altered in clinical
cases of major depressive disorder. Thus, as a secondary aim, we sought to investigate
the strains’ neurobiological profile to determine the neural underpinning of its
depressive-like phenotype and relevance to the clinic.

1.1.9 Specific Aims:
Aim 1: To investigate the effects of perinatal fluoxetine treatment on anxiety- and
depressive-like behaviours in male offspring and measures of key glutamatergic
markers, NMDA and group 1 metabotropic glutamate receptors, and associated
scaffolding proteins in the PFC and HPC at adolescence.

Aim 2: To investigate the effects of perinatal fluoxetine treatment on anxiety- and
depressive-like behaviours in female offspring and measures of key glutamatergic
markers, NMDA, AMPA and group 1 metabotropic glutamate receptors, and associated
scaffolding proteins in the PFC and HPC at adolescence.

Aim 3: To investigate the effects of perinatal fluoxetine treatment on female offspring
measures of neurotrophic factor BDNF and its receptors, TrkB and p75, as well as
measured of neuronal maturation NeuN, in the PFC and HPC of adolescent offspring.
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Aim 4: To investigate whether neurobiological changes evident in adolescence are
present in earlier development. Specifically, to investigate the effects of perinatal
fluoxetine treatment on male offspring measures of key glutamatergic markers, NMDA,
AMPA and group 1 metabotropic glutamate receptors, and associated scaffolding
proteins in the PFC and HPC at postnatal day 14.

1.1.10 Rationale and Hypotheses
The hypotheses of this research studies were:
1. Perinatal exposure to fluoxetine treatment will result in behavioural alterations
such as increases in anxiety- and depressive-like behaviours. Moreover, these
behaviours will coincide with alterations in neurobiology relevant to
neurodevelopmental, psychiatric and affective disorders including changes in
glutamatergic and neurotrophic signaling, and neuron cell counts. Furthermore,
the changes will be differentially influenced by sex and strain.

2. The Wistar-Kyoto rodent model of endogenous depression will exhibit increases
in anxiety-like behaviours, a reduced propensity to explore, and increased
immobility in aversive situations. In addition, the strain will exhibit alterations in
glutamatergic and neurotrophic signaling at adolescence, and changes in
morphological measures of neuronal maturation, likened to those seen in clinical
cases of major depressive disorder. It is hypothesized that alterations in
glutamatergic signaling will be present in the strain at early developmental time
periods (postnatal day 14) and across sexes at adolescence.
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Chapter 2

2.1 Study rationale and aims
With approximately 10% of pregnant women prescribed antidepressant drugs for the
treatment of depressive disorders, there is a growing concern regarding the potential
long-term effects of this exposure on offspring. However, there is inherent difficulty in
discerning the effects of antidepressant exposure from that of innate maternal
depression in clinical studies. While there is emerging rodent research examining the
effects of maternal stress +/- antidepressant treatment on offspring, research is needed
in clinically relevant models of innate depression to determine the effects of maternal
antidepressant treatment on offspring behaviour and associated neurobiological
systems. In this study we evaluated the effect of maternal antidepressant (fluoxetine)
treatment on anxiety-like and depressive-like behaviours in male adolescent offspring.
Given that glutamatergic dysfunction has been previously linked to these behaviours as
well as neuropsychiatric and neurodevelopmental disorders in the clinic, we
additionally examined glutamatergic and associated synaptic markers in the prefrontal
cortex and ventral hippocampus of these offspring. To model the clinical scenario and
enhance the relevance of the study, the effects of maternal antidepressant treatment
was assessed using a rodent model of depression, the WKY rat strain. Furthermore, by
using the WKY, we aimed to establish the glutamatergic and behavioural profile of the
strain, compared to a control strain (SD) at adolescence. Indeed, with the growing
interest in antidepressant treatments targeting the glutamatergic system, such as
Ketamine, the WKY strain presents itself as a novel tool for investigating the
neurobiology of depressive-like phenotypes and mechanism of action of antidepressant
drugs.
2.2 Manuscript details
The results of Chapter 2 are published in the Journal of Psychopharmacology, titled
‘Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviors and
alters glutamatergic markers in the prefrontal cortex and hippocampus of male
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adolescent rats: a comparison between Sprague-Dawley rats and Wistar-Kyoto rat
model of depression’.
2.3 Author contribution
S. Millard performed the experiments, acquired and analyzed the data, wrote the first
draft of the manuscript, which all authors reviewed and approved for publication.
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Article removed for copyright reasons
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Supplementary Materials
Supplementary Table 1.1. Immunoblot antibody details

Antibody
anti-NR1
anti-NR2A
anti-NR2B
anti-PSD95
anti-mGluR1a
anti-mGluR5
anti-Neurochondrin
(Norbin)
anti-Homer1b/c
anti-β-Actin
anti-GAPDH
HRP Conjugated Secondary

Concentration
1:5000
1:5000
1:5000
1:5000
1:15 000
1:5000
1:7500

Manufacturer (Cat #)
Millipore (MAB363)
Millipore (MAB5530)
Millipore (MAB5578)
Millipore (MAB530)
Cell Signalling (D5H10)
Abcam (Ab27190)
Abcam (Ab130507)

1:7500
1:100 000
1:25 000
1:5000

Abcam (Ab211415)
Millipore (MAB1501)
Osenses (OSG00032W)
Millipore (AP307P/AP308P)
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Chapter 3

3.1 Study rationale and aims
In chapter 2, we have shown that perinatal exposure to fluoxetine increases anxiety-like
and depressive-like behaviours in male adolescent offspring of both the SD (healthy
control) and WKY (innate depression model) rat strains. Furthermore, we showed that
this was accompanied by widespread deficits in glutamatergic receptors and associated
scaffolds. The primary aim of the present study was to determine whether the effects
of perinatal fluoxetine exposure on anxiety- and depressive-like behaviours and
associated glutamatergic markers also occur in female offspring. Although limited,
previous work has demonstrated that perinatal fluoxetine exposure in models of
maternal stress reduces synaptic markers PSD-95 and synaptophysin, in exposed female
offspring, suggesting that alterations in the glutamatergic system could be present.
Secondly, considering that depressive disorders are more prevalent in females
compared to males, symptoms which commonly emerge at adolescence, we sought to
investigate the glutamatergic profile of female WKY offspring that may underlie their
depressive- and anxiety-like phenotype. This is especially relevant considering the
emergence of many new drugs for the treatment of depression that target the
glutamatergic system. For example, Ketamine, a potent NMDA receptor antagonist, is
increasingly used as a rapid acting antidepressant; this has highlighted a potential role
for the glutamatergic system in the neurobiology of depression. Accordingly, by
implementing relevant preclinical models, such as the WKY strain, we will be able to gain
a deeper understanding as to the neurobiology of depressive-like phenotypes and
mechanism of action for novel therapeutics.
3.2 Manuscript details
Chapter 3 was submitted to the journal of ‘Psychopharmacology’ and is currently under
review for publication. The manuscript is titled ‘Adolescent female Wistar-Kyoto rats
display global reductions in cortical and hippocampal NMDA receptor subunits and are
resistant to the effects of perinatal Fluoxetine exposure on anxiety- and depressive-like
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behaviours’.
3.3 Author contributions
S. Millard performed the experiments, acquired and analyzed the data, wrote the first
draft of the manuscript, which all authors reviewed and approved for publication.
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Abstract
Rationale: There is increasing concern regarding the use of selective serotonin reuptake
inhibitors (SSRIs) in pregnancy. Animal studies repeatedly show increased anxiety- and
depressive-like behaviours in offspring exposed perinatally to SSRIs, however much of
this research is in male offspring.
Objectives: The primary aim of this study was to investigate the effects of perinatal SSRI
exposure on emotionality-related behaviours in female offspring and associated
glutamatergic markers, using a clinically relevant Wistar-Kyoto (WKY) rat model of
depression. Secondly, we sought to investigate the glutamatergic profile of female WKY
offspring that may underlie their depressive- and anxiety-like phenotype.
Methods: WKY and Sprague-Dawley (SD) rat dams were treated with the SSRI, fluoxetine
(FLX; 10 mg/kg/day), or vehicle, throughout gestation and lactation (5 weeks total).
Female adolescent offspring underwent behaviour testing followed by quantitative
immunoblot of glutamatergic markers in the prefrontal cortex (PFC) and ventral
hippocampus (vHPC).
Results: Naïve female WKY offspring displayed reductions in NMDA and AMPA receptor
subunits as well as PSD-95 in both vHPC and PFC. Perinatal FLX treatment did not
influence behaviour in female WKY offspring, but did increase anxiety-like behaviour in
SD offspring. Perinatal FLX exposure did not influence NMDA or AMPA receptor subunit
expression in female WKY or SD offspring; it did however have restricted effects on
group I mGluR expression in SD and WKY offspring and reduce the glutamatergic
synaptic scaffold, PSD-95.
Conclusion: These findings suggest female offspring of the WKY strain exhibit deficits in
glutamatergic markers and are more resilient to the behavioural effects of perinatal FLX
exposure compared to SD.
Keywords: SSRI, Wistar-Kyoto, Maternal Depression, Perinatal, Neurodevelopment,
Antidepressant
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1. Introduction
The incidence of major depressive disorder (MDD) is on the rise (Huybrechts et al.,
2013a; Kessler, 2003), with women almost twice as likely to develop the disorder
compared to men (Albert, 2015). The greatest risk of developing MDD for women is
during childbearing years (Bennett et al., 2004); approximately 10% of women are
prescribed antidepressant drugs to ameliorate depressive and associated symptoms
during pregnancy (Bennett et al., 2004; Cooper et al., 2007; Huybrechts et al., 2013a).
Selective serotonin reuptake inhibitors (SSRIs) such as Fluoxetine (FLX), are the most
common class of antidepressant drug for the treatment of maternal depression
(Mitchell et al., 2011a; Oberlander et al., 2009a). SSRIs target the serotonergic system
by binding to and inhibiting the serotonin reuptake transporter (SERT) on the
presynaptic nerve terminal (Hiemke and Härtter, 2000a); this results in increased
serotonin within the synaptic cleft and subsequently increased serotonergic
neurotransmission (Hiemke and Härtter, 2000a). SSRIs such as FLX are highly lipophilic
in nature (Holladay et al., 1998), readily crossing the placenta (up to ~70% of maternal
levels) (Heikkinen et al., 2002a) and are present in breast milk (Hendrick et al., 2001a),
consequently exposing the neonate during the perinatal period.

During neurodevelopment, the serotonergic system is one of the first monoaminergic
neurotransmitter systems to arise (Sodhi and Sanders-Bush, 2004a). Serotonin plays a
key role in several neurodevelopmental processes including neuronal migration,
differentiation and synaptogenesis (Bonnin et al., 2007; Edgar and Price, 2001; Lavdas
et al., 1997; Sodhi and Sanders-Bush, 2004a; Vitalis and Parnavelas, 2003). In particular,
serotonin has been shown to facilitate the maturation and development of
glutamatergic neurons, particularly those in the prefrontal cortex (PFC) (Bonnin et al.,
2007; Edgar and Price, 2001; Lavdas et al., 1997; Soiza-Reilly et al., 2018; Vitalis and
Parnavelas, 2003). During development, glutamatergic neurons transiently express
SERT, where it is hypothesised that the developing neurons take up and use serotonin
as a neurotrophic factor which guides development of neuronal circuits (Sodhi and
Sanders-Bush, 2004a; Vitalis and Parnavelas, 2003). Aberrant glutamatergic signalling,
in particular via ionotropic N-Methyl-D-Aspartate (NMDA) and α-amino-3-hydroxy-5102

methyl-4-isoxazolepropionic acid

(AMPA) receptors,

in addition to Group I

metabotropic receptors (mGluRs), has been linked to several neurodevelopmental,
psychiatric and mood disorders including autism, ADHD, schizophrenia, depression and
anxiety (Deschwanden et al., 2011; Hashimoto et al., 2007; Javitt, 2004; Lakhan et al.,
2013; Musazzi et al., 2012; Rojas, 2014; Yuan et al., 2015). Accordingly, given the ability
of SSRIs to reach the developing foetus and newborn, the question arises does early
developmental SSRI exposure influence glutamatergic neurotransmission and
associated behaviours in offspring? There are conflicting reports in clinical studies
regarding the effects of perinatal SSRI exposure on behaviours and associated disorders
in offspring (for review see Millard et al., 2017). Teasing out the effects of maternal SSRI
use and the maternal psychopathology on exposed offspring in the clinic however is
difficult, and more investigation is required to fully discern the potential risk (or benefit)
associated with perinatal SSRI use.

Current preclinical literature investigating the effects of perinatal or developmental SSRI
exposure on offspring behaviour and neurobiology have reported increases in anxietyand depressive-like phenotypes and alterations in serotonergic and neuronal markers
following perinatal SSRI exposure (Millard et al., 2017). However, the limited
implementation of relevant models of depression in these studies makes it difficult to
compare to the clinic. The interaction between maternal depressive phenotypes and
SSRI use may represent a significant variable in the effects of SSRI-exposure on offspring.
To address this limitation, we investigated the effects of perinatal SSRI exposure using
an established rodent model of depression, the Wistar-Kyoto strain (WKY). We have
previously shown that perinatal FLX treatment increases anxiety- and depressive-like
behaviours and differentially alters key glutamatergic markers in the PFC and ventral
hippocampus (vHPC) of exposed male adolescent offspring (Millard et al., 2019).
Importantly, these changes were independent of rat strain, suggesting that irrespective
of maternal depressive phenotypes, male offspring are susceptible to a deleterious
effect of perinatal FLX treatment. However, the effects of SSRI exposure on female
offspring have not been as thoroughly investigated despite the fact that male and female
rodents display sexual dimorphism in baseline behaviour (Kokras and Dalla, 2014; Ma et
al., 2019), and are differentially affected by SSRI treatment (Kokras and Dalla, 2014).
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Furthermore, it’s been shown that male SERT-KO mice display high baseline
emotionality (anxiety-like behaviour) compared to SERT-KO females which display
normal baseline, but increased susceptibility to high emotionality states in response to
aging or stress (Joeyen-Waldorf et al., 2009). Accordingly, discerning the effects of SSRI
treatment and maternal depression on female offspring using a clinically relevant model
of depression is essential to understand the role that these factors play on female
neurodevelopment. Thus, the first aim of the present study was to assess the effects of
perinatal FLX exposure on behaviour in adolescent female offspring and glutamatergic
profile in the PFC and vHPC.

The WKY strain is frequently used as an endogenous model of depression due to the
observation that the strain displays behavioural and physiological measures similar to
those seen in clinical cases of MDD (Burke et al., 2016; Nam et al., 2014). Given that
ketamine, a potent NMDA receptor antagonist, is increasingly used as a rapid acting
antidepressant (Sanacora and Schatzberg, 2015), this has pointed to the glutamatergic
system as potentially playing a role in the neurobiology of depression. Accordingly, as
depressive disorders are more prevalent in females (Albert, 2015), symptoms of which
commonly emerge at adolescence (Costello et al., 2003), we aimed to determine
whether glutamatergic markers (including NMDA, AMPA and group I metabotropic
receptors (mGluR1/5)) and their respective scaffolding proteins, are altered in female
adolescent WKY offspring.

2. Materials and Methods
2.1. Animals
All experiments were approved by the University of Wollongong’s Animal Ethics
Committee in accordance with the Australian Code for the Care and Use of Animals for
Scientific Purposes (AE14/31). Male and female WKY and Sprague-Dawley (SD; control
strain) rats were purchased from the Animal Resource Centre (WA, Australia). Animals
were housed at the University of Wollongong Animal Housing Facility in a temperature
controlled environment (200C ± 2) under a 12:12 hour light-dark cycle (lights on at 0700),
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and provided ad libitum access to laboratory chow and water. Animals were allowed to
acclimatize for one-week prior to mating. Following the mating period, pregnant dams
were assigned randomly to a FLX or vehicle (VEH) treatment group. Following birth,
(postnatal day (PN)0), pups were housed with their dam and litter mates until 3-4 weeks
of age, after which they were weaned and housed 2-3 per cage with littermates of the
same sex.

2.2. Perinatal SSRI Treatment
Treatment procedures were followed as previously described (Millard et al., 2018).
Briefly, from gestational day (GD)0 until PN14 (week prior to weaning), FLX
Hydrochloride (LKT Laboratories, St. Paul, MN, USA) (10 mg/kg dissolved in tap water)
or VEH (tap water) was administered orally via drinking water. Water consumption and
body weight were monitored, and dosage adjusted daily. In total, 27 dams and their
litters were used in the present study, 12 FLX treated (SD=6, WKY=6) and 15 VEH treated
dams (SD=7, WKY=8) (Figure 3.1).

2.3. Behavioural Testing
Beginning at PN37, corresponding to adolescence in rodents (Semple et al., 2013),
female offspring (SD-VEH n=14; WKY-VEH n=7; SD-FLX n=14; WKY-FLX n=15) underwent
a behavioural test battery to assess anxiety-like behaviours, immobility in the face of
adversity and behavioural despair. The EPM and forced swim test (FST) were conducted
between 1200 and 1700 hours. Procedures followed for behavioural tests were based
on those implemented as previously detailed (Millard et al, 2019). Further details of
procedures carried out for behavioural testing can be found in supplementary materials
(Figure 3.1).

2.4. Immunoblotting
Immunoblot procedures were performed as previously described (Millard et al., 2019).
On PN42 (48 hours post final behavioural test), adolescent female offspring were
weighed (Supplementary fig 3.1), euthanized via CO2 asphyxiation and the PFC (Bregma
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+3.70 mm) and vHPC (Bregma -2.80 mm) dissected in accordance with a standard rat
brain atlas (Paxinos and Watson, 2007). Protein (5 g/well) from brain regions were
separated using 4-20% TGX precast gels (Bio-Rad, Australia), transferred onto PVDF
membranes (Bio-Rad) and membranes blocked with either 5% BSA or skim milk (w/v)
for 1hr at room temperature. Membranes were incubated overnight in primary
polyclonal antibodies (NR1, NR2A, NR2B, GluA1, PSD95, mGluR1, mGluR5, Homer1bc
and β-Actin; Supplementary Table 3.1), then subsequently with HRP-conjugated
secondary antibodies (1:5000; AP307P/AP308P, Millipore). Amersham ECL western
blotting detection reagent (GE Healthcare, Australia) was then applied to membranes,
followed by exposure to Hyperfilm (GE Healthcare, Australia). Films were scanned using
a GS-800 scanner (Bio-Rad) and densitometry values were quantified. Relative values for
each protein were normalised to respective β-actin levels and an internal control value,
to account for protein loading and gel-gel variability, respectively. Each sample
(n=7/group) was run in triplicate.

2.5. Statistical Analysis
Data were analysed using SPSS statistical software (NY, IBM Corp. v21.). Normality was
confirmed using a Kolmogorov-Smirnov test. Two-way Analyses of Variance (ANOVA)
were used to determine any effects of treatment (FLX or VEH) or strain (WKY or SD) on
behavioural parameters and relative protein densities. Where interactions were found,
one-way ANOVAs were used to identify differences between groups. Correlations
between immobility time in the FST and relative glutamatergic protein densities were
assessed using Pearson’s test for correlation. Significance was set at an alpha level of p
= 0.05.
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Fig 3.1 Experimental design and treatment paradigm. Abbreviations: EPM = Elevated Plus Maze; FLX =
Fluoxetine; FST = Forced Swim Test; GD = Gestational Day; PN = Postnatal Day; SD = Sprague-Dawley;
VEH = Vehicle; WKY = Wistar-Kyoto.

3. Results
3.1. Adolescent Behaviour
Elevated Plus Maze

Fig 3.2 Total distance travelled, and duration of time spent in closed and open arms of the EPM.
Abbreviations: Flx = Fluoxetine; SD = Sprague Dawley; Veh = Vehicle’ WKY = Wistar Kyoto. Data
expressed as mean seconds (sec) or centimetres (cm) + SEM; *p<0.05, ***p<0.001. ###p<0.001
compared to SD (overall strain effect).

Locomotor activity in the EPM was influenced by TREATMENT (F1,49=4.863; p<0.05),
STRAIN (F1,49=6.719; p<0.05) and a significant interaction between STRAIN x TREATMENT
(F3,49=6.201; p<0.05). FLX exposure reduced distance travelled in the EPM in SD (-65%;
p<0.05) but not WKY offspring, whilst WKY VEH rats travelled less than SD VEH rats (71%; p<0.05). Similarly, there was a significant effect of TREATMENT (F1,49=12.350;
p<0.01), STRAIN (F1,49=15.704; p<0.001) and a STRAIN x TREATMENT interaction
(F3,49=6.283; p<0.05) on time spent in the closed arms of the EPM. FLX exposed SD, but
not WKY, offspring spent more time in the closed arms of the EPM compared to VEH
controls (+25%; p<0.001), while WKY VEH offspring spent an increased amount of time
in the closed arms compared to SD VEH offspring (+27%; p<0.001). Time in the open
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arms was influenced by STRAIN only (F1,49=11.167; p<0.01), with WKY offspring spending
less time in the open arms of the EPM compared to SD offspring (-86%).
Forced Swim Test

Fig 3.3 Duration of time spent immobile in the forced swim test. Abbreviations: Flx = Fluoxetine; SD =
Sprague Dawley; Veh = Vehicle; WKY = Wistar Kyoto. Data expressed as mean seconds (sec) + SEM.
###p<0.001 compared to SD (overall strain effect).

In the FST, offspring of the WKY strain displayed increased immobility time (+110%; F1,41
= 59.42; p<0.001) compared to SD offspring. There were no significant effects of
TREATMENT and no STRAIN x TREATMENT interactions.
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3.2. Immunoblot

Fig 3.4 Relative levels of NMDA subunits NR1, NR2A and NR2B, AMPA subunit GluA1 and associated scaffolding protein PSD-95 in the PFC (a-e) and vHPC (g-j) at PN42.
Abbreviations: PFC = Prefrontal Cortex; SD = Sprague Dawley; vHPC = Ventral Hippocampus; WKY = Wistar Kyoto. Data expressed as mean values + SEM. *p<0.05 ^p=0.055;
#p<0.05, ##p<0.01, ###p<0.001 compared to SD (overall strain effect).
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Female WKY rats expressed reduced relative protein levels of NR1 in the PFC (-17%,
F1,27=5.933; p<0.05), but not the vHPC, and reduced NR2A (PFC: -54%, F1,27=37.474,
p<0.001; vHPC: -34%, F1,27=23.285, p<0.001), NR2B (PFC: -55%, F1,27=43.732, p<0.001;
vHPC: -23%, F1,27=5.952, p<0.05) and PSD-95 (PFC: -24%, F1,27=12.324, p<0.01; vHPC: 41%, F1,27=16.428, p<0.001) in both the PFC and vHPC, compared to offspring of the SD
strain. There was no effect of TREATMENT on NMDA subunits in either brain region.
However, FLX exposed offspring did show reduced relative levels of PSD-95 in the vHPC
(-23%, F1,27=4.052, p=0.055), but not the PFC. There were no STRAIN x TREATMENT
interactions in either brain region on NMDA receptor subunits or PSD-95. In both the
PFC and vHPC there were significant effects of STRAIN on GluA1 protein levels (PFC:
F1,27=7.155; p<0.05; vHPC: F1,27=8.545, p<0.01) as well as a significant STRAIN x
TREATMENT interaction in the PFC (F3,27=4.036, p=0.056). In the PFC, WKY VEH offspring
expressed reduced GluA1 levels compared to SD VEH (-36%, p=0.014); in the vHPC, WKY
offspring showed reduced overall expression of GluA1 compared to SD offspring (-17%,
p=0.007). FLX exposure did not influence GluA1 levels in the PFC or vHPC of either strain.

Fig 3.5 Relative levels of mGluR1 dimeric and monomeric forms in the PFC and vHPC at PN42.
Abbreviations: PFC = Prefrontal Cortex; SD = Sprague Dawley; vHPC = Ventral Hippocampus; WKY = Wistar
Kyoto. Data expressed as mean values + SEM. *p<0.05, **p<0.01; #p<0.05 compared to SD (overall strain
effect).
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In both the PFC and vHPC, there were significant effects of STRAIN (PFC: F1,27=4.156,
p<0.05) and significant STRAIN x TREATMENT interactions (PFC: F 3,27=8.790, p<0.01;
vHPC: F3,27=14.735, p<0.01) influencing mGluR1 dimer levels. Post-hoc analyses revealed
that FLX exposed SD offspring showed reduced levels of mGluR1 dimer in the vHPC
compared to SD-VEH offspring (p<0.05; -36%). In addition, FLX exposed WKY offspring
had increased cortical and hippocampal mGluR1 dimers compared to FLX exposed SD
offspring (PFC: p<0.01; +77%; vHPC: p<0.05; +59%), but not compared to their WKY
vehicle controls. mGluR1 monomers in the PFC were affected by STRAIN (F1,26=5.206,
p<0.05), with WKY rats showing an overall reduction compared to SD rats (-42%).
mGluR1 monomers in the vHPC were influenced by TREATMENT (F1,27=4.913, p<0.05),
with FLX exposed offspring showing overall reductions compared to vehicle (-26%).
There were no significant STRAIN x TREATMENT interactions for mGluR1 monomer in
either brain region.

Fig 3.6 Relative levels of mGluR5 dimeric and monomeric forms, and associated scaffolding protein
Homer1b/c in the PFC and vHPC at PN42. Abbreviations: PFC = Prefrontal Cortex; SD = Sprague Dawley;
vHPC = Ventral Hippocampus; WKY = Wistar Kyoto. Data expressed as mean values + SEM. ^p=0.066;
##p<0.01, compared to SD (overall strain effect).

In the PFC there was a significant effect of STRAIN (F1,28=4.707; p<0.05) and significant
STRAIN x TREATMENT interactions (F28,3=9.033; p<0.010) on mGluR5 dimer levels. Posthoc analyses revealed that FLX exposed offspring of the WKY strain showed increased
relative mGluR5 dimer levels in the PFC compared to WKY VEH controls, that bordered
on significance (+25%; p=0.06). In both the PFC and vHPC there was a significant effect
of STRAIN on mGluR5 monomer levels (PFC: F1,28=13.177, p<0.01; vHPC: F1,27=13.448,
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p<0.010) with female WKY rats showing overall reductions in mGluR5 monomer levels
compared to SD rats (-43%; -70%), but no effects of TREATMENT or TREATMENT x
STRAIN interactions were detected. Moreover, no effects of TREATMENT, STRAIN or any
significant interactions were detected for Homer1b/c levels in either brain region.

Fig 3.7 Correlation between Immobility time in the FST (x-axis) and relative levels of NMDA receptor
subunits, AMPA GluA1 subunit and PSD-95 (y-axis) in the PFC (a-d) and vHPC (e-f). Abbreviations: PFC =
Prefrontal Cortex; SD = Sprague Dawley; vHPC = Ventral Hippocampus; WKY = Wistar Kyoto.
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Given the known relationship between depressive-like behaviours and the
glutamatergic system we sought to determine the correlation between immobility in the
FST and key glutamatergic markers in the PFC and vHPC. In the PFC, all NMDA receptor
subunits as well as the scaffolding protein PSD-95 were negatively correlated with
immobility time (NR1: r= -0.499, p<0.01; NR2A: r = -0.555, p<0.01; NR2B: r = -0.440,
p<0.05; PSD-95: r = -0.462; p<0.05). In the vHPC, only negative correlations for NR2A (r
= -0.4245; p<0.05) and AMPA receptor subunit GluA1 (r = -0.533; p<0.01) were observed
(for full list of correlations see supplementary tables 3.2 and 3.3).

4. Discussion
4.1 Perinatal FLX exposure does not affect the emotionality-related behavioural
phenotype of female WKY rats but does increase anxiety-like behaviour in SD rats.

In the present study perinatal FLX exposure did not influence the anxiety-like phenotype
or FST immobility in female adolescent offspring of the WKY strain, but significantly
increased anxiety-like behaviours in SD offspring. Conversely, in male offspring we have
previously shown that perinatal FLX treatment increases anxiety-like behaviours and FST
immobility in both SD and WKY offspring (Millard et al., 2018), suggesting that in a
rodent model of innate depression, adolescent females are more resilient to the
behavioural effects of maternal FLX exposure compared to males. SSRIs such as FLX
block the SERT and subsequently increase serotonergic activity on serotonin receptors
including 5HT1 and 5HT2 receptors. Recent evidence suggests that an imbalance in
serotonergic signalling between 5HT1A and 5HT2A/C receptors during early life, influences
the development of anxiety-like and depressive-like behaviours, at least in male mice
(Sarkar et al., 2014). Based on our collective findings of differential effects of perinatal
FLX exposure (Millard et al., 2019), we suggest that differences in the developmental
trajectory and/or perinatal expression of serotonergic receptors (and SERT) between the
sexes and the WKY and SD strains could underpin the sex-specific and strain-specific
effects of perinatal SSRI exposure. In line with this hypothesis is the finding that male
and female SERT-KO rodents exhibit differences in emotionality related behaviours
throughout life (Joeyen-Waldorf et al., 2009), and that male and female rodents are
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differentially affected by SSRI treatment (Kokras and Dalla, 2014; Ma et al., 2019).
Furthermore, clinical findings have reported sex differences in serotonin receptor and
SERT binding with males exhibiting increased 5HT2A receptor and SERT binding, and
decreased 5HT1A receptor binding in the HPC and cortical areas compared to females
(Jovanovic et al., 2008; Soloff et al., 2010). Differences in serotonergic phenotypes
between sexes within WKY and SD strains is less well-established, though some evidence
suggests that adult male WKY exhibit reduced 5HT1a mRNA in the dorsal raphe nucleus,
and reduced SERT and 5HT1a receptor binding in the cortex and HPC compared to male
SD counterparts (Lemos et al., 2011; Pare and Tejani-Butt, 1996). Future investigations
underlying sexual dimorphism and strain specific differences in serotonergic
development will be important to understand the sex-specific and strain-specific effects
of perinatal SSRI exposure on offspring.

To our knowledge this study is the first to assess the effects of perinatal FLX exposure in
an endogenous model of depression, on female offspring. However, several previous
studies have utilized environmental stress paradigms to produce depressive phenotypes
in rodent dams; they have reported no changes in anxiety-like behaviours in the OFT
(Rayen et al., 2011) or EPM (Boulle et al., 2016a, 2016b) in either female or male
adolescent (Rayen et al., 2011) or adult (Boulle et al., 2016a, 2016b; Kiryanova et al.,
2017) offspring, however this was following low dose postnatal SSRI exposure (5
mg/kg/day; postnatal days PN0-PN21). They did however show increased immobility
time in the FST in female, but not male offspring (Boulle et al., (2016a, 2016b) and Rayen
et al., (2011)), suggesting female offspring may be more prone to the effects of postnatal
SSRI exposure on emotionality-related behaviours in the stress model. Moreover,
Gemmel et al., (2019, 2017) recently reported that the sex-specific effects of FLX
exposure extend to social behaviour in pre-adolescent and adult offspring in a model of
gestational stress coupled with perinatal FLX treatment (10mg/kg/day GD0-PND21). Of
interest, they showed increased social investigation in female adult, but not preadolescent, offspring suggesting that perinatal FLX exposure influences female social
behaviour in later life (Gemmel et al., 2019). These findings reinforce that FLX exposure
has sex specific effects on behaviour that may be dependent on dose, offspring age and
period of exposure, and that environmental and endogenous models of maternal
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depression can differentially influence these effects. Future studies implementing
rodent models of depression and wider behavioural test batteries will be critical to
determining the full effects of perinatal FLX exposure on offspring.

4.3 Maternal FLX treatment reduces PSD-95, but differentially affects group 1 mGluRs in
SD and WKY offspring
We have previously shown that perinatal FLX exposure reduced NMDA receptor NR1
and NR2A subunits, the scaffolding protein PSD-95 and mGluR1 expression in male WKY
as well as SD offspring (Millard et al, 2018). In the present study, perinatal FLX treatment
had much more restricted effects on the glutamatergic system of female offspring
including reductions in PSD-95 and the mGluR1 monomer in the vHPC of both strains.
We also report differential effects of perinatal FLX exposure on group 1 mGluR
functional dimer expression, with SD offspring showing reduced mGluR1 dimers in the
vHPC and WKY offspring showing increased mGluR5 dimer expression in the PFC. The
variation in these findings further highlights the importance of implementing relevant
models of maternal psychopathology, as well as considering the influence of sex when
investigating the effects of perinatal SSRI exposure.

PSD-95 is an important regulator of glutamatergic neurotransmission and structural
organisation of post-synaptic densities, through its scaffolding and trafficking of NMDA
and AMPA receptors to the postsynaptic membrane and assembly of receptorassociated signalling complexes (Chen et al., 2011; Xu et al., 2008). Despite the reduction
in hippocampal PSD-95 in the present study following FLX exposure, there were no
changes in levels of NMDA or AMPA receptor subunits, suggesting that levels of these
proteins were not altered by the effects of perinatal FLX treatment. However
considering the role of PSD-95 in the stabilisation of NMDA and AMPA receptors at the
membrane surface (Hruska et al., 2015), it may be that membrane expression of these
receptors could be reduced or interaction of these receptors with auxiliary protein
complexes such as Stargazin (a member of the transmembrane AMPA receptor
regulatory proteins (TARP)) could be disrupted (Kim and Sheng, 2004; Shaikh et al.,
2016).
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Group 1 mGluRs play key roles in activity-dependant synaptic plasticity processes such
as long term potentiation (LTP) and long term depression (LTD) (Niswender and Conn,
2010). These G-protein-coupled receptors undergo homodimerisation via disulphides
bonds (Romano et al., 1996) to form functional dimeric complexes (Niswender and
Conn, 2010). We have shown that perinatal FLX exposure increases mGluR5 dimer
expression in the PFC of female adolescent WKY offspring. Similarly, previous work from
our lab has shown that male rats exposed to perinatal FLX treatment also show
increased dimeric mGluR5 expression in WKY (as well as SD), but in the vHPC (Millard et
al., 2019). Furthermore, we have shown that FLX exposure reduced monomeric mGluR1
in female offspring of both strains, but reduced dimeric mGluR1 in the vHPC of SD
offspring only. Collectively, these findings suggest group I mGluRs are sensitive to
developmental FLX exposure. Although both group 1 mGluRs play key roles in LTP and
LTD through co-localisation and modulation of NMDA receptor signalling (Heidinger et
al., 2002), they do display differential expression patterns (Lüscher and Huber, 2010). In
comparison to mGluR5 which is located abundantly throughout the PFC and HPC and
expressed uniformly on multiple cell types, mGluR1 is found primarily in the CA1 region
where it localised to several distinct interneuron populations (Camiré et al., 2012;
Martin et al., 1992). Activation of mGluR1 results in increased intracellular calcium and
depolarization of CA1 pyramidal neurons (Mannaioni et al., 2001), whereas activation of
mGluR5 produces suppression of calcium-activated potassium currents and potentiation
of the NMDA receptor (Neyman and Manahan-Vaughan, 2008). Accordingly, it may be
suggested that the reduced hippocampal dimeric mGluR1 observed in the present study
could result in abhorrent LTP and LTD processes, particularly in the CA1 region of the
vHPC, and subsequent alterations in cognition and memory. Given that cognition was
not assessed in the present study this remains speculative, however other studies have
previously shown that disruption to mGluR1/5 signalling, such as that produced in
mGluR1/5 -/- mice, results in significant alterations in context-specific learning (Aiba et
al., 1994; Gil-Sanz et al., 2008). Alterations to group 1 mGluR signalling have also been
linked to several neurodevelopmental disorders, including fragile X syndrome and
Autism (Matosin and Newell, 2013; Pop et al., 2014). Future investigations into the
effects of perinatal SSRI treatment, group 1 mGluR signalling and cognitive behaviour
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will help elucidate the potential risk or benefits that SSRIs pose to neurodevelopment.
4.2 Cortical and Hippocampal reductions in NMDA subunits and PSD-95 in the WKY
strain; a rodent model of depression.
Previous investigations into the neurobiology underlying the depressive- and anxietylike phenotype observed in the WKY strain has largely focused on abnormalities in the
serotonergic system. However, given the growing interest in the glutamatergic system
in the neurobiology of neuropsychiatric and mood disorders, and as a potential target
for anti-depressive therapeutics (Hovelsø et al., 2012; Javitt, 2004; Sanacora et al.,
2012), we sought to investigate the glutamatergic profile of the WKY strain.
Furthermore, given the extensive works in the current literature linking antidepressant
properties of glutamatergic antagonists (i.e. ketamine) with reduced immobility time in
the FST (Browne and Lucki, 2013), we investigated whether immobility time was
correlated with relative densities of glutamatergic markers. Here we report reductions
in NMDA receptor NR1 (PFC only), NR2A and NR2B subunits, AMPA receptor GluA1
subunit and the glutamatergic scaffolding protein, PSD95, in the PFC and vHPC of female
adolescent WKY rats compared to SD rats. We have previously shown that male
adolescent WKY offspring also display reductions in NR1, NR2A, NR2B and PSD95,
however only in the PFC (Millard et al., 2018), suggesting that the reduced NMDA profile
of the WKY is more extensive in females. In line with other studies we also observed a
significant increase in immobility in the FST and reduced exploratory behaviour in the
EPM in WKY offspring (Burke et al., 2016; Nam et al., 2014; Pare and Tejani-Butt, 1996;
Rittenhouse et al., 2002; Will et al., 2003). Furthermore, we observed an inverse
correlation between immobility time and NMDA and AMPA receptor subunits,
particularly in the PFC suggesting that reductions in these glutamatergic markers are
associated with the depressive-like phenotype of the WKY strain (see fig. 3.7). A reduced
NMDA and AMPA receptor phenotype in cases of depression has been well-documented
in human studies. Specifically, findings from post-mortem investigations have reported
reduced levels of NR2A, NR2B and PSD95 in the PFC (Feyissa et al., 2009) and reduced
NR2A (Beneyto and Meador-Woodruff, 2008) transcripts in the dorsolateral PFC of
depressed individuals. Furthermore, other studies have reported reductions in GluA1,
NR1, NR2A and NR2B transcript expression in the perirhinal cortex of depressed
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subjects (Beneyto et al., 2007) and reduced NMDA receptor binding (CGP-39653) in the
anterior PFC of suicide victims (Nowak et al., 1995). Collectively, these post mortem
findings provide further support that NMDA and AMPA receptor dysfunction may
contribute to the depressive-like phenotype observed in the WKY strain and clinical
cases of MDD.

Preclinical investigations into the glutamatergic profile of the WKY strain are limited;
however, Lei et al., (2009) reported a reduction in [3H]MK-801 binding in the cingulate
cortex, striatum and hippocampus of adult male WKY compared to Wistar rats,
suggesting a reduced number of functional NMDA receptors, similar to our findings in
female adolescent WKY rats. There has also been growing interest in the use of
ketamine, an NMDA receptor antagonist, to treat depressive disorders (Berman et al.,
2000; Sanacora and Schatzberg, 2015). In particular, given the depressive-like
phenotype of the WKY strain, studies have evaluated the effects of ketamine on WKY
behaviour and NMDA receptor signalling. Tizabi and colleagues (2012) observed that
chronic ketamine treatment for 10 days, decreased immobility in the FST and increased
hippocampal AMPA/NMDA binding ratio in adult female WKY rats compared to Wistar,
which was driven by an increase in AMPA receptors, rather than a change in NMDA
receptor densities. Other studies have noted increases in AMPA receptor subunit (GluA1
and GluA2) expression in the PFC and HPC, and increased AMPA receptor binding
following ketamine treatment in rats (see review Aleksandrova et al., 2017). In addition,
recent evidence suggests that ketamine’s antidepressant properties are produced
through indirect influences on AMPA receptors rather than direct antagonism of NMDA
receptors (Zanos et al., 2016; Zhou et al., 2014), supporting the notion that NMDA
receptor hypofunction may contribute to depressive-like phenotypes and clinical cases
of MDD. Finally, we also noted decreased group 1 mGluR monomers in the WKY strain.
Given that group 1 mGluRs potentiate the action of NMDA receptors, it may be plausible
to suggest that the depressive-like behaviour of the WKY strain could be attributable in
part to dysfunctional signalling between group 1 mGluRs and NMDA receptors.
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5. Conclusion
In summary, our findings show that perinatal FLX exposure does not impact affective
behaviour in female WKY adolescent offspring, as measured by the EPM or FST, but does
increase anxiety-like behaviour in female SD offspring, highlighting the importance of
including relevant models of psychopathology. Furthermore, perinatal FLX exposure
does not influence expression of ionotropic glutamate receptors in female WKY or SD
offspring; it does however have restricted effects on group I mGluR expression in SD and
WKY offspring and reduce the glutamatergic synaptic scaffold, PSD95, suggesting
synaptic stabilisation could be disrupted. We have also shown that naïve female WKY
rats exhibit reduced cortical and hippocampal NMDA and AMPA receptor subunits and
group 1 mGluRs, compared to SD rats, which may contribute to the underlying
depressive phenotype observed in the strain. This phenotype parallels those reported in
clinical cases of MDD, validating the use of the WKY in studies of MDD biology and
investigating potential therapeutics. Taken together with our previous findings in males,
this suggests that female offspring, in a clinically relevant model of depression, are more
resilient to the effects of perinatal FLX exposure. Considering that maternal
antidepressant use can be critical to reducing harm and risky behaviour in sufferers of
MDD, future investigations should consider whether these effects extend into
adulthood and determine ways to attenuate any effects on offspring. Importantly,
future investigations should address these considerations with the aim of maintaining
effective treatment strategies for MDD in pregnancy.
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Supplementary Materials

1. Behavioural Testing Procedures
Elevated Plus Maze
To assess anxiety-like behaviour in adolescent offspring the EPM was used as previously
described (Millard et al., 2018). Briefly, the apparatus consisted of two perpendicular
pairs of arms; one closed and one open, with respective dimensions 50cm x 7cm x 30cm
(arm length x platform width x wall height). The maze was elevated 60cm above ground
and lighting intensity across the arms was set at a constant ~100 LUX. Upon
commencement of the test, rats were placed in the centre of the apparatus facing an
open arm; rats were tested individually for 5 minutes, monitored and recorded. The
primary parameter used to measure anxiety-like behaviour in the EPM is the duration
of time spent in the open arms versus the closed arms, representing the animals’ natural
tendency to engage in exploratory behaviour (Walf and Frye, 2007).

Forced Swim Test
To assess passivity in the face of adversity in adolescent offspring the FST was used as
previously described (Millard et al., 2018). Briefly, the apparatus consisted of an opaque
cylinder (30cm diameter x 50cm depth) filled to a level 1.25 x length of the rat (measure
from snout to tail) with (25 ± 0C) water (Slattery and Cryan, 2012). Tests were conducted
under standard ceiling lighting (~500-750 LUX) and performed over two days. The first
day (habituation) involved placing the subject in the water for 15 minutes. The second
day (test day) was performed 24hrs post habituation, and involved placing the subject
in the test apparatus, then monitored and recorded for duration of 5 minutes. Test
water was changed between subjects, temperature adjusted, and the procedure
repeated. The primary parameter used to measure depressive-like behaviours in the FST
is the duration of time the animal spends immobile (floating without active movement),
or unengaged in escape driven behaviour (Slattery and Cryan, 2012).
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Supplementary Table 3.1. Immunoblot antibody details

Antibody
anti-NR1
anti-NR2A
anti-NR2B
Anti-GluA1
anti-PSD95
anti-mGluR1a
anti-mGluR5
anti-Homer1b/c
anti-β-Actin
HRP Conjugated Secondary

Concentration
1:5000
1:5000
1:5000
1:5000
1:5000
1:15 000
1:5000
1:7500
1:100 000
1:5000

Manufacturer (Cat #)
Millipore (MAB363)
Millipore (MAB5530)
Millipore (MAB5578)
Abcam (ab31232)
Millipore (MAB530)
Cell Signalling (D5H10)
Abcam (Ab27190)
Abcam (Ab211415)
Millipore (MAB1501)
Millipore (AP307P/AP308P)

2. Offspring Bodyweight PN42

Supplementary Figure 3.1. Average offspring body weight at Postnatal Day (PN)42. Abbreviations: SD =
Sprague Dawley; Veh = Vehicle; WKY = Wistar Kyoto. Data expressed as mean grams (g) + SEM ;
###p<0.001 compared to SD (overall strain effect).

There was a significant effect of STRAIN (F1,49=108.365; p<0.001) on female body weight
at PN42. Offspring of the WKY strain demonstrated reduced body weight (-34%) overall
compared to SD offspring.
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3. Correlations between immunoblot markers and behavioural parameters
Supplementary table 3.2 Immunoblot PFC vs. behavioural parameters

Supplementary table 3.3 Immunoblot vHPC vs. behavioural parameters
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Chapter 4

4.1 Study rationale and aims
In chapter 3, we showed that perinatal fluoxetine exposure has minimal effects on
glutamatergic markers of adolescent female offspring, but does cause consistent
reductions in the postsynaptic scaffold, PSD-95, in the hippocampus of SD and WKY
female offspring, as well as strain specific effects on Group I mGluRs. Previous works
have shown that PSD-95 levels, which can be used as an indicator of overall
glutamatergic synapses, are inextricably linked to the activity of the neurotrophin, BDNF.
BDNF participates in neurogenic and neuroprotective mechanisms through the
activation of Tyrosine Kinase B (TrkB). BDNF is not only important in normal
neurodevelopmental processes but is also upregulated in adult brains in response to
SSRI treatments, where it is critical to neurogenic activity. Based on these observations,
we sought to investigate the effects of perinatal fluoxetine exposure on the BDNF-TrkB
system and brain region morphology, measured by quantifying mature neurons, in
female adolescent offspring. Furthermore, alterations in BDNF-TrkB signaling, and
reductions in cortical and hippocampal volumes have previously been reported in
clinical cases of major depressive disorder. Females are twice as likely to develop major
depressive disorder, symptoms of which commonly emerge at adolescence. The WKY
rat strain is a robust preclinical model of depression and the neurobiological profile of
which has not yet been thoroughly investigated. Therefore, we sought to investigate the
neurotrophic profile and neuronal cell counts, in female adolescent WKY rats, and
determine whether changes in these parameters might correlate with their depressivelike phenotypes and apparent resilience to the effects of perinatal FLX exposure on
affective behaviours, previously reported in chapter 2.
4.2 Manuscript details
The results of Chapter 4 have been prepared for publication as a manuscript titled,
Perinatal Fluoxetine exposure influences cortical and hippocampal BDNF signaling and
differentially alters NeuN+ cell counts in female adolescent Wistar-Kyoto and Sprague123

Dawley rats
4.3 Author contributions
S. Millard performed the experiments, acquired and analyzed the data, wrote the first
draft of the manuscript, which all authors reviewed and approved for publication.
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Background:
Approximately 10% of maternal sufferers of depression take antidepressants, such as
selective serotonin reuptake inhibitors (SSRIs). SSRIs are thought to mediate their effects
through the modulation of BDNF-TrkB signalling, which increases neurogenic and
neuroprotective processes. Little is known regarding the effects of perinatal SSRI
exposure on these pathways and processes in offspring.
Aim:
Using a clinically relevant rodent model of depression, the Wistar-Kyoto rat, we sought
to investigate whether alterations in BDNF-TrkB signalling and neuronal maturation in
the prefrontal cortex and hippocampus contribute to the strain’s depressive-like
phenotype. Furthermore, we sought to determine whether perinatal Fluoxetine
exposure modulates the same markers in female offspring at adolescence.
Methods:
Sprague-Dawley and Wistar-Kyoto rat dams were exposed daily to fluoxetine
(10mg/kg/day) or vehicle from gestational day 0 to postnatal day 14. Female offspring
underwent quantitative immuno-detection of BDNF-TrkB signalling markers, and
immunohistochemistry of neuron specific nuclear protein (NeuN+), in the hippocampus
and prefrontal cortex.
Results:
Wistar-Kyoto offspring exhibited cortical and hippocampal deficits in NeuN+ cells;
perinatal fluoxetine exposure ameliorated cortical, but exacerbated hippocampal,
deficits. In Sprague-Dawley offspring perinatal fluoxetine exposure induced deficits in
NeuN+ cells in both brain regions, similar to levels observed in Wistar-Kyoto at baseline.
In addition, deficits in cortical and hippocampal NeuN+ counts correlated with
emotionality-related behaviours. Fluoxetine-exposure had strain-independent effects
on BDNF-TrkB markers.
Conclusions:
These findings suggest that in a rodent model of depression, neuronal cortical and
hippocampal deficits exist and could contribute to the strain’s depressive-like
phenotype. Furthermore, perinatal fluoxetine has brain region specific effects with the
ability to correct deficits in cortical neuron number but exacerbate deficits in the
hippocampus. Further investigation into how changes in these brain regions relate to
behaviour using the Wistar-Kyoto model, will be critical to further dissecting the
influence that fluoxetine exposure can have in the context of maternal depressive
phenotypes.

Keywords: SSRI, Wistar-Kyoto, Maternal Depression, Perinatal, Neurodevelopment,
BDNF, Antidepressant, Fluoxetine, NeuN
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1. Introduction
Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting
~10% of the adult population (NIMH, 2019; WHO, 2017). Women are almost twice as
likely to suffer from the disorder compared with men (Albert, 2015) and women are
most likely to experience depression during child bearing years (Evans et al., 2001).
Accordingly, ~10% of pregnant women take antidepressants to ameliorate symptoms
(Huybrechts et al., 2013b). Selective serotonin reuptake inhibitors (SSRIs) are the
frontline antidepressant of choice in ~80% of cases for the treatment of maternal
depression (Mitchell et al., 2011b; Oberlander et al., 2009b). SSRIs such as Fluoxetine
target the serotonergic system by binding and inhibiting the serotonin transporter
(SERT) resulting in increased available serotonin within the synaptic cleft, and
subsequent increased downstream signalling (Hiemke and Härtter, 2000a). In the adult
brain SSRIs such as fluoxetine are also thought to mediate their therapeutic effects, at
least in part, by increasing BDNF and promoting hippocampal neurogenesis
(Martinowich and Lu, 2007). Evidence has shown that SSRIs cross the placental barrier
(Heikkinen et al., 2002b) and are excreted in breast milk (Hendrick et al., 2001b), raising
the possibility that these downstream effects on BDNF and neurogenesis could also
occur in the exposed fetus during critical periods in neurodevelopment.

Through interactions with neurotrophins such as brain derived neurotrophic factor
(BDNF), the serotonergic system plays a key role in several neurodevelopmental
processes

including

neuronal

differentiation,

proliferation,

migration

and

synaptogenesis (Bonnin et al., 2007; Edgar and Price, 2001; Sodhi and Sanders-Bush,
2004b; Vitalis and Parnavelas, 2003). The functions of BDNF are mediated through two
receptors, TrkB and p75 (Martinowich and Lu, 2007). Most of the neurotrophic functions
of BDNF, such as neuronal growth, survival and plasticity, are mediated through TrkB
signalling pathways (Martinowich and Lu, 2007). Conversely, proBDNF, the precursor to
BDNF, preferentially binds to p75, which activates a separate set of intracellular
signalling cascades associated with the activation of pro-apoptotic mechanisms and
NMDA receptor mediated long term depression (Lu et al., 2005; Martinowich and Lu,
2007). PSD-95 is the major scaffolding protein at excitatory synapses and is found
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abundantly throughout the hippocampus and cortex (Broadhead et al., 2016; Pinto et
al., 2013). The activity of the BDNF-TrkB signalling pathway is inextricably linked to levels
of PSD-95, with studies demonstrating that all three downstream signalling cascades of
TrkB increase expression of PSD-95 at synapses (Yoshii et al., 2003; Yoshii and
Constantine-Paton, 2014, 2007). BDNF-TrkB signalling, through the modulation of PSD95, directly influences dendritic growth, synapse formation, maturation and stabilization
(Hu et al., 2011) and directly contributes to the protection of neurons (Jeon et al., 2015).
More recently, Jeon et al., (2015) demonstrated that neutralizing BDNF in a dosedependent manner, reduces the number of neuron specific nuclear protein positive
(NeuN+) hippocampal CA1 neurons in the presence of thrombin, a pro-apoptotic
protease (Jeon et al., 2015). NeuN+ is expressed in post-mitotic neurons, and is
extensively used as a marker of mature neurons (Gusel’nikova and Korzhevskiy, 2015).
Collectively, these findings provide evidence that alterations in BDNF-TrkB signalling
directly influences the number of mature neurons and synaptic proteins.

Using a rodent model of depression (Wistar-Kyoto (WKY)) we recently showed that
perinatal exposure to Fluoxetine (FLX) had largely negligible effects on glutamatergic
receptors (AMPA, NMDA and group 1 mGluRs) in female adolescent offspring, but did
reduce PSD-95 in the hippocampus of both WKY and Sprague Dawley (SD) rats (Millard
et al., 2019). Given the association between PSD-95 and BDNF signalling and the fact
that PSD-95 is abundantly found in synapses, we hypothesised that fluoxetine-induced
reductions in PSD-95 could be indicative of reductions in neuronal numbers and altered
BDNF signalling, which are known to be associated with psychiatric and affective
disorders (Coley et al., 2019, 2019; Gittins and Harrison, 2004, 2004; Hu et al., 2011).
Furthermore, previous work has also demonstrated that perinatal fluoxetine exposure
in environmental models of depression can influence neurogenic and synaptic markers,
such as doublecortin and synaptophysin (Rayen et al., 2011), and also neurotrophic
markers including BDNF in exposed offspring (Boulle et al., 2016b, 2016a). These findings
suggest that maternal depressive phenotypes could influence the effects of perinatal
fluoxetine exposure on offspring neurotrophic markers and neuronal maturation.

We have also previously reported deficits in PSD-95 in female adolescent WKY control
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rats compared to SD controls, suggesting that synaptic dysfunction could underpin the
strains’ depressive-like phenotype (Millard et al., 2019). In line with this finding, one
study has reported reduced PSD-95 in the prefrontal cortex of depressed individuals
(Feyissa et al., 2009). Others investigating the WKY strain have found reduced
hippocampal volume, and deficits in BDNF and markers of neurogenesis in adult male
WKY rats (Gormley et al., 2016; Kin et al., 2017; Vinod et al., 2012), all of which have
been reported in clinical cases of MDD (aan het Rot et al., 2009). Furthermore, one study
has reported reduced NeuN+ neurons in the hippocampus of clinical cases of MDD
(Boldrini et al., 2013), suggesting that reduced cortical and hippocampal volumes in
MDD could be underpinned by reductions in mature neurons. To date, little investigation
into the neurotrophic profile of female WKY rats has been carried out.

Work from our lab, and others, have shown that the effects of perinatal FLX exposure
on offspring are influenced by maternal factors, such as exposure to stressors and dam
strain (Boulle et al., 2016a, 2016b; Gemmel et al., 2017; Millard et al., 2019; Rayen et
al., 2011). We previously demonstrated that perinatal FLX exposure increases anxietylike behaviours in female adolescent control rats (SD), but had no effects on these
behaviours in female WKY offspring (Millard et al., 2019). Thus, the aim of this study was
twofold. First, to determine whether alterations in BDNF signalling and neuronal number
are present in the prefrontal cortex (PFC) and hippocampus of female WKY rats at
adolescence, and whether these correlate to their depressive-like phenotype. This last
point is especially important considering nearly all studies investigating this model of
depression focus on outcomes in males (Albert, 2015; Millard et al., 2019c, WKY review,
under review). Second, to investigate the effects of perinatal fluoxetine exposure on
BDNF signalling and neuronal number in offspring, and to determine whether offspring
strain differentially influences the effects of exposure.

2. Materials and Methods

2.1. Animals and Perinatal SSRI Treatment
Animal and perinatal SSRI treatment procedures were followed as previously described
(Millard et al., 2019). Briefly, male and female WKY and Sprague-Dawley (SD; control
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strain) rats were purchased from the Animal Resource Centre (WA, Australia). Animals
were housed at the University of Wollongong Animal Housing Facility in a temperaturecontrolled environment (20OC ± 2) under a 12:12 hour light-dark cycle (lights on at 0700)
and provided ad libitum access to laboratory chow and water. Animals were allowed to
acclimatize for one-week prior to mating. Following the mating period, pregnant dams
were randomly assigned to a FLX or a vehicle (VEH) treatment group. Following birth,
(postnatal (PN)0), pups were housed with their dam and litter mates until 3-4 weeks of
age, after which they were weaned and housed 2-3 per cage with littermates of the
same sex. From gestational day (GD)0 until PN14, FLX Hydrochloride (LKT Laboratories,
St. Paul, MN, USA) (10 mg/kg dissolved in tap water) or VEH (tap water) was
administered orally via drinking water to the dams. Water consumption and body weight
were monitored, and dosage adjusted daily. In total, 27 dams and their litters were used
in the present study, 12 FLX treated (SD=6, WKY=6) and 15 VEH treated dams (SD=7,
WKY=8), and 28 offspring (7/group) (Figure 4.1).

Figure 4.1. Experimental timeline. Abbreviations: FLX = Fluoxetine; GD = Gestational Day; IHC =
Immunohistochemistry; PN = Postnatal Day; SD = Sprague-Dawley; VEH = Vehicle; WB = Western Blot;
WKY = Wistar-Kyoto.

2.2 Histological Procedures
Histological procedures were performed as previously described (Osborne et al., 2019).
On PN42 (after behavioural testing (detailed in Millard et al., 2019b), adolescent female
offspring were euthanized via CO2 asphyxiation and brains were collected. Rat brains
were sectioned coronally in alternating 14μM or 500µM sections using a cryostat (-17oC;
Jung CM 3000, Leica Instruments GmbH, Nussloch, Germany). Sections were collected
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from the PFC (containing the prelimbic cortex; Bregma level +3.72mm to +2.52mm) and
hippocampus (Bregma level -2.92mm to -6.00mm). Consecutive sections (series of 3
sections per region, per rat, taken at 1 in every 10 sections) were collected for
immunohistochemistry experiments (14µM) and thaw-mounted onto PolysineTM slides
(Sigma-Aldrich, Castlehill, NSW, Australia) then stored at -20OC until further analysis.
Sections (3 per region, per rat) collected for Immunoblot experiments (500µM) were
mounted on glass slides and regions of interest (PFC and hippocampus) were
microdissected using a micropuncture kit, then stored at -80OC until further use. This
dissection protocol enabled the investigation of both immunohistochemistry analysis
and protein levels from the same animals.

2.3. Immunoblotting
Immunoblot procedures were performed as previously described (Millard et al., 2019).
Protein (10 μg/well) from PFC and hippocampus were separated using 4-20% TGX
precast gels (Bio-Rad, Australia), transferred onto PVDF membranes (Bio-Rad) and
membranes blocked with either 5% BSA or skim milk (w/v) for 1hr at room temperature.
Membranes were incubated overnight in primary polyclonal antibodies BDNF, TrkB and
p75 (further details for antibodies and bands quantified can be found in supplementary
table 4.1), then subsequently with HRP-conjugated secondary antibodies (1:5000;
AP307P/AP308P, Millipore). Amersham ECL western blotting detection reagent (GE
Healthcare, Australia) was then applied to membranes, followed by exposure to
Hyperfilm (GE Healthcare, Australia). Films were scanned using a GS-800 scanner (BioRad) and densitometry values were quantified for mature (14KDa) and pro (32KDa)
forms of BDNF, full length TrkB (140KDa) and p75 (75KDa). Relative values for each
protein were normalised respective to β-Actin levels and an internal control value, to
account for protein loading and gel-gel variability, respectively. Each sample (n=7/group)
was run in triplicate.

2.4. Immunohistochemistry
3,3’-diaminobenzidine (DAB) immunohistochemistry (IHC) for NeuN was carried out on
fresh frozen brain sections as detailed previously by Fung et al., (2010). Briefly, sections
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containing the PFC and hippocampus were thawed at room temperature for 20minutes
and then fixed in 4% paraformaldehyde in PBS (137 mM NaCl, 2.7mM KCl, 8mM
Na2HPO4, 2mM KH2PO4, pH 7.4) for 10minutes at room temperature then washed in
PBS. Endogenous peroxidases were then quenched using 3% methanol and H 2O2
solution for 20minutes at room temperature. Sections were again washed in PBS then
blocked in 10% goat serum in diluent (0.10% bovine serum albumin (BSA), 0.3% triton X100 in PBS) for 1 hour at room temperature. Rabbit anti-NeuN antibody (abcam
ab177487, 1:500 in diluent) was applied overnight at 40C. Following washing in PBS, goat
anti rabbit IgG biotinylated secondary antibody (ab6720, 1:500 in diluent) was applied
for 1 hour at room temperature. Slides were again washed and incubated in avidinbiotin-peroxidase complex (Vectastain ABC kit; Vector Laboratories) and treated with
DAB (Sigma, in PBS with 0.003% H2O2) for 15 minutes. Slides were counterstained with
Hematoxylin (Sigma, H3136) and coverslipped. For a negative control, the primary
antibody was omitted and did not show immunoreactivity.

2.5. NeuN+ Quantification
The protocol for quantifying NeuN+ immunoreactive cells was followed as previously
detailed (Allen et al., 2016). NeuN+ immunoreactive cells were imaged using the Leica
ICC50 HD microscope camera (Leica, Wetzlar, Germany), same brightness and contrast
settings and counted under a 10x objective. Cells were counted throughout the
prelimbic cortex and CA1, CA3 and Dentage Gyrus (DG) regions of the hippocampus on
every 10th section (3 series), areas of interest were identified and defined using a
standard rat brain atlas (Paxinos and Watson, 2007) (figures 4.2 and 4.3). For the
prelimbic cortex (PrL), superficial (<600um) and deep layers (>600um) (measured from
the longitudinal fissure) were quantified separately, then added to give combined PrL
NeuN+/mm2. The distance of <600um from the longitudinal fissure was chosen in order
to capture primarily cell layers I, II and III, whilst >600um captured deeper layers, V and
VI (Douglas and Martin, 2004; Paxinos and Watson, 2007; Santana and Artigas, 2017).
Cells were considered NeuN+ immunoreactive if their staining profile revealed an
intensely stained, medium round or oval cell body, and nucleus revealed by hematoxylin
counterstain. NeuN+ immunoreactive cells were quantified using ImageJ (NIH), the open
source imaging analysis program (Schneider et al., 2012). All images underwent
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standardized parameter setting of illumination to hold brightness and contrast constant,
an automatic threshold was used to identify immunoreactive cells within the area(s) of
interest. NeuN+ immunoreactive cell counts were converted to number of NeuN+
cells/mm2. Using the measurement function on imageJ (NIH), area was determined by
measuring a representative section of the PrL (figure 4.2), and for the hippocampus
(figure 4.3) by using the freehand selection tool on imageJ (NIH). All quantification was
completed by a researcher blind to the conditions.

Figure 4.2: Representative image showing areas of NeuN+ Cells/mm2 quantified in the (a) superficial
(<600µM) and (b) deep layers (>600µM) of the prelimbic cortex. Abbreviations: ACA = Anterior
Commissure; CG1 = Cingulate Cortex; fmi = Forceps Minor Corpus Callosum; HPC = Hippocampus; IL =
Inralimbic Cortex; M1 = Primary Motor Cortex; M2 = Secondary Motor Cortex; PFC = Prefrontal Cortex;
PrL = Prelimbic Cortex.
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Figure 4.3: Representative NeuN staining in the hippocampus. NeuN+ Cells/mm2 were quantified in the
CA1, CA3 and dentate gyrus regions. Abbreviations: DG = Dentate Gyrus

2.6. Statistical Analysis
Data were analysed using SPSS statistical software (NY, IBM Corp. v25.). Normality was
confirmed using a Kolmogorov-Smirnov test. Two-way Analyses of Variance (ANOVA)
were used to determine any effects of treatment (FLX or VEH) or strain (WKY or SD) on
relative protein densities and NeuN+ cell counts. Where interactions were found, oneway ANOVAs were used to identify differences between groups. Correlations between
time in the open and closed arms of the elevated plus maze (EPM) and immobility in the
forced swim test (FST) (as previously reported in Millard et al 2019b) with NeuN+ cell
counts and relative BDNF signalling protein densities were assessed using Pearson’s test
for correlation. Significance was set at an alpha of p = 0.05.
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3. Results
3.1. Immunoblot
No effects of TREATMENT, STRAIN or any significant TREATMENT x STRAIN interactions
were detected in the PFC (Figure 4.4; a and b). In the hippocampus, there was a
significant effect of TREATMENT on relative levels of proBDNF (F1, 27 = 4.744, p=0.039)
and BDNF (F1, 27 = 8.980, p=0.007). Overall, fluoxetine exposed offspring showed reduced
levels of proBDNF (-21%) and increased levels of BDNF (+110%) in the hippocampus
compared to vehicle exposed offspring (Figure, 4.4; c and d).

Figure 4.4: Relative levels of proBDNF and BDNF in the PFC (a, b) and HPC (c, d) at PN42. Abbreviations:
HPC = Hippocampus; PFC = Prefrontal Cortex; SD = Sprague-Dawley; WKY = Wistar Kyoto. Data expressed
as mean values + SEM. *p<0.05, **p<0.01

In the PFC there was a significant effect of TREATMENT on relative levels of TrkB (F1, 27 =
6.917, p = 0.015) and a non-significant trend of effect on levels of p75 (F1, 27 = 3.541,
p=0.072). There was also a significant effect of strain influencing p75 levels in the PFC
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(F1, 27 = 5.128, p=0.033). Overall, FLX exposure increased relative levels of TrkB (+28%)
and reduced levels of p75 (-16%;) in the PFC. Furthermore, offspring of the WKY strain
exhibited reduced levels of p75 (-17%) in the PFC compared to SD offspring. In the
hippocampus, there was a significant effect of TREATMENT on TrkB levels, with a 28%
reduction in TrkB (F1, 27 = 10.361, p = 0.004) and a significant TREATMENT x STRAIN
interaction influencing relative levels of p75 (F3, 25 = 6.445, p=0.018). Post-hoc analyses
revealed a non-significant trend of effect reducing p75 levels in fluoxetine exposed WKY
offspring (-14%; p=0.075) compared to respective WKY vehicle controls. No further
TREATMENT, STRAIN or TREATMENT x STRAIN interactions were detected (figure 4.5).

Figure 4.5: Relative levels of TrkB and p75 in the PFC (a, b) and HPC (c, d) at PN42. Abbreviations: HPC =
Hippocampus; PFC = Prefrontal Cortex; SD = Sprague-Dawley; WKY = Wistar Kyoto. Data expressed as
mean values + SEM. *p<0.05, **p<0.01, ^p=0.072 ^^p=0.075; #p<0.05 compared to SD (overall strain
effect)
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3.2. Immunohistochemistry
In superficial, deep and combined cell layers of the PrL there were significant
TREATMENT x STRAIN interactions (Superficial: F3, 24 = 9.169; p=0.006; Deep: F3, 24 =
13.647; p=0.001; Combined: F3, 24 = 13.858; p=0.001). Post-hoc analyses revealed that
fluoxetine exposed WKY offspring showed increased NeuN+ cell counts/mm 2 in
superficial (+25%, p=0.021), and combined cell (+19%, p=0.05) layers compared to WKY
vehicle. In contrast, SD Fluoxetine offspring showed a tendency towards reduced NeuN+
cell counts/mm2 in the combined cell layers (-14%, p=0.084) which was driven by a
significant reduction in the deep layers ( -18%, p=0.017). Furthermore, WKY-VEH rats as
a model of depression showed a reduction in NeuN+ cell counts in combined layers and
the deep layers specifically compared to SD-Veh offspring (Combined cell layers: -17%,
p=0.025; Deep layers: -22%, p=0.003) (figure 4.6).

Figure 4.6: NeuN+ Cells/mm2 were quantified in the (a) superficial (<600µM) and (b) deep layers
(>600µM) of the prelimbic cortex. The sum of superficial (a) and deep (b) layer NeuN+ cell/mm2 were
given as combined NeuN+ cell/mm2 (c). Abbreviations: ACA = Anterior Commissure; CG1 = Cingulate
Cortex; fmi = Forceps Minor Corpus Callosum; HPC = Hippocampus; IL = Inralimbic Cortex; M1 = Primary
Motor Cortex; M2 = Secondary Motor Cortex; PFC = Prefrontal Cortex; PrL = Prelimbic Cortex; SD =
Sprague-Dawley; WKY = Wistar Kyoto. Data expressed as mean NeuN+ cells/mm2 + SEM. *p≤0.05
**p<0.01; ^p= 0.084

In the hippocampus, there was a significant effect of TREATMENT (CA1: F1, 26=18.788,
p<0.001) and STRAIN (CA1: F1, 26= 11.415, p<0.01, DG: F1, 27=11.764, p<0.01) on NeuN+
cell counts in the CA1 and DG regions. Overall FLX-exposed offspring exhibited reduced
NeuN+ cell counts in the CA1 (-22%) region compared to vehicle exposed. In addition,
offspring of the WKY strain exhibited reductions in NeuN+ cell counts in both the CA1 (18%) and DG (-12%) regions of the hippocampus compared to SD offspring (figure 4.7).
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Figure 4.7: NeuN+ Cells/mm2 were quantified in the CA1 (a), CA3 (b) and dentate gyrus (c) regions of
the hippocampus. Abbreviations: DG = Dentate Gyrus; SD = Sprague-Dawley; WKY = Wistar Kyoto. Data
expressed as mean NeuN+ cells/mm2 + SEM. ***p<0.01; ##p<0.01 compared to SD (overall strain effect).

3.3. Correlations
To determine if any significant relationship(s) existed between BDNF/TrkB signalling and
NeuN+ cell counts/mm2 with previously measured anxiety- and depressive-like
behaviours in the EPM and FST of the same female offspring (Millard et al., 2019b, under
review), we employed Pearson’s test of correlations.

While measures of PFC p75 were associated with anxiety-related parameters in the EPM
(Supp table 1), NeuN+ neuronal counts in the PrL and hippocampus showed the most
consistent relationship with anxiety- and depressive-like behaviours across both
behavioural tests. Combined NeuN+ cell counts in the PrL were negatively correlated
with immobility time in the FST (r = -0.420; p = 0.026), as well as time spent in the closed
arms of the EPM (r = -0.399; p = 0.035); an association that was driven by the deeper
layers (FST: r = -0.474; p = 0.011, EPM: r = -0.525; p = 0.004) (Figures 4.8 + 4.9). Further
correlations were detected with NeuN+ cell counts in the deeper layers of the PrL and
distance travelled (r = 0.452; p = 0.016), and time spent in the open arms of the EPM (r
= 0.356; p = 0.063) (Supp table 1). In the Hippocampus, NeuN+ neuronal counts in the
CA1 regions correlated with all previously measured behavioural parameters including,
distance travelled (r = 0.569; p = 0.002), and time in the open (r = 0.373; p = 0.055) and
closed arms (r = -0.438; p = 0.022) of the EPM, as well as immobility time in the FST (r =
-0.501; p = 0.008) (Supp table 2). Finally, NeuN+ counts in the dentate gyrus was
negatively correlated with time spent in the closed arms of the EPM (r = -0.487; p =
0.009) and immobility duration in the FST (r = -0.509; p = 0.006) (figures 4.8 + 4.9).
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Figure 4.8: Correlations between NeuN+ densities (NeuN/mm2) in the (a) superficial, (b) deep and (c)
combined PrL cell layers, and (d) CA1, (e) CA3 and (f) DG regions of the HPC with time spent in the closed
arms of the EPM. Abbreviations: DG = Dentate Gyrus; EPM = Elevated Plus Maze; HPC = Hippocampus; PrL
= Prelimbic Cortex.

139

Figure 4.9: Correlations between NeuN+ densities (NeuN/mm 2) in the (a) superficial, (b) deep and (c)
combined PrL cell layers, and (d) CA1, (e) CA3 and (f) DG regions of the HPC with immobility time in the
FST. Abbreviations: DG = Dentate Gyrus; FST = Forced Swim Test; HPC = Hippocampus; PrL = Prelimbic
Cortex.

4. Discussion
This study provides evidence that in a rodent model of depression, NeuN+ cell counts
are reduced in the PFC and hippocampal CA1 and DG regions of female WKY offspring
at adolescence, which may underlie the depressive- and anxiety-like phenotype of the
strain. Furthermore, perinatal FLX exposure restored cortical NeuN+ deficits in WKY
rats, to levels observed in controls (SD-VEH) but exacerbated deficits present in the
hippocampal CA1 region. In SD offspring, perinatal FLX exposure induced PFC and
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hippocampal deficits in NeuN+ counts similar to that observed in the WKY strain at
baseline. In this study, we also provide evidence that perinatal FLX exposure induces
changes in neurotrophic markers in the PFC and hippocampus of female adolescent
offspring, largely irrespective of strain. Specifically, in the PFC, FLX exposure increased
TrkB and decreased p75, but did not induce changes in BDNF (pro- or mature forms) in
both SD and WKY strains. In the hippocampus, perinatal FLX exposure increased mature
BDNF, but decreased proBDNF and TrkB in both strains. Collectively these findings
suggest that perinatal FLX exposure can influence PFC and hippocampal BDNF-TrkB
signalling largely irrespective of strain and can rescue deficits in PFC NeuN+ counts in
WKY offspring, whilst producing detrimental effects in SD offspring.

4.1 Neuronal number is reduced in the prefrontal cortex and hippocampus of female
adolescent WKY rats; and mediated by exposure to perinatal Fluoxetine in a brain region
specific manner

In the present study, we found that female WKY offspring exhibit reductions in NeuN+
cells in the deep PrL layers, and CA1 and DG regions of the hippocampus compared to
SD offspring, all of which correlated with immobility time in the FST (figure 4.9) and time
spent in the closed arms of the EPM (figure 4.8). Taken with our previous findings of
reduced PSD-95 and glutamatergic receptors in this strain (Millard et al., 2019a; Millard
et al., 2019b), this suggests that the reduced hippocampal and cortical volumes reported
in WKY rats (Cominski et al., 2014; Gormley et al., 2016) could be due to losses in
neuronal synapses (PSD-95) and neuron cell bodies (NeuN+) and may underpin their
innate anxiety- and depressive-like phenotype (Millard et al., 2019c, WKY review). In
agreeance with our findings, another study reported reductions in BrdU+/DCX+ ratios in
the dentage gyrus, a region characterized by high rates of neurogenesis, in adult (albeit
male) WKY rats (Kin et al., 2017). Reduced cortical and hippocampal volume, as well as
alterations in neurogenesis have all been reported in clinical cases of major depressive
disorder (Bremner et al., 2000). Accordingly, recent evidence suggest widespread
reductions in the gray matter volume and cortical thickness of clinically depressed
patients (Grieve et al., 2013) with atrophy and neuronal loss becoming a significant
feature of major depressive disorder (Duman and Li, 2012). Collectively, data from the
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current study provides further evidence that dysfunction in neurogenesis and neuronal
morphology could underpin depressive-like phenotypes and clinical cases of major
depressive disorder. Future investigations following the developmental sequelae of
depressive-like phenotypes and markers of neurogenesis/neuronal morphology in the
WKY strain could help decipher the aetology of major depressive disorder in the clinic.

We have shown that perinatal fluoxetine exposure in the WKY strain corrected NeuN+
deficits in the prelimbic region of the PFC, but exacerbated deficits in the hippocampus.
Smilarly, a previous investigation into the effects of perinatal fluoxetine exposure in a
model of maternal adversity showed that fluoxetine exposure had a deleterious effect
on hippocampal doublecortin, a marker of immature neurons, in offspring exposed to
prenatal stress (Rayen et al., 2015). Furthermore, we showed that perinatal FLX
exposure induced deficits in NeuN+ cell counts in both the prelimbic cortex and
hippocampus of SD offspring, suggesting that WKY may be more resilient to the effects
of perinatal FLX exposure on cortical NeuN+. The main prelimbic cortex projection sites
include that of the agranular insula cortex, nucleus accumbens, the basolateral nucleus
of the amygdala and the raphe nuclei of the brainstem (Vertes, 2004). Moreover, the
PrL receives extensive monosynaptic glutamatergic projections from the ventral
hippocampus, which make up the hippocampo-prefrontal pathway (Ghoshal and Conn,
2015). These areas of the brain are physiologically implicated in functions including
anhedonia and the reward response, fear and anxiety, and emotionality-related
behaviours (Davis et al., 2010; Heshmati and Russo, 2015; Kesner and Gilbert, 2007).
Furthermore, the raphe nuclei of the brainstem houses serotonergic cell bodies,
dysfunction of which has been heavily associated with mood and anxiety-related
disorders (Lowry et al., 2008; Michelsen et al., 2008). Brainstem monoamine groups,
such as serotonergic cell bodies in the raphe nucleus, are modulated by dense
glutamatergic neurons from layer V pyramidal neurons of the medial PFC (comprised of
prelimbic and infralimbic cortices) (Santana and Artigas, 2017; Yamashita et al., 2017),
and serotonergic activation within the medial PFC mediates anxiolytic behaviours via
5HT1A receptors (Yamashita et al., 2018). In addition, these deeper layers of the medial
PFC also contain the highest proportion (compared to superficial layers I-III) of
pyramidal, and GABAergic neurons expressing monoamine receptors (5HT,
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Dopaminergic and adrenergic) (Li et al., 2010; Santana and Artigas, 2017). Therefore, the
neuronal deficits we observed in FLX exposed SD offspring, specifically in the deep
cortical layers which are characterized by dense connectivity to brain regions implicated
in emotionality-related phenotypes, could contribute to aberrations in behaviour. In
support of this notion, we have previously reported that female adolescent SD, but not
WKY offspring exposed to perinatal FLX treatment, exhibit increases in anxiety-like
behaviours, such as reduced exploratory behaviour and locomotor activity (Millard et
al., 2019b). Moreover, reductions in PrL NeuN+ cell counts correlated with an increased
anxiety-like phenotype in all parameters of the EPM (Figure 4.8). This finding coincides
with findings from a study showing that damage to the PrL results in decreased
exploratory behaviours in the OFT and EPM (Jinks and McGregor, 1997). Given that
NeuN stains neurons indiscriminately, we cannot be certain whether glutamatergic,
GABAergic or other monoaminergic neurons were affected and are contributing to the
behavioural phenotype observed. More recently though, optogenetic inhibition
specifically of PrL pyramidal neurons has been shown to produce a robust anxiety-like
phenotype in the OFT and EPM (Wang et al., 2015). Collectively, these findings suggest
that female SD offspring may be more sensitive to the effects of perinatal FLX exposure,
which could be mediated through alterations in cortical modulation of serotonergic
signalling. Future studies investigating the effect of perinatal FLX exposure on distinct
neuronal subtypes in the PrL will help decipher the mechanism through which exposure
alters adolescent behaviours.

The differential effects of perinatal FLX exposure on NeuN+ cell counts in the PrL
observed between strains might be explained by the underlying serotonergic phenotype
they each exhibit, and the role of serotonin in development. Migrating glutamatergic
thalamic neurons projecting to sensory cortices, as well as pyramidal neurons in the PFC
and hippocampus, transiently express the serotonin transporter from embryonic day 17
to PN12 (Chen et al., 2016; Gaspar et al., 2003b). The transient expression of SERT
suggests that migrating glutamatergic neurons take up serotonin as a borrowed
neurotransmitter aiding in migration and proliferation of developing neurons (Gaspar et
al., 2003b; Millard et al., 2017). It is plausible to suggest that increases in serotonin
during this time, caused by perinatal FLX exposure, could disrupt the migration of SERT143

expressing neurons to thalamic and cortical areas including the PFC. Evidence from
genetic studies suggests that selective deletion of SERT from glutamatergic neurons (i.e.
thalamocortical neurons), results in disrupted thalamocortical afferent organization and
barrel cortex formation (Chen et al., 2016, 2015; Teissier et al., 2017). Furthermore, SERT
KO mice which exhibit a hyper-serotonergic state similar to perinatal SSRI exposed
rodents (Velasquez and Bonnin, 2016), display aberrations in neurodevelopment and
associated behaviours (for review see Millard et al., 2017). Accordingly, SSRIs target the
SERT, and reductions in available SERT (as demonstrated in SERT -/- mice) attenuate the
ability for SSRIs to exert their effects (Ansorge et al., 2004). In the WKY strain, the
serotonergic phenotype is downregulated, evident through reductions in cortical and
hippocampal SERT expression, and reduced serotonin content with raphe cell bodies
(Lemos et al., 2011; Pare and Tejani-Butt, 1996; Yamada et al., 2013). Based on these
observations it could be suggested that WKY rats display some resilience to the effects
of SSRI exposure, because i) they exhibit an innate reduction in SERT, and therefore
ability for SSRIs to exert their effects, and/or ii) downregulation of the serotonergic
system and therefore attenuated release of serotonin in response to SSRIs (Millard et
al., 2019c, WKY review). Furthermore, not only did we observe behavioural resistance
to the effects of perinatal FLX exposure (Millard et al., 2019b, under review), but an
amelioration of NeuN deficits in the PFC of female WKY rats. This finding suggest that
perinatal SSRI exposure could even ‘correct’ levels of endogenous serotonin in
hyposerotonergic rats during neurodevelopment, resulting in amelioration of a
depressive-like phenotype or at least resistance to the detrimental effects of exposure.
Whilst this remains speculative until further research is conducted, in the clinic,
response to SSRIs is determined by specific SERT alleles carried by individuals (Murphy
and Moya, 2011). Therefore, it may be that maternal SSRI treatment could have
differential effects on the mother and developing child depending on genetic expression
and functionality of SERT during development.

Ultimately, these data show that the effects of perinatal FLX exposure on
neurodevelopment and behaviour in a rodent model of depression are attenuated and
could be explained by underlying strain differences in serotonergic phenotypes. These
findings highlight the need to implement relevant models of depression when
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investigating the effects of SSRI exposure on offspring. Future studies investigating
differences in SERT expression during neurodevelopment between rodent models of
depression, will help elucidate the mechanism through which perinatal SSRI exposure
produces detrimental effects.

4.2. Perinatal FLX exposure causes alterations in cortical and hippocampal BDNF-TrkB
signalling pathways
We previously showed that FLX exposure in SD and WKY adolescent female offspring
had largely negligible effects on glutamatergic receptors, but did reduce the key
scaffolding protein, PSD-95, in the hippocampus (Millard et al., 2019b). Based on these
findings and the link between PSD-95 and the BDNF-TrkB signalling pathway (Yoshii and
Constantine-Paton, 2014, 2007), we hypothesised that perinatal FLX exposure would
induce alterations in BDNF-TrkB signalling in these female offspring. Indeed, we showed
that perinatal FLX exposure reduced relative expression of hippocampal TrkB in both
strains. Interestingly, we also observed an increase in hippocampal BDNF, and decrease
in proBDNF suggesting increased BDNF protein turnover. This finding seems paradoxical
considering the observed reductions in NeuN+ and PSD-95 that indicate reduced
neuronal and synaptic growth. However, it may be that the increased BDNF turnover is
a compensatory reaction to hippocampal stress or aberrant development resulting from
perinatal FLX exposure. Accordingly, one study has shown that stress induces increases
in hippocampal BDNF mRNA as a potential compensatory response to preserve
hippocampus homeostasis (Marmigère et al., 2003).

Previous studies demonstrated that perinatal FLX exposure reduced BDNF mRNA in the
hippocampus in adult female rats and reduced both BDNF and TrkB mRNA in the
hippocampus of adult male offspring, largely irrespective of exposure to maternal stress
(Boulle et al., 2016a, 2016b). This finding seems to conflict with our own considering we
observed increases in mature BDNF; however, we did observe decreases in proBDNF,
which might suggest decreased mRNA levels and transcription of the protein. It must be
noted that the BDNF production pathway is complex and heavily regulated at several
levels from gene to protein (Greenberg et al., 2009; Zheng et al., 2012). For example,
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preproBDNF is synthesised in the endoplastic reticulum before being cleaved to form
proBDNF, after which proBDNF may be converted to mature BDNF via proteolytic
cleavage intracellularly or in immature secretory granules and stored (Dieni et al., 2012;
Greenberg et al., 2009). Therefore, drawing comparisons between levels of mRNA and
functional protein needs to be taken with caution. Interestingly, we observed changes
in BDNF/TrkB signalling irrespective of strain, but strain specific changes in behaviour
(Millard et al., 2019a; Millard et al., 2019b). This finding suggests that changes in
BDNF/TrkB signalling caused by perinatal FLX exposure, might not underpin anxiety-like
behaviours in female adolescent offspring, but could contribute to other behavioural
phenotypes such as deficits in cognition. In support of this, several recent studies have
linked cognitive function at adolescence, such as changes in spatial learning and memory
with alterations in BDNF/TrkB signalling (Han et al., 2011; Li et al., 2016; Uysal et al.,
2015). Furthermore, taken together with the observation that perinatal FLX exposure
reduced hippocampal neuronal number, and the association between hippocampal
function and cognitive related behaviours (Lisman et al., 2017); this raises the question
regarding the effects of FLX exposure on female cognition at adolescence.

A large body of research has linked dysfunction of neurotrophic factors, such as BDNFTrkB signalling, with major depressive disorder and depressive-related behaviours
(Belmaker and Agam, 2008; Brunoni et al., 2008). However, we observed only minor
differences between strains in measures of the BDNF-TrkB signalling pathway, with
female WKY rats exhibiting reduced p75 in the PFC only. The negligible differences in
neurotrophic factors between strains seems paradoxical given the role that BDNF-TrkB
signalling plays in the expression and trafficking of NMDA receptors and associated
synaptic scaffolding protein PSD-95 (Caldeira et al., 2007; Yoshii and Constantine-Paton,
2014) and the fact that we previously observed reductions in these markers (Millard et
a., 2019a; Millard et al., 2019b). Furthermore, other previous investigations have
reported reductions in cortical, hippocampal and serum BDNF in adult WKY rats,
however these studies have been conducted in males (Janke et al., 2015; O’Mahony et
al., 2011; Vinod et al., 2012). It may be that female WKYs exhibit more subtle differences
in the BDNF-TrkB signalling system compared to males. Indeed, it has been shown that
absolute levels of brain BDNF are higher in females rats, and that early life stressors
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decreases BDNF transcription in the male hippocampus only (Chan and Ye, 2017).
Therefore, we might expect that comparisons in the BDNF-TrkB signalling systems
between male and females would yield conflicting or at least differential results.
Ultimately, further investigation into the BDNF-TrkB signalling profile of the WKY strain
across sexes and multiple developmental time periods will help elucidate the
neurobiological profile underpinning the strains behavioural phenotype.
5. Conclusion
In summary, our results show that adolescent female WKY rats exhibit widespread
deficits in both PFC and hippocampal NeuN+ counts, which could contribute to the
neurobiology underpinning the strains’ depressive-like phenotype. Furthermore,
perinatal FLX exposure corrected NeuN+ deficits in the prelimbic cortex of WKY
offspring, and conversely produced detrimental effects in the PrL of SD offspring. These
strain-specific differences in PrL NeuN+ counts could underpin the female WKY
resilience, and SD susceptibility, to the anxiogenic behavioural effects of perinatal FLX
exposure at adolescence. Furthermore, perinatal FLX exposure also caused alterations
to PFC and hippocampal BDNF-TrkB signalling in adolescent female offspring irrespective
of strain. Collectively, these findings suggest that deficits in PrL NeuN+ cell counts, rather
than alterations in BDNF/TrkB signalling, could underpin anxiety-like behaviours
observed in fluoxetine exposed female adolescent SD offspring. Taken together with
previous findings, these data suggest that in female offspring, perinatal FLX exposure
has strain specific effects on behaviour and neurobiology. These findings highlight the
importance of using models of depression when investigating the effects of perinatal
SSRI treatment on offspring. Further research investigating the effects of perinatal FLX
exposure on offspring behaviour and BDNF/TrkB signalling between sexes and in a wider
test battery, will help decipher the consequences of exposure on offspring. Given the
growing incidence of maternal depression and the use of SSRIs, it is crucial to find ways
to reduce harm in sufferers of MDD. Ultimately, more investigation utilizing valid rodent
models of depression, and both sexes, will be critical to understanding the
neurodevelopmental effects of perinatal SSRI exposure.
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Supplementary Materials
Supplementary Table 4.1: Antibody details

Antibody
anti-BDNF
anti-TrkB
anti-p75
Anti-NeuN
anti-β-Actin
HRP Conjugated Secondary

Concentration
1:2500
1:5000
1:500
1:500
1:100 000
1:5000

Manufacturer (Cat #)
Abcam (ab108319)
Abcam (ab18987)
Abcam (ab8874)
Abcam (ab177487)
Millipore (MAB1501)
Millipore (AP307P/AP308P)

Supplementary Table 4.2: Summary table of correlations between Immunoblot markers and
NeuN cell counts in the PFC, with previously measured behavioural parameters.

Abbreviations: EPM = Elevated Plus Maze; FST = Forced Swim Test; HPC = Hippocampus; PFC =
Prefrontal Cortex; PrL = Prelimbic Cortex
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Supplementary Table 4.3: Summary table of correlations between Immunoblot markers and
NeuN cell counts in the HPC, with previously measured behavioural parameters.

Abbreviations: EPM = Elevated Plus Maze; FST = Forced Swim Test; HPC = Hippocampus; PFC =
Prefrontal Cortex; PrL = Prelimbic Cortex
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Chapter 5

5.1 Study rationale and aims
Previous works from this thesis (Chapter 2 and 3), found that perinatal fluoxetine
exposure increased anxiety-like behaviours and forced swim test immobility in exposed
offspring at adolescence. In addition, fluoxetine exposed offspring exhibited alterations
in glutamatergic NMDA and group 1 mGluR receptor signaling across prefrontal cortex
and hippocampus areas, suggesting that alterations in the glutamatergic system could
underpin these behaviours. We also observed that males were most susceptible to the
effects of perinatal Fluoxetine exposure, with both Sprague-Dawley and Wistar-Kyoto
offspring displaying adverse behavioural and neurobiological responses to exposure.
Whilst these findings are largely in agreeance to preclinical findings, most of the
preclinical literature investigating the effects of perinatal fluoxetine exposure has been
conducted using adolescent or adult rodents. Therefore, in the present study we sought
to investigate the effects of perinatal fluoxetine exposure on the glutamatergic profile
of male offspring at postnatal day 14, with the aims of determining whether previous
changes observed at adolescence arise at an earlier developmental time period. This last
point should be emphasized given that earlier time periods could represent a window
of opportunity for therapeutic intervention in the prevention of the negative effects of
perinatal fluoxetine exposure previously reported in this thesis at adolescence.
5.2 Manuscript details
The results of Chapter 5 have been prepared for publication as a manuscript titled,
Perinatal Fluoxetine treatment increases NMDA receptor subunits NR2A and NR2B at
postnatal day 14 in Sprague-Dawley, but not Wistar-Kyoto rats
5.3 Author contributions
S. Millard performed the experiments, acquired and analyzed the data, wrote the first
draft of the manuscript, which all authors reviewed and approved for publication.
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1. Introduction
Increasing evidence suggests that perinatal SSRI exposure can increase the risk for
adverse outcomes in exposed offspring, such as an

increased

risk for

neurodevelopmental disorders and associated behaviours (Millard et al., 2017). Clinical
studies investigating the effects of perinatal SSRI exposure in offspring as early as birth
have reported reductions in cord blood neurotransmitter metabolites, including
serotonin, noradrenaline, 5-HIAA and HVA levels (Laine et al., 2003). Furthermore, one
study found reduced levels of S100β (a marker of nervous system pathology (Michetti
et al., 2012)) in cord serum of neonates exposed prenatally to SSRIs (Pawluski et al.,
2009); a finding consistent with those observed in offspring exposed to prenatal alcohol
and cocaine (Akbari et al., 1994; Michetti et al., 2012; Tajuddin and Druse, 1999).
Collectively, these studies suggest that perinatal SSRI exposure can alter
neurodevelopment, the manifestations of which arise as early as birth in humans
(equivalent to postnatal day 14 in rodents, (Semple et al., 2013)).

Preclinical evidence has largely shown that SSRI exposure during the perinatal period
can lead to neurobiological and behavioural alterations in exposed offspring at
adolescence and adulthood (Millard et al., 2017). However, to date, the majority of
these studies assess the effects of perinatal SSRI exposure in otherwise healthy rodents.
Indeed, untreated maternal depression is itself associated with an increased risk for
neurobiological and behavioural abnormalities in exposed offspring (Bonari et al., 2004;
Davalos et al., 2012), and therefore should be taken into consideration when assessing
the safety of perinatal SSRI use. This last point should be emphasized given that the
interaction between maternal depressive phenotypes and perinatal SSRI exposure could
represent a considerable variable. To address this limitation and isolate and compare
the effects of perinatal SSRI +/- maternal depressive phenotypes on offspring, we
previously investigated the effects of perinatal FLX exposure on offspring adolescence
in a rodent model of maternal depression.

By using a rodent model of depression, the Wistar-Kyoto (WKY) rat (Millard et al., 2019b,
Will et al., 2003) we showed that perinatal exposure to FLX exacerbates anxiety- and
153

depressive-like behaviours in male WKY rats, and imparts these same behaviours in a
control strain (Sprague-Dawley) at adolescence (Millard et al., 2019). Furthermore,
exposure to perinatal FLX treatment differentially altered key glutamatergic markers in
the prefrontal cortex (PFC) and ventral hippocampus (vHPC), irrespective of strain,
suggesting that in male offspring, perinatal exposure to FLX treatment is deleterious to
exposed offspring, irrespective of maternal depressive phenotypes (Millard et al., 2019).
To determine whether the alterations in glutamatergic neurobiology that we previous
reported in adolescence (Millard et al; chapter 2) indicate a continuum of aberrant
glutamatergic signalling beginning at an earlier time period, we sought to investigate the
effects of perinatal FLX exposure on the same markers at PN14.

2. Materials and Methods
Animals and Perinatal SSRI Treatment
Male and female SD and WKY rats were obtained from the Animal Resource Centre,
Western Australia. Rats were housed at the University of Wollongong Animal Housing
Facility in a temperature-controlled environment (200C±2) under a 12:12 hour light-dark
cycle (lights on at 0700). The rats were provided with ad libitum access to water and
laboratory chow. Females were housed 1 per cage; males were housed 2 per cage of the
same strain. Following a minimum of one-week acclimatisation, male and female SD or
WKY rats were paired to elicit mating. At the conclusion of the mating period, pregnant
dams were randomly assigned to a FLX or vehicle (VEH) (water) treatment group.
Pregnant SD and WKY dams were dosed with FLX Hydrochloride (LKT Laboratories, St.
Paul, MN, USA) (10 mg/kg dissolved in tap water) or VEH (tap water), for the full
gestational term and a further two weeks of the lactation period (i.e. five weeks in total),
with the last day of treatment corresponding to PN14 of the offspring as previously
detailed (Millard et al., 2019a, 2019b) (figure 5.1). Following the birth of pups, which
was designated as post-natal day 0 (PN0), pups were housed with their dam and litter
mates until PN14 days of age, at which time they were euthanised and tissue collected
for immunoblot analysis.
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Figure 5.1: Timeline of perinatal fluoxetine treatment and immunoblot analysis. Abbreviations: FLX:
Fluoxetine; GD: Gestational Day; PN: Postnatal Day; SD: Sprague-Dawley; Veh: Vehicle; WKY: WistarKyoto.

Immunoblotting
Male rats were euthanised at PN14 (equivalent to birth in humans (Semple et al., 2013))
and the last day of perinatal SSRI treatment, via rapid decapitation and the PFC (Bregma
+3.70mm) and vHPC (Bregma -2.80mm) were dissected according to a standard rat brain
atlas (Paxinos and Watson, 2007). Immunoblotting procedures were carried out as
detailed previously (Millard et al., 2019a, 2019b). Briefly, equal amounts of protein
(5ug/well) were separated in 4-20% Tris-Glycine-eXtended (TGX) precast gels (Bio-Rad,
Australia) under non-reducing conditions (Lum et al., 2016). Following electrophoresis,
proteins were transferred onto polyvinylidene difluoride (PDVF) membranes (Bio-Rad,
Australia) and membranes blocked with 5% BSA or skim milk (w/v) for 60 minutes at
room temperature. The membranes were incubated overnight in primary polyclonal
antibodies (NR1, NR2A, NR2B, PSD-95, mGluR1, mGluR5, Homer1b/c and β-Actin;
Supplementary Table 5.1). Membranes were subsequently incubated with horseradish
peroxidase conjugated secondary antibodies. Bands were visualised using Amersham
ECL western blotting detection reagent (GE Healthcare, Australia) and membranes
exposed to Hyperfilm (GE Healthcare, Australia). Films were scanned using a GS-800
scanner (Bio-Rad) and densitometry values were quantified. For primary polyclonal
antibodies NR2A and NR2B, an extra band was detected under the expected band of
165KDa, these extra bands are not present in adolescent male tissue and we are unsure
as to the identity of these bands. Accordingly, we quantified only the expected 165KDa
band. Relative densitometry values for each protein were normalised to their respective
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β-actin levels and an internal control value, to account for protein loading and gel-gel
variability, respectively. Each sample (n=5/group) was run in triplicate.

Statistical Analysis
Two-way Analyses of Variance (ANOVA) were used to determine any effects of
treatment (FLX or VEH) or strain (WKY or SD) on relative protein densities. Normality
was confirmed using Kolmogorov-Smirnov tests. One-way ANOVA were used to identify
differences between groups. Where significant interactions were found, a post-hoc,
pairwise comparison test was performed to detect significant differences between
groups. Significance was set at an alpha level of p = 0.05.

3. Results
NMDA and PSD-95
In the PFC there were significant effects of TREATMENT (NR2B: F1,19=7.741, p=0.013),
STRAIN (NR2A: F1,19=13.290, p=0.003; NR2B: F1,19=6.062, p=0.026; PSD-95: F1,19=5.092,
p=0.039) and significant TREATMENT x STRAIN interactions (NR2A: F2,18=22.127, p=0.00;
NR2B: F2,18=3.331, p= 0.087 (borderline significance)) influencing NR2A, NR2B and PSD95 levels. Post-hoc analyses revealed that Fluoxetine-exposed offspring of the SD strain
had increased relative NR2A levels in the PFC compared to SD vehicle offspring (+52%,
p=0.004). Moreover, WKY-VEH (+46%, p=0.036) and SD-FLX (+50%, p=0.023) offspring
exhibited increased levels of NR2B compared to SD-VEH offspring. There were no
significant effects of TREATMENT, STRAIN or any significant interactions detected in the
vHPC for any other markers (figure 5.2).
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Figure 5.2 Relative levels of N-methyl-D-aspartate (NMDA) receptor subunits NR1, NR2A, NR2B and
scaffolding protein post-synaptic density 95 (PSD-95) in the prefrontal cortex (PFC) (a - d) and ventral
hippocampus (vHPC) (e - h) at post-natal day (PN) 14. Data expressed as mean values + standard error of
the mean (SEM). *p<0.05, **p<0.01, #p<0.05 Wistar-Kyoto (WKY) compared to Sprague-Dawley (SD)
(overall strain effects).

Group1 mGluRs and Homer1b/c
In the PFC there was a borderline effect of TREATMENT (F1, 18=3.953, p=0.065), with
Fluoxetine exposed offspring showing overall reductions in mGluR1 monomeric levels
compared to vehicle offspring (-17%). No effects of TREATMENT, STRAIN or TREATMENT
x STRAIN interactions were detected in either brain region for either dimeric or
monomeric mGluR1 (figure 5.3).
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Figure 5.3 Relative levels of metabotropic glutamate receptor subtype 1 (mGluR1) monomer and dimeric
forms in the prefrontal cortex (PFC) (a - b) and ventral hippocampus (vHPC) (c - d) at post-natal day (PN)
14. Data expressed as mean values + standard error of the mean (SEM). ^p=0.065

In the PFC there were significant effects of STRAIN (mGluR5 Dimer: F1,19=5.692, p=0.031;
mGluR5 Monomer: F1,19=5.376, p=0.035; Homer1b/c: F1,19=8.841, p=0.009) and
TREATMENT (Homer1b/c: F1,19=10.449, p=0.006), but no TREATMENT x STRAIN
interactions on levels of mGluR5 Dimer, Monomer, and Homer1b/c. In the vHPC,
significant effects of STRAIN (F1,
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= 10.044, p=0.006) influenced levels of mGluR5

monomer only, with no other effects being detected. Overall, fluoxetine exposed
offspring showed reductions in Homer1b/c (-20%) in the PFC compared to vehicle
offspring. In addition, WKY offspring showed increases in mGluR5 dimers (+11%) and
decreases in mGluR5 monomers (-30%) and Homer1b/c (-18%) in the PFC compared to
SD offspring. In contrast, WKY offspring displayed increases in monomeric mGluR5
(+97%) in the vHPC compared to SD offspring overall (figure 5.4).
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Figure 5.4 Relative levels of metabotropic glutamate receptor subtype 5 (mGluR5) monomer and dimeric
forms, and scaffolding protein Homer1bc in the prefrontal cortex (PFC) (a – c) and ventral hippocampus
(vHPC) (d – f) at post-natal day (PN) 14. Data expressed as mean values + standard error of the mean
(SEM). **p<0.01, #p<0.05, ##p<0.01 Wistar-Kyoto (WKY) compared to Sprague-Dawley (SD) (overall strain
effect).

4. Discussion
4.1. Perinatal fluoxetine exposure increases NMDA receptor NR2A and NR2B subunits in
the prefrontal cortex of SD, but not WKY, offspring.
We have previously reported that maternal fluoxetine treatment reduces NMDA
receptor NR1 and NR2A subunits, and the scaffolding protein PSD-95, in the PFC of male
offspring at adolescence (PN42), in both SD and WKY strains (Millard et al., 2019). We
observed an exacerbation of anxiety- and depressive-like phenotypes in the same male
adolescent WKY offspring exposed to fluoxetine and an inducement of these behaviours
in exposed SD offspring (Millard et al., 2019). Based on these findings, we aimed to
determine whether perinatal FLX exposure causes changes to glutamatergic markers at
an earlier time period (PN14), with the ultimate aim of identifying a developmental
window where pharmaceutical or therapeutic interventions could prevent the
aberrations caused by FLX exposure observed at adolescence. Furthermore, we
hypothesised that maternal depression, modelled using a rodent model (WKY strain),
could potentially influence the effects of perinatal FLX exposure on offspring
neurodevelopment at PN14.
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In the present study perinatal fluoxetine exposure caused robust increases in NMDA
receptor NR2A and 2B subunits, in the PFC of SD, but not WKY, juvenile offspring. In
addition, fluoxetine exposure reduced Homer1b/c a key scaffolding protein (Nelson et
al., 2004), in the cortex of exposed rats, irrespective of strain. Taken together with our
previous findings, the present data suggests that a) the consequences of perinatal FLX
exposure manifests in early stages of development and b) that either innate and/or
maternal depressive phenotypes could confer resistance or at least delay the effects of
perinatal FLX exposure on the glutamatergic system. These findings offer invaluable
insight into the differential effects of perinatal Fluoxetine exposure on the
developmental trajectory of key glutamatergic receptors in a rodent model of
depression compared to a standard control strain (for summary of FLX-induced changes
across PN14 and PN42 ages see table 5.1).

To our knowledge this is the first study to assess the effects of perinatal FLX exposure
on glutamatergic markers in exposed offspring at PN14. Furthermore, comparing our
findings to the current literature is difficult granted the scarcity of study’s investigating
the effects of perinatal FLX exposure on offspring at PN14, even fewer are those
implementing appropriate models of maternal depression +/- FLX treatment (for review
see Millard et al., (2017)). Despite this, some studies have shown detrimental effects of
FLX exposure on otherwise healthy offspring, evident in early developmental time
periods (Millard et al., 2017). Specifically, one study has reported a decrease (~50%) in
the dendritic complexity index (DCI), which takes into account dendritic length and
branching, of somatosensory layer II/III neurons in SSRI exposed offspring as early as
PN6 (Smit-Rigter et al., 2012). Similarly, others have demonstrated that perinatal FLX
treatment causes significant decreases (-6%) in the number of foetal frontal lobe
neurons (Swerts et al., 2010), and reductions in the number of terminal tips (~51%) of
thalamocortical afferent arbors of the somatosensory cortex at PN7 (Lee, 2009).
Similarly, studies utilizing genetic approaches to manipulate the serotonergic system in
early development (i.e. SERT-KO and MAOA-KO), have demonstrated striking
aberrations in thalamocortical connectivity, barrel cortex and deep cortical layers
formation (van Kleef et al., 2012). Collectively these findings suggest that perinatal
fluoxetine exposure can influence dendritic branching, neuronal number and potentially
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synapse formation. We also report that perinatal fluoxetine exposure reduced the key
scaffolding protein, homer1b/c in the cortex of offspring irrespective of strain.
Homer1b/c binds to the C terminus of group 1 mGluRs (mGluR1 and mGluR5) and
regulates cell-surface targeting and clustering of these receptors (Shiraishi-Yamaguchi
and Furuichi, 2007). Homer1b/c has also been shown to form co-clusters with PSD-95,
and is found abundantly in excitatory synapses (Tu et al., 1999). Evidence from in vitro
investigations have demonstrated that homer1b/c plays a key role in the enlargement
of dendritic spine heads (Sala et al., 2001) and that spine head size is correlated with the
strength of the synapse (Tada and Sheng, 2006). Based on these findings it could be
hypothesized that deficits in homer1b/c, caused by perinatal fluoxetine exposure, could
result in altered dendritic head formation and subsequent deficiencies in synaptic
strength. Future studies investigating the effects of perinatal fluoxetine exposure on
developing glutamatergic synapses at early time periods will help elucidate whether
changes in Homer1b/c equate to alterations in dendrites themselves.

Interestingly we observed increases in both NR2A and NR2B subunits at PN14, but no
changes in the obligatory NR1 subunit. The obligatory NR1 subunit is synthesized in
excess; almost 10x compared to other NMDA receptor subunits, so the paring of NR2
with NR1 subunits is high (Huh and Wenthold, 1999). Furthermore, the pool of
intracellular NR1 is rapidly degraded and only becomes stable and is expressed on the
cellular membrane once it assembles with NR2 subunits (Huh and Wenthold, 1999).
These findings collectively suggest that the expression of NR2 subunits controls the
number of functional NMDA receptors (Huh and Wenthold, 1999). Given that we
observed an overall increase in both NR2A and NR2B subunits, it might be suggested
that during neurodevelopment, perinatal fluoxetine exposure increases available NMDA
receptors in the developing brain. Taken with the above findings, increased NMDA
receptors in development could critically alter neuronal, dendritic and synaptic
development; alterations of which could persist into adolescence similar to what we
have previously shown (Millard et al., 2019). Indeed, NMDA receptors are required for
activity-dependent development of synapses by promoting the insertion of obligatory
NR1 containing NMDA and AMPA receptors into synapses (Ewald and Cline, 2009).
Deviation from homeostatic levels of functional NMDA receptors could result in altered
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synaptic formation and maturation (Ewald and Cline, 2009). Furthermore, it could be
hypothesized that the reductions in PSD-95 observed at adolescence as a result of
perinatal fluoxetine exposure, are the result of altered NMDA receptor signaling in early
development, however more research is required to confirm this hypothesis.

One hypothesis underpinning how early serotonergic manipulation results in such
striking neurodevelopmental consequences, is associated with the early role that
serotonin plays in the development. Serotonergic neurons arise in the developing brain
at GW5 in humans (GD13 in rats) and is one of the earliest monoaminergic systems
generated in development (Gaspar et al., 2003a; Lambe et al., 2011; Sundström et al.,
1993; Whitaker-Azmitia, 2001). Furthermore, the serotonin system plays a key role in
the development of other systems, such as the glutamatergic system (Vitalis and
Parnavelas, 2003); indeed developing glutamatergic neurons have been shown to
transiently express SERT as early as GD17, suggesting that the uptake of serotonin by
glutamatergic neurons is key for their early development (Chen et al., 2016, 2015;
Narboux-Nême et al., 2008; Verney et al., 2002). Furthermore, serotonin has been
shown to modulate the response of developing thalamocortical axons to guidance cues
(Bonnin et al., 2007) and play a key role in early telencephalic development (Millard et
al., 2017; Vitalis and Parnavelas, 2003). Based on these findings it is plausible to suggest
that alterations to serotonin in early development, such as SSRI inhibition of SERT on
developing glutamatergic neurons, could have downstream consequences that manifest
in altered glutamatergic signaling in juvenile and adolescent time periods. Until much
further investigation is carried out however this hypothesis remains speculative.
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Table 5.1 Summary showing the effects of perinatal FLX treatment by brain region, age and strain (arrow
depicts the directional change caused by FLX exposure compared respective vehicle offspring of the same
strain).

The attenuated effect of perinatal FLX exposure on glutamatergic markers in the WKY
strain at PN14 may be attributable to the strains innate hypo-serotonergic phenotype.
Specifically, the WKY strain exhibits decreased SERT in the cortex and HPC (Paré and
Tejani-Butt, 1996), and decreased serotonin and burst firing of serotonergic neurons in
the raphe nucleus (Bruzos-Cidón et al., 2014; Yamada et al., 2013). Thus, it might be
hypothesised that the hyposerotonergic phenotype observed in the WKY strain greatly
attenuates the capacity for SSRIs to exert their potentially deleterious effects on other
neurotransmitter systems, such as glutamate. Until more research is conducted this
hypothesis remains speculative. Instead, the present findings highlight an area of
research that requires further investigation to truly elucidate whether innate maternal
depressive phenotypes attenuate the effects of SSRI exposure on offspring. Ultimately,
future research investigating whether early developmental time periods offer a window
for therapeutic intervention will be crucial to minimizing neurodevelopmental insults
caused by SSRI exposure, whilst maintaining effective treatment for maternal MDD.
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4.2. The WKY rodent model of depression displays alterations in NMDA and mGluR5
signalling in the cortex and hippocampus at PN14.
Clinical studies have contributed significantly to our current understanding of the
neurobiology of MDD; however, a number of caveats including low sample sizes, and
incomplete medical history and medication records, are common (Rajkowska, 2003).
Most important is the difficulty associated with tracking developmental sequelae
leading to the onset of MDD in clinical cases. Preclinical models, like the WKY strain, in
which we can track tracking neurobiological changes over key neurodevelopmental time
periods, offer an invaluable tool in which this limitation can be addressed (for review
see Millard et al., 2019c, WKY review).

Here we have shown that the WKY strain exhibits robust alterations in NMDA and
mGluR5 receptor subunits in the PFC, and to a lesser extent the vHPC, at in juvenile WKY
rats compared to a control strain. Specifically, male WKY rats showed increases in NMDA
receptor NR2B subunit and dimeric mGluR5, but reductions in the monomeric mGluR5
and associated scaffolding proteins Homer1b/c and PSD-95 in the PFC. Moreover, rats
of the WKY strain also showed increased monomeric form of mGluR5 in the vHPC
compared to SD offspring. Comparing our findings to the current literature is difficult
given the lack of studies investigating glutamatergic alterations in other preclinical
models of depression at early developmental time periods. However, we have
previously reported no alterations in dimeric mGluR5, but reductions in NMDA receptor
NR1, 2A and 2B subunits, as well as the scaffolding protein PSD-95, in the PFC of male
WKY adolescent rats. Collectively, these findings suggest that perturbations in mGluR5
present at PN14 may be transient, but changes in the NMDA receptor persist and are
enhanced in adolescence. Given that the NMDA and mGluR5 receptors play key role in
neurodevelopmental process (Catania et al., 2007; Gambrill and Barria, 2011), it may be
plausible to suggest that alterations in early signalling may underpin neurobiological and
behavioural alterations in the strain at adolescence, and later life.

Functional NMDA receptors are heterodimer complexes comprised of two obligatory
NR1 subunits, and a combination of two NR2 (NR2A-D) or NR3 (A-B) subunits. (Cull164

Candy and Leszkiewicz, 2004; Ozaki et al., 1997). NR2A and NR2B subunits possess
distinct electro-physical properties, subcellular localization, and trafficking (Jantzie et al.,
2015). The NR2A subunit possess fast decay times and is responsible for short excitatory
postsynaptic currents (EPSC) whilst NR2B subunits are slower in decay times and
catalyse longer EPSCs (Ewald et al., 2008; Jantzie et al., 2015). NMDA receptor activation
is essential for neurodevelopmental processes such as neuronal differentiation and
synaptic establishment and outgrowth, whilst NMDA receptor inhibition is critical for
the synaptic pruning (du Bois and Huang, 2007). In rodents, NMDA receptor expression
reaches peak expression within the first two weeks after birth, coinciding with the peak
period in synaptogenesis, then decreases in adulthood (du Bois and Huang, 2007;
Semple et al., 2013). During neonatal stages of neurodevelopment, NR2B is the
predominant NMDA receptor subunit where it is highly expressed on immature neurons,
whilst in postnatal development a ‘developmental switch’ occurs in which NR2A
becomes the predominant subunit (Williams et al., 1993). This switch in subunit
composition coincides with the distinct roles that the subunits play in
neurodevelopment (Gambrill and Barria, 2011). For example, it is thought that the NR2B
is required for synaptogenesis and dendritic growth, whilst NR2A is required for the
stabilization and consolidation of synapses (Gambrill and Barria, 2011). The PFC is
unique in that the developmental switch from NR2B to NR2A appears to be absent
(Monaco et al., 2015). Furthermore, NR2B levels in the PFC do not decline over the
course of development compared to other areas, and are persistently high in the adult
rat PFC (Monaco et al., 2015). Interestingly, we observed an increase in the NR2B subunit
of the PFC in WKY offspring at PN14, suggesting that NMDA subunit ratios could be
altered in the PFC of WKY rats. Alterations to NMDA receptors and subunit composition
in neurodevelopment can lead to increased risk for neurodevelopment and
neuropsychiatric disorders later in life (Burnashev and Szepetowski, 2015; Lakhan et al.,
2013).

Studies have shown that perinatal NR2A receptor antagonism, which would be expected
to alter the NR2A:NR2B ratio in a similar manner to the increase in NR2B observed in
the present study, results in deficits in spatial learning, social interaction, prepulse
inhibition, cognition and exploratory behaviour (for review see du Bois and Huang,
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(2007)). In addition, prenatal exposure to Phencyclidine (PCP), a non-competitive NMDA
receptor antagonist, causes impaired cell proliferation and decreased glutamatergic
neuron density in the prefrontal cortex of exposed mice (Toriumi et al., 2012).
Furthermore, studies have shown that PCP-induced apoptosis and the development of
long-lasting behavioural deficits are due to the blockade of NR1/NR2A containing NMDA
receptors, rather than NR1/NR2B (Anastasio et al., 2009). Collectively, these studies
suggest that alterations in NMDA receptor signaling and subunit ratios in development
cause behavioural and morphological changes to the brain. Taken together with the
present findings it could be hypothesised that the anxiety- and depressive-like
phenotype observed in the WKY strain might originate from alterations in cortical NMDA
subunits ratios.

Evidence has shown that mGluR5 plays a key role in the developmental switch that
occurs between the NMDA receptor subunits, NR2A and NR2B, influencing the
development of the NR2A:NR2B subunit ratios (Matta et al., 2011). Specifically, Matta
et al., (2011) demonstrated that the NR2B to NR2A switch requires activation of NMDA
and mGluR5 receptors, and their downstream signalling (Matta et al., 2011). Further
evidence for the importance of mGluR5 in neurodevelopment has been given by the
broad expression pattern of the receptor in early life. During neurodevelopment mGluR5
is expressed in the developing human cortex as early as gestational week (GW) 9, with
high expression in ventricular and subventricular zones (Boer et al., 2010). The early
expression of this receptor suggests a role in the development of the forebrain, with a
growing body of evidence implicating mGluR5 in processes such as neuronal
proliferation, differentiation and survival of neural stem/progenitor cells (Catania et al.,
2007)). Activation of mGluR5 has been shown to play a key role in neuroblast
proliferation in the ventral telencephalon (Gandhi et al., 2008), and differentiation and
proliferation of neuronal progenitors in the hippocampus (Xiao et al., 2013). Studies
manipulating expression or activation of mGluR5, have demonstrated significant
consequences for neuronal populations and morphology. Specifically, studies have
demonstrated that in utero exposure to MPEP, an mGluR5 antagonist, results in large
reductions in striatal neuron number (Gandhi et al., 2008), and reductions in the number
of dividing neuroprogenitors in subventricular zone and dentate gyrus of the
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hippocampus in vitro (Giorgi-Gerevini et al., 2005). Furthermore, mGluR5 KO mice
exhibit disruptions in somatosensory barrels and thalamocortical afferents `(BallesterRosado et al., 2010), as well as significant reductions in layer IV spine density (Wijetunge
et al., 2008). Collectively these studies implicate mGluR5 in key neurodevelopmental
processes and suggest that changes to mGluR5 signalling in early development can have
profound downstream consequences. In the present study we report that in a rodent
model of depression, expression of the functional dimeric mGluR5 is increased, whilst
the constituent monomeric form in the PFC is decreased at PN14. In addition, the key
scaffolding proteins Homer1b/c and PSD-95 were significantly decreased in the PFC of
the WKY strain, suggesting that mGluR5 signalling at the cell surface may have been
attenuated. Emerging evidence suggests that Homer1b/c plays a key role in the
trafficking of mGluR5 at the membrane, as well as coupling of the receptor to
downstream receptors including Inositol Phosphate3 (Mao et al., 2005). Accordingly, the
increases in dimeric mGluR5 observed in the WKY PFC may be indicative of a
compensatory response to decreases in the scaffolding and therefore surface expression
of the receptor. Thus, it may be hypothesised that reductions in available homer1b/c
(and PSD-95) results in an accumulation of dimeric mGluR5 within the cytosol and
therefore attenuation of mGluR5 signalling and alterations in neurodevelopment.
Future investigations should aim to determine whether increases in mGluR5 at PN14 in
the WKY strain, are representative of membrane or cytosolic levels through
experimental methods such as tissue fractionation. This will help elucidate the location
of mGluR5 and whether this corresponds to increase levels and altered signaling of the
receptor.
5. Conclusion
In summary, our findings demonstrate that perinatal fluoxetine exposure has negligible
effects on NMDA receptor signalling at PN14, in a rodent model of depression. In
contrast, SD rats demonstrated marked increases in both NMDA receptor subunits,
NR2A and NR2B. We have previously shown that perinatal fluoxetine exposure reduces
NMDA receptor subunits NR1 and NR2A at adolescence irrespective of strain and
exacerbates anxiety- and depressive-like behaviours in WKY offspring whilst imparting
these same behaviours in SD offspring. These findings suggest that at PN14, offspring of
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the WKY strain are either resistant to or exhibit a delayed response to the effects of
perinatal FLX exposure on glutamatergic receptors. In addition, we have shown that the
WKY rat demonstrates innate alterations in scaffolding proteins, Homer1b/c and PSD95, and glutamate NMDA and mGluR5 receptors, namely in the PFC at PN14. These
innate changes in glutamatergic proteins could represent changes in neurodevelopment
that later underpin the strains innate depressive- and anxiety-like phenotype.
Ultimately, this study has shown that the effects of perinatal FLX exposure at PN14 are
more prominent in a control strain, and that the WKY rodent model of depression
exhibits alterations in glutamatergic markers early in life.
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Chapter 6

6.1 Overview

With the growing incidence of depression and use of antidepressants during the
perinatal period (Cooper et al., 2007; Huybrechts et al., 2013a; Marcus and
Heringhausen, 2009), questions have been raised about the effects of antidepressant
exposure on offspring behaviour and neurobiology (Millard et al., 2017). There is
conflicting evidence from clinical studies regarding the effects of perinatal SSRI exposure
on offspring behaviour and associated disorders in offspring (Millard et al., 2017).
However, some studies have suggested that perinatal SSRI exposure is associated with
an increased risk for neurodevelopmental and psychiatric disorders, including autism,
MDD and ADHD, in offspring (Millard et al., 2017). Although clinical studies are
invaluable in clarifying the risk associated with maternal SSRI exposure; they are
confounded by underlying maternal psychopathology such as MDD and/or maternal
adversity (Millard et al., 2017; Petersen et al., 2014). Current preclinical literature
investigating the effects of perinatal SSRI exposure on behaviour and neurobiology in
offspring have largely focused on outcomes in otherwise healthy male offspring (Millard
et al., 2017). These studies have reported alterations in social interaction, cognitive
function, anxiety- and depressive-like behaviours (Millard et al., 2019, 2017). However,
there has been no investigation of the effects of perinatal Fluoxetine exposure in rodent
models of innate or endogenous depression that closely model MDD. Indeed, the
interaction between maternal depressive phenotypes and SSRI use may represent a
significant variable in the effects of SSRI-exposure on offspring and could have significant
implications in the clinic.

In this study, we used the WKY rat model of depression to determine the effects of SSRI
exposure on offspring behaviour and neurobiology, relative to neurodevelopmental and
psychiatric disorders, and in the context of the maternal psychopathology. In addition,
by using the WKY strain, it allowed us to gain deeper insight into the neurobiology of
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depressive-like phenotypes.

The major findings from this thesis are;

1) Perinatal Fluoxetine exposure induced affective-related behavioural changes in
exposed offspring and caused abnormalities in glutamatergic signalling. These
effects were more widespread in males, but also depend, at least in females, on
the strain of rat used.

2) Perinatal Fluoxetine exposure induced changes in BDNF-TrkB signalling of
exposed female offspring at adolescence, but differentially altered NeuN+ cell
counts in a strain specific manner, by ameliorating cortical NeuN+ deficits in
female WKY but not SD offspring.

3) Perinatal Fluoxetine exposure induced strain-specific changes in glutamatergic
signaling in juvenile male rats, with exposed SD, but not WKY offspring exhibiting
increases in NMDA receptor NR2A and 2B subunits.
4) The Wistar-Kyoto rat model of endogenous depression exhibits widespread
deficits in cortical and hippocampal glutamatergic markers and NeuN+ cell
counts, compared to a control strain, the Sprague-Dawley rat, which may be
associated with their depressive-like behavioural phenotype.

The studies presented in chapters 2 to 5 investigated the effects of perinatal FLX
treatment on the behaviour and neurobiology of exposed offspring using a relevant
model of maternal depression. In depth discussions were included within chapters 2 to
5 therefore, this chapter will provide a general discussion around the key observations
that were found, potential mechanisms, limitations and recommendations.
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6.2 Adolescent male offspring are more susceptible to the effects of perinatal FLX
exposure on adolescent behaviour compared to females, and irrespective of strain.

While there is an emerging body of preclinical studies investigating the effects of
developmental SSRI exposure on offspring behaviour, the majority of these have been
conducted under control conditions (i.e. no model of maternal psychopathology) or in
models of maternal stress (Millard et al., 2019, 2017). Furthermore, the majority has
focused on outcomes in male offspring. These limitations in the field were addressed in
this thesis by utilizing a current rodent model of endogenous depression, the WistarKyoto rat, to model the effects of maternal psychopathology +/- SSRI treatment on
offspring of both sexes. The data from chapters 2 and 3 show that perinatal fluoxetine
exposure exacerbated anxiety-like behaviours and FST immobility in male, but not
female, adolescent WKY offspring. In addition, FLX exposure imparted an anxiety-like
phenotype in SD offspring of both sexes, but additionally increased immobility in the FST
of male SD offspring (Table 6.1). Overall, these findings suggest that females are more
resilient to the behavioural effects of perinatal fluoxetine exposure (at least using these
measures), and furthermore, that females with an innate depressive phenotype (i.e.
WKY rats) are most resilient (further discussion on potential mechanisms behind this
resilience can be found later). Our behavioural findings are in agreeance with the current
clinical literature suggesting that in general males are more susceptible to anxiety
disorders at adolescence (Lawrence et al., 2015) and neurodevelopmental disorders
such as autism and ADHD, which are characterized by anxiety related phenotypes
(Ramtekkar et al., 2010; Werling and Geschwind, 2013).

The finding that sexual dimorphism is present in the behavioural response to perinatal
fluoxetine treatment has been previously reported in the preclinical literature, with
some studies suggesting that males may be more susceptible (Butkevich et al., 2019;
Gemmel et al., 2017; Houwing et al., 2019). While to our knowledge, the works in this
thesis are the first to assess the effects of perinatal fluoxetine exposure using an
endogenous model of depression (at least on female adolescent offspring), several
previous studies have used environmental stress paradigms, or genetic models to model
maternal depression +/- SSRI exposure (Millard et al., 2017). For example, by using
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heterozygous SERT deficient dams and exposure to early life maternal separation,
Houwing et al., (2019) recently demonstrated that perinatal fluoxetine exposure
reduces ultrasonic vocalization at postnatal day 6, particularly in SERT+/+ males (Houwing
et al., 2019). Moreover, perinatal fluoxetine exposure reduced juvenile social play in
males, irrespective of exposure to early life stress, but only reduced social play in control
females. This finding is in agreeance with our own suggesting that perinatal fluoxetine
exposure influences male offspring behaviour regardless of exposure to maternal
depressive-like phenotypes or vulnerability but has restricted effects on females. The
study by Houwing et al., (2019) also found that perinatal fluoxetine reduced adult play
behaviour in control males only but had no effect on adult females. Based on this finding
we could speculate that the fluoxetine-induced alterations in emotionality-related
behaviours, and sexual dimorphism found in the present study could persist to
adulthood. Recent works by Gemmel et al., (2019, 2017) have also reported sex-specific
effects of perinatal fluoxetine exposure on social behaviour. Specifically, Gemmel et al.,
(2017) reported that perinatal fluoxetine increases pre-adolescent social aggressive play
in both sexes, but decreases time grooming a novel conspecific in males only.
Furthermore, sex differences in response to perinatal FLX exposure persisted to
adulthood, with adult females displaying increased social investigation, whilst males
showed increased social play (Gemmel et al., 2019). Consistent with our findings in
adolescent offspring, Rayen et al., (2011) reported that prenatal stress with perinatal
SSRI treatment increases FST immobility in male and female offspring but had negligible
effects on behaviour in the OFT. Regarding anxiety-like phenotypes, and the influence
of SSRI exposure and maternal stress, several previous studies reported no changes in
adolescent (Boulle et al., 2016b, 2016a; Rayen et al., 2011) or adult (Kiryanova et al.,
2016) behaviour in the OFT or EPM of either male or female offspring, following lower
dose (5mg/kg/day) postnatal SSRI exposure. Differences in dosages, treatment timeline
and model of maternal depression however likely contributed to differences between
our findings and these studies.

Other works have also suggested that the sexual dimorphism present in the behavioural
response to perinatal fluoxetine treatment goes beyond emotionality-related
behaviours. For example, Butkevich et al., (2019) demonstrated that prenatal fluoxetine
172

exposure reduced depressive-like behaviours and sensitivity to thermal pain in offspring
caused by prenatal stress, independently of sex (Butkevich et al., 2019). However, when
prenatal fluoxetine was combined with buspirone, a 5HT1a receptor antagonist, the
effects were more antinociceptive compared to buspirone alone, but only in males
(Butkevich et al., 2019). These findings suggest that males were more responsive to the
attenuating effects of prenatal fluoxetine + buspirone on inflammatory pain-like
behaviour compared to females and indicate that males may be more susceptible to the
effects of serotonergic agents during development on pain responses. Overall, this study
provides further evidence that male and female offspring respond differentially to
serotonergic agents during development and highlight the need for further investigation
emphasizing sex differences. Ultimately, findings from this thesis and the current
literature suggest that perinatal fluoxetine exposure has sex specific effects on
behaviour that may be dependent on dose, offspring age and period of exposure, and
that environmental and endogenous model of maternal depression can differentially
influence these effects.
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6.3 Perinatal Fluoxetine treatment causes alterations in glutamatergic signaling in a
sex specific manner

We found evidence that perinatal Fluoxetine exposure caused increases in affectiverelated behaviours, including increased anxiety-like phenotypes, and increased
immobility in the forced swim test. Deciphering the neurobiological underpinnings of
these behaviours will be imperative to understanding the full extent of the effects of
perinatal fluoxetine exposure. Furthermore, by understanding the neurobiology behind
the behaviours we might ultimately be able to find novel ways to reduce the adverse
effects of fluoxetine exposure, if any, in the clinic.

Given that SSRIs, such as Fluoxetine, target the serotonergic system (Hiemke and
Härtter, 2000b), most preclinical studies investigating the effects of perinatal Fluoxetine
exposure have focused on outcomes of offspring serotonergic markers (Millard et al.,
2017). Whilst the serotonergic system is an undoubtedly important target of
investigation with these studies, it may also be that other neurotransmitter systems are
also implicated. Indeed, aberrant glutamatergic signalling, particularly via ionotropic NMethyl-D-Aspartate (NMDA) and group 1 metabotropic receptors (mGluRs), have been
linked to several neurodevelopmental, psychiatric and mood disorders, including
autism, ADHD, schizophrenia, depression and anxiety (Deschwanden et al., 2011;
Hashimoto et al., 2007; Javitt, 2004; Musazzi et al., 2012; Rojas, 2014; Yuan et al., 2015).
Accordingly, it was hypothesised that perinatal Fluoxetine exposure during development
could be altering markers of glutamatergic neurotransmission.

As expected, it was found that fluoxetine exposure caused marked alterations in
glutamatergic markers in adolescent male offspring with more restricted effects in
female offspring. Male offspring showed marked reductions in NMDA receptor NR1 and
NR2A subunits and the scaffolding protein, PSD-95, in the prefrontal cortex of both SD
and WKY adolescent offspring. Moreover, FLX exposure reduced PSD-95, and increased
mGluR5 and associated scaffolding protein, Homer1b/c, in the ventral hippocampus of
the same male offspring (Table 6.2). In females, the effects of exposure on offspring
were attenuated with exposed offspring exhibiting reduced PSD-95 in the ventral
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hippocampus only and no changes in NMDA receptor subunits regardless of strain.
Furthermore, only minor strain specific differences were observed for group 1 mGluRs
in females (Table 6.2). Given that we observed more widespread glutamatergic and
behavioural dysfunction in males, these findings support the notion that females are
more resilient to the effects of perinatal FLX exposure.

It is well known from preclinical studies that the NMDA receptor and associated
scaffolding proteins are implicated in the SSRI mechanism of action (Boyer et al., 1998;
Millard et al., 2019; Musazzi et al., 2012; Park et al., 2014), however less is known about
the effects of perinatal SSRIs on these markers during neurodevelopment. In line with
our findings, Boyer et al., (1998) reported that chronic citalopram treatment in adult
rodents resulted in reductions in NMDA receptor subunits NR1 and NR2A in the frontal
cortex (Boyer et al., 1998). These findings suggest that the mechanism through which
the effects of perinatal Fluoxetine exposure influence NMDA receptor subunit
expression in the PFC of adolescence, are similar to those that occur in chronic use in
adults. Furthermore, we also observed reductions in PSD-95, particularly in the
hippocampus, and across both sexes and strains. These findings suggest that perinatal
fluoxetine exposure can cause reductions in available synaptic connections between
neurons. Indeed, given that PSD-95 plays a key role in regulating cell surface expression
of the NMDA receptor (Sheng and Kim, 2011), by directly anchoring NR2 subunits (Tu et
al., 1999); it may be that perinatal FLX exposure through its influence on PSD-95, is
affecting glutamatergic signaling in exposed offspring.

In chapter 2 we found that perinatal FLX exposure caused deficits in glutamatergic
receptor subunits and associated scaffolding proteins, particularly in adolescent male
offspring. To determine whether the alterations in glutamatergic signaling at
adolescence indicate a continuum of aberrant glutamatergic dysfunction beginning at
an earlier time period, we sought to investigate the effects of perinatal FLX exposure on
the same markers in postnatal day 14 offspring. The findings presented in chapter 5
showed that perinatal FLX exposure increased NMDA receptor subunits NR2A and NR2B
in the prefrontal cortex of SD, but not WKY offspring, but reduced mGluR1 monomer
and associated scaffolding protein Homer1b/c irrespective of strain. This finding is in
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contrast to the indiscriminative effects of perinatal FLX treatment on NMDA receptor
subunits NR1, NR2A and scaffolding protein PSD-95 at adolescence. Collectively these
findings suggest that i) the consequences of perinatal FLX exposure manifests in early
stages of development, and ii) that the WKY strain exhibits a delayed response to the
effects of FLX exposure on NMDA receptor signaling.

Comparing our findings to the literature is difficult given that investigation into the early
effects of perinatal FLX exposure using relevant models of depression are limited.
However, some studies have shown detrimental consequences of perinatal FLX
exposure as early as PN6 and PN7 (Lee, 2009; Smit-Rigter et al., 2012). Specifically, one
study reported deficits in dendritic complexity in the somatosensory layer neurons of
SSRI exposed 6-day old mice (Smit-Rigter et al., 2012). Others have also shown that
perinatal FLX exposure reduces the number of foetal frontal lobe neurons (Swerts et al.,
2010), and the number of terminal tips of thalamocortical afferents in PN7 mice (Lee,
2009). In addition, preliminary findings from our own lab investigating the effects of
daily fluoxetine treatment on growth of human neurospheres (obtained from human
fetal cortical stem cells) showed that after 10 consecutive days of FLX treatment,
neurosphere growth was attenuated at all experimental FLX concentrations (figure 6.1).
Furthermore, we observed increases in immunoblot measures of pro-apoptotic
markers, Caspase and Bax at day 10, suggesting that perinatal FLX treatment can
influence neuronal growth by mediating apoptotic mechanisms in early development
(figure 6.2). The use of human foetal stem cells provides an exciting opportunity to
determine the effects of fluoxetine exposure in a human derived model. Specifically,
neurospheres provide a unique tool for assessing early neurodevelopmental processes
in vitro, such as progenitor proliferation, migration and differentiation (Lobo et al.,
2003). Accordingly, neurospheres could provide a medium through which the specific
mechanisms underlying the effects of fluoxetine exposure in early development can be
investigated. Further studies determining how exposure to fluoxetine (and other drugs)
can influence early developmental processes and glutamatergic markers will be an
important avenue forward for the screening of drug effects.
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a)

Figure 6.1: Preliminary findings showing (a) the effects of daily fluoxetine treatment on the average
diameter of human derived neurospheres (n=24 neurospheres/group). (b) Representative images of
neurosphere size across FLX concentrations at day 10. Neurospheres were treated daily with FluoxetineHydrochloride using a dose response curve ([0.0], [0.1], [1.0] and [5.0]). Daily medium changes were
accompanied by the addition of fluoxetine. Images of neurospheres were taken daily. Following day 10,
neurospheres were collected for immunoblot analysis of apoptotic markers. *p<0.05 compared to all
other treatment concentrations.
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Figure 6.2: Preliminary findings showing the effects of daily fluoxetine treatment on neurosphere markers
of pro-apoptotic markers, Caspase and Bax, at day 10. Statistical analyses were not performed due to low
sample sizes (n=8-12 neurospheres/group, from one biological and technical replicate), figures indicate
preliminary trends only.

Ultimately, the main findings from chapter 5 suggest that perinatal Fluoxetine exposure
can significantly alter glutamatergic signaling, and that the NMDA receptor is particularly
vulnerable. Furthermore, male offspring of the WKY strain display some resilience, or at
least a delayed response to the effects of perinatal FLX treatment at PN14. However,
this strain effect is null in adolescence. Indeed, as will be discussed, the differences
observed between strain may be underpinned by their innate serotonergic phenotype.
Future investigations assessing the effects of perinatal Fluoxetine exposure should
identify early time periods that could represent windows of opportunity to provide
adjunct treatment with could limit consequences of exposure.
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6.4 Perinatal FLX exposure causes deficits in NeuN+ cell counts in the prefrontal cortex
of Sprague-Dawley rats, but ameliorates deficits in Wistar-Kyoto rats.

Despite the apparent resilience to the effects of perinatal FLX exposure on glutamatergic
signaling and behaviour in female offspring, we did observe a consistent trend in which
perinatal FLX exposure, regardless of sex or strain, markedly reduced PSD-95 in the
ventral hippocampus of exposed offspring. This consistent observation led to the
hypothesis that perinatal FLX exposure reduces available glutamatergic synapses in the
hippocampus (and PFC in males), and that deficits in neurons could underpin the
reduced synapses. To test this hypothesis, in chapter 4 we investigated the effects of
perinatal FLX exposure on adolescent female offspring cortical and hippocampal NeuN
cell counts and BDNF/TrkB signalling. We decided to investigate the BDNF/TrkB
signalling system due to the fact that SSRIs such as fluoxetine are thought to mediate
their therapeutic effects, at least in part, by increasing BDNF and promoting
hippocampal neurogenesis (Martinowich and Lu, 2007). Furthermore, through
interactions with neurotrophins such as BDNF, the serotonergic system plays a key role
in several neurodevelopmental processes including neuronal differentiation,
proliferation, migration and synaptogenesis (Bonnin et al., 2007; Edgar and Price, 2001;
Sodhi and Sanders-Bush, 2004b; Vitalis and Parnavelas, 2003). The functions of BDNF
are mediated through two receptors, TrkB and p75 (Martinowich and Lu, 2007).
Therefore, we reasoned that alterations to the serotonergic system in development,
caused by Fluoxetine exposure, could likely alter BDNF-TrkB signalling.

The decision to first focus on outcomes in adolescent females was twofold. Firstly, whilst
the primary aim of this thesis was to determine the effects of perinatal FLX exposure on
offspring, the second was aimed at profiling the neurobiology of the WKY rodent model
of depression. We previously demonstrated that perinatal FLX exposure increases
anxiety-like behaviours in female adolescent control rats (SD), but had no effects on the
behaviour of WKY offspring (Millard et al., 2019). Therefore, by investigating the
neurobiology that underpins the WKY strains resilience to perinatal FLX exposure, we
might gain a deeper understanding as to the implications of perinatal SSRI use in the
clinic, and how neuronal cell counts relate to the depressive-like phenotype of the WKY
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strain. Secondly, major depressive disorder is twice as prevalent in females (Huybrechts
et al., 2013a; Marcus and Heringhausen, 2009), symptoms of which commonly emerge
at adolescence (Thapar et al., 2012); thus by investigating the BDNF/TrkB and NeuN
profile of the female WKY strain at adolescence we might gain a deeper understanding
as to the neurobiology and aetiology of MDD (as is discussed later in this chapter).
Finally, it must be acknowledged that due to experimental tissue constraints, we could
only perform immunohistochemistry and immunoblot analyses for this chapter on
female offspring.

Here we found that perinatal fluoxetine exposure reduced NeuN+ counts in the
prefrontal cortex of exposed Sprague-Dawley offspring, but corrected deficits in the
WKY rats that were present in the strain at baseline. We previously showed that female
SD, but not WKY, offspring exposed to perinatal fluoxetine treatment exhibited
increased anxiety-like behaviours. Furthermore, we found that deficits in PFC NeuN+ cell
counts consistently correlated with anxiety-like phenotypes in the EPM. Collectively
these findings suggest that female SD, but not WKY offspring, may be more susceptible
to the detrimental effects of perinatal FLX exposure on PFC NeuN+ counts, and that
these changes could underlie the induced anxiety-like behaviour. This finding coincides
with findings from a study showing that damage to the PFC results in decreased
exploratory behaviours in the OFT and EPM (Jinks and McGregor, 1997). More recently
however, a study demonstrated that optogenetic inhibition of PFC pyramidal neurons
produces a robust anxiety-like phenotype in the OFT and EPM of test subjects (Wang et
al., 2015). Whilst this finding seems to conflict with our own, we cannot be certain in the
present study what specific neuronal populations were reduced in the PFC as a result of
perinatal FLX exposure, given that NeuN+ stains mature neurons indiscriminately.
Indeed, it might be that specific subpopulations of neurons such as GABA or other
monoaminergic neurons are more vulnerable to the effects of perinatal fluoxetine
exposure. Future studies should aim to determine whether neuronal subpopulations are
differentially affected by perinatal fluoxetine exposure.

We also observed that perinatal Fluoxetine exposure caused reductions in NeuN+ counts
in the CA1 region of the hippocampus and altered BDNF-TrkB signalling in both brain
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regions, however these effects were irrespective of strain. Given that we observed
changes in BDNF/TrkB signalling across both strains (SD and WKY) but strain specific
alterations in anxiety-like behaviours, this finding suggests that changes in BDNF/TrkB
signalling caused by FLX exposure, are unlikely to underpin anxiety-like behaviours
observed in the present thesis, but could contribute to other behavioural phenotypes
not measured. For example, several recent studies have linked BDNF/TrkB signalling
with cognitive function at adolescence, (Han et al., 2011; Li et al., 2016; Uysal et al.,
2015), including spatial learning and memory. Future studies investigating the effects of
perinatal FLX exposure on BDNF/TrkB signalling on cognition related behaviours, using
a relevant model of maternal depression, will help elucidate the full behavioural
consequences (or benefits) of exposure on offspring.

6.5 The potential mechanistic neurobiology behind the strain- and sex-specific effects
of perinatal FLX exposure on offspring.

One of the main findings from this thesis was that female offspring, particularly those of
the WKY strain, exhibited increased resilience to the effects of perinatal FLX exposure
on measured glutamatergic, neurotrophic and behavioural parameters. Whilst more
investigation is required to determine the neurobiology and mechanism underlying this
resilience, possible causes can be speculated considering evidence from the current
literature. One key piece of information that needs to be considered is the fact that SSRIs
specifically target the serotonin transporter, therefore any factors that might influence
available levels of SERT across strain or sex will ultimately influence the ability for SERT
to exact its effects.

During neurodevelopment, SERT expression coincides with the emergence of
serotonergic neurons in the raphe nucleus (embryonic day 13 for rodents, gestational
week 10 for humans) (Hansson et al., 1998; Millard et al., 2017; Rubenstein, 1998). By
embryonic day 17, serotonergic fibers project into the telencephalon and spread
throughout the cerebral cortex (Sodhi and Sanders-Bush, 2004a). Whilst SERT is largely
expressed on serotonergic neurons throughout development and maturity, it is also
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transiently expressed on non-serotonergic neurons in early development. Specifically,
migrating glutamatergic thalamic neurons projecting to sensory cortices, as well as
pyramidal neurons in the PFC and hippocampus transiently express SERT from
embryonic day 17 to postnatal day 12, where it becomes limited to serotonergic neurons
(Chen et al., 2016; Gaspar et al., 2003a). This transient expression of SERT in
neurodevelopment suggests that early glutamatergic neurons take up serotonin as a
borrowed neurotransmitter aiding in the migration and proliferation of developing
neurons (Gaspar et al., 2003a; Millard et al., 2017). Accordingly, manipulation to the
serotonergic system during early neurodevelopment, such as that caused by perinatal
SSRI exposure, could disrupt the migration and development of SERT-expressing
neurons to thalamic and cortical areas. Furthermore, given that SSRIs specifically target
SERT, then reductions in available SERT during neurodevelopment could attenuate the
ability for SSRIs to exert their effects. Indeed, at least one study has shown that SERT -/mice exhibit resilience to the effects of postnatal SSRI treatment and display increases
in anxiety- and emotional related behaviours (Ansorge et al., 2004). This finding suggests
that i) SERT is required during neurodevelopment of brain systems involved in emotional
and stress-related behaviours, and ii) that reductions in available SERT attenuate the
effect of SSRIs on behaviour (Ansorge et al., 2004).

Evidence from in vivo clinical studies suggest that females exhibit lower SERT binding in
the prefrontal cortex (Mann et al., 2000) and decreased whole brain serotonin synthesis
(Nishizawa et al., 1997) compared to males. Furthermore, evidence from SERT KO
studies, which model SSRI exposure (i.e. both increase synaptic serotonin levels beyond
physiological levels) suggest that males are slightly more vulnerable to genetic deletion,
evident through increases in neohypophagia (Olivier et al., 2008). Collectively these
findings suggest that males may be more susceptible to consequences of SERT
manipulation, such as those produced by genetic KO or SSRI exposure. In the same vein,
rats of the Wistar-Kyoto strain exhibit a hyposerotonergic phenotype and increased
resistance to SSRI treatment (Bruzos-Cidon et al., 2015; Griebel et al., 1999; Lemos et
al., 2011; Pare and Tejani-Butt, 1996; Yamada et al., 2013). Specifically, studies have
shown that the WKY rat displays deficits in cortical and hippocampal SERT binding (Pare
and Tejani-Butt, 1996), and reduced serotonergic burst firing and serotonin content in
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the dorsal raphe nucleus (Bruzos-Cidon et al., 2015; Yamada et al., 2013). Furthermore,
WKY exhibit decreased mRNA levels of the serotonin autoreceptor, 5HT1a, and the
enzyme responsible for serotonin production, tryptophan hydroxylase 2, in the dorsal
raphe nucleus (Lemos et al., 2011). Collectively these findings suggest that the female
sex and rats of the WKY strain are less susceptible to the effects of SSRI treatment
potentially due to a reduced availability of SERT and/or a hyposerotonergic phenotype.
Indeed, during neurodevelopment these two factors compounded (sex and strain) could
explain the increased resilience to the effects of perinatal FLX treatment on the
glutamate system that we observed in female WKY rats in this thesis. Future studies
investigating differences in the ontogeny of SERT between sexes, strain and throughout
developmental time periods will help substantiate this hypothesis. Irrespective, it is
clear that perinatal FLX treatment alters neurodevelopment of the glutamatergic and
neurotrophic systems, and consequently emotional-related behaviours, in a strain and
sex-specific manner. Further investigation into the apparent resilience of the female
WKY strain to perinatal FLX treatment, will help elucidate the effects of maternal SSRI
treatment and maternal psychopathology on offspring in the clinic.

6.6 The WKY model of endogenous depression: aberrations in glutamatergic signaling
and neuronal morphology, relevant to major depressive disorder

The second aim of this thesis was to investigate the glutamatergic and neurotrophic
profile of the WKY strain, a rat model of endogenous depression. Major depressive
disorder is one of the leading causes of disease related disability worldwide (WHO,
2017), the incidence of which has risen ~20% in the last decade alone (WHO, 2017).
Women are twice as likely to develop major depressive disorder, the incidence of which
rises sharply after puberty, and by adolescence exceeds a 4% prevalence rate
(Huybrechts et al., 2013a; Marcus and Heringhausen, 2009; Thapar et al., 2012). SSRIs
are the leading form of pharmaceutical intervention for the treatment of MDD
(Huybrechts et al., 2013a; Mitchell et al., 2011a), however their effectiveness has been
questioned given their inefficacy in ameliorating depressive symptoms in ~50% of
patients and latency of effect (Papakostas and Fava, 2009; Rosenzweig-Lipson et al.,
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2007). This treatment-resistance results in a higher burden of cost to the patient and
healthcare system (Rosenzweig-Lipson et al., 2007). Due to the burden of disease, there
is increasing need to understand the neurobiology underpinning major depressive
disorder and to develop effective treatment strategies.

In chapters 2 and 3, we investigated the glutamatergic and behavioural profile of the
WKY strain in both sexes at adolescence compared to respective Sprague-Dawley
controls. We have recently shown that the WKY strain has reduced relative levels of all
NMDA receptor subunits and Post Synaptic Density protein 95 (PSD-95), a key
scaffolding protein, in the PFC of males, and in the PFC and ventral Hippocampus of
female adolescent rats (Table 6.3). In addition, female WKY showed further reductions
in the AMPA receptor subunit, GluA1 in the PFC and ventral Hippocampus (Millard et al.,
2019a, Millard et al., 2019b). Whilst we did not assess AMPA receptor subunits in male
offspring, this finding suggests that deficits in the glutamatergic profile of the WKY strain
might extend to the main excitatory glutamate receptor AMPA.

We have also shown that adolescent WKY offspring displayed a robust anxiety- and
depressive-like phenotype in both sexes, compared to Sprague-Dawley offspring.
Although the behavioural phenotype of the WKY is well established in the preclinical
literature and corresponds with our own findings, the findings regarding the
immunoblot glutamatergic profile of the WKY strain at adolescence are the first to be
reported. Our findings presented here suggest that the WKY strain exhibits robust
deficits in cortical and hippocampal glutamatergic signaling, and that deficits in these
markers might contribute to the strain’s anxiety- and depressive-like phenotype.
Accordingly, others investigating the glutamatergic profile of the WKY strain have also
reported reductions in NMDA receptor binding in the PFC and hippocampus (Lei et al.,
2009; Lei and Tejani-Butt, 2010). These findings have been mirrored in clinical cases of
depression, with evidence from postmortem tissue reporting reductions in NMDA
receptors subunit NR1, NR2A, NR2B, and PSD-95 protein levels in the PFC (Beneyto and
Meador-Woodruff, 2008; Feyissa et al., 2009). Whilst NMDA receptor hypofunction
seems paradoxical considering the potent antidepressant Ketamine is a NMDA receptor
antagonist (Zanos and Gould, 2018), it should be noted that ketamine produces
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antidepressant properties at low doses where it partially inhibits NMDA receptors but
enhances AMPA receptor signaling. Indeed, the antidepressant properties of Ketamine
are thought to be mediated by increased AMPA receptor mediated excitatory synaptic
function, rather than NMDA receptor antagonism (Zanos et al., 2016; Zorumski et al.,
2015). Irrespective, these findings implicate alterations in glutamatergic signaling in
clinical cases of MDD and the WKY strain.

To understand the aetiology of the glutamatergic dysfunction present in the WKY strain,
in chapter 4 we investigated the same glutamatergic profile in the same brain regions in
male WKY neonates (PN14). Investigating the neurobiological profile of the WKY strain
at early time periods (and other models of depression) is critical to decipher the
developmental sequelae of depression, especially considering the limited number of
clinical studies focusing on this point. Furthermore, by investigating earlier time periods
we might gain insight into potential windows of interventional opportunity for the
treatment of the disorder, which could help prevent onset. Interestingly we found that
the WKY strain exhibited alterations in NMDA and mGluR5 receptor signaling in the PFC,
and to a lesser extent in the vHPC compared to male Sprague-Dawley controls.
Specifically, male WKY rats showed increases in NMDA receptor subunit NR2B and
dimeric mGluR5, but reductions in monomeric mGluR5 and associated scaffolding
protein Homer1b/c and PSD-95 in the PFC at PN14 (Table 6.3). Given that older
adolescent WKY offspring exhibited no changes in dimeric mGluR5, but reductions in
NMDA receptor subunits, NR1, NR2A and NR2B, as well as the scaffolding protein PSD95; these findings suggest that perturbations in mGluR5 present at PN14 may be
transient, but changes in the NMDA receptor persist and are enhanced in adolescence.
Given that the NMDA and mGluR5 receptors play key role in neurodevelopmental
process (Catania et al., 2007; Gambrill and Barria, 2011), it is plausible to suggest that
alterations in early glutamatergic signalling may underpin neurobiological and
behavioural alterations in the strain at adolescence, and later life.

Finally, in chapter 5 we investigated the neurotrophic profile and a marker of neuronal
maturation in the WKY strain of female adolescent rats. Despite the high prevalence of
depression in females (almost 2x compared to males (Albert, 2015)), there is very limited
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investigating into the neurobiology of preclinical models of depression in females. In this
thesis, we have shown for the first time that female adolescent WKY rats display deficits
in relative expression of p75, and NeuN+ cell counts in the PFC, CA1 and DG regions of
the HPC compared to respective Sprague-Dawley controls. Furthermore, deficits in
NeuN+ cell counts all correlated with immobility in the FST and time spent in the closed
arms of the EPM. Taken with previous findings, this data shows that WKY rats exhibit
reduced hippocampal and cortical neuronal bodies and synaptic connections (evident
through deficits in PSD-95) which may underpin their behavioural phenotype. Other
studies investigating the neurobiology of the WKY strain have reported reduced
hippocampal and cortical volumes, reducing resting cortical blood perfusion and
impaired hippocampal synaptic plasticity and LTP (Cominski et al., 2014; Gormley et al.,
2016). Moreover, another reported reductions in BrdU+/DCX+ rations in the DG, a
region characterized by high rates of neurogenesis (Kin et al., 2017). Interestingly,
reduced cortical and hippocampal volume, deficits in neurogenesis, widespread
reductions in gray matter volume and cortical thickness as well as neuronal atrophy and
loss have all been documented in clinical cases of MDD (Bremner et al., 2000; Duman
and Li, 2012; Grieve et al., 2013). These findings suggest that the WKY strain displays
strikingly similar neuronal and cortical characteristics to those with MDD and provide
further support for the use of the strain as an endogenous model of depression.

Overall, findings presented in this thesis pertaining to the neurobiology underpinning
the WKY strain suggest that deficits in glutamatergic, neurotrophic and neurogenic
markers may underpin the strains depressive-like phenotype. Furthermore, given the
marked similarities between the phenotype of the WKY strain and clinical cases of MDD,
we have provided further evidence in support for use of the strain as a preclinical model
of endogenous depression.
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6.7 Limitations:
There are several limitations of this thesis that must be considered, including those in
relation to behavioural measures, drug treatment design and depression model used.

Behaviour
Firstly, symptoms of neuropsychiatric and neurodevelopmental disorders are complex
and extend far beyond anxiety- and depressive-like phenotypes, to include
abnormalities in cognition, social and emotional behaviour (American Psychiatric
Association, 2013), of which the present study did not assess. Furthermore, as discussed
in chapter 2, the findings of increased immobility in the forced swim test needs to be
taken with caution given the absence of additional behavioural tests assessing other
facets of depressive-like phenotypes (e.g. anhedonia in the sucrose preference test). It
has been argued that immobility in the forced swim test represents a behavioural
adaptation, i.e. a coping mechanism in the face of an aversive stressor, rather than
innate learned helplessness or behavioural despair (Molendijk and de Kloet, 2015).
Moreover, we observed a decrease in locomotor activity in offspring during the OFT and
EPM, as the result of perinatal fluoxetine exposure, suggesting that the increased
immobility in the forced swim test could represent a ‘false-positive’ (Slattery and Cryan,
2012). Despite this, other studies investigating the effects of perinatal SSRI exposure on
offspring behaviour have observed increased immobility in the forced swim test in the
presence and absence of changes in locomotor activity in the open field test and
elevated plus maze (Millard et al., 2019, 2017). This suggests that perinatal fluoxetine
exposure induces changes in immobility in the forced swim test, independent of changes
in locomotor activity.

Furthermore, we observed marked reductions in the scaffolding protein, PSD-95, as a
result of perinatal FLX exposure. Abnormalities in PSD-95 have been heavily implicated
in cognitive related behaviours and neurodegeneration (Coley et al., 2019; Leuba et al.,
2008), however cognition was not measured in this thesis. Regardless, future studies
investigating the effects of perinatal fluoxetine exposure on offspring behaviours related
to neurodevelopmental and neuropsychiatric disorders should implement a wider test
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battery.

Another observation that must be highlighted is the fact that the WKY strain tended to
exhibit a potential ‘floor and ceiling effect’, particularly in females, which could have
influenced the interpretation of these results. For example, at baseline the WKY strain
exhibited a ‘ceiling’ level of time spent in the closed arms of the elevated plus maze, of
which further increases caused by perinatal fluoxetine treatment would not have been
detected. Therefore, interpretation needs to be taken with caution and further studies
are required to confirm the influence that WKY strain has on behavioural responses to
SSRIs.

Another limitation to the present thesis is the fact that the effects of fluoxetine
treatment on dam behaviour were not assessed. Previous studies have shown that
maternal behaviour and care are factors known to influence offspring development and
behaviour (Ahmadiyeh et al., 2004; Curley and Champagne, 2016), therefore this should
be considered for future investigations. Despite this limitation however, previous works
investigating the effects of perinatal fluoxetine exposure in models of maternal stress
on offspring, have shown that treatment with the same dose of fluoxetine as used in the
present study does not influence maternal care behaviours but does have an anxiolytic
effect on dams (Gemmel et al., 2018; Pawluski et al., 2012). Furthermore, there is no
evidence suggesting that dam fluoxetine treatment further exacerbates maternal
behaviours. Despite this fact, we cannot rule out that maternal dam behaviours did not
influence the effects of perinatal FLX treatment on offspring measured neurobiology and
behaviour.

Tissue, Timing and Resources
Finally, this thesis investigated the glutamatergic profile of male, but not female
offspring at PN14, and similarly, the neurotrophic profile of female, but not male
offspring at PN42 (chapters 5 and 4 respectively). Resources, timing and tissue
constraints restricted the ability to include both sexes in all studies in this thesis. To gain
a deeper understanding of the sex-specific effects of perinatal FLX exposure on offspring
glutamate and neurotrophic systems, both sexes should be included in all respective
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investigations. Therefore, future investigations should investigate the effects of
perinatal FLX exposure on glutamatergic markers in females at PN14, and neurotrophic
profile of males at PN42.

Perinatal Fluoxetine model
To model perinatal fluoxetine exposure, SD and WKY dams were dosed with fluoxetine
hydrochloride (10mg/kg/day dissolved in tap water) or vehicle (tap water), for the full
gestational term (beginning at the end of the mating period) and a further two weeks of
the lactation period (i.e. 5 weeks in total), with the last day of treatment corresponding
to postnatal day 14 of the offspring. Fluoxetine was administered in light resistant
gravity fed bottles to limit drug degradation via photolysis (Lam et al., 2005). Dam water
consumption and body weight was recorded daily throughout the treatment period to
ensure correct dosage. Bottles were replaced with fresh Fluoxetine or vehicle solution
daily to minimise drug degradation whilst allowing dosage to be adjusted based on
dams’ body weight and water intake. This dose (10mg/kg/day) and method was chosen
based on its’ common implementation in current literature (Millard et al., 2017).
Furthermore, evidence from clinical neuroimaging studies have shown that clinically
efficacious doses of SSRIs results in 80% or greater SERT occupancy (Meyer et al., 2004).
In rodents this has been achieved with dosages ranging between 8 – 12mg/kg/day
(Capello et al., 2011), which have been shown to produce antidepressant effects
(Dulawa et al., 2004). To minimize unwarranted stress to the animals and to model a
more clinically relevant scenario, fluoxetine was administered orally. It has previously
been shown that 10mg/kg Fluoxetine administration via oral pathways resulted in high
bioavailability and metabolite-to-parent drug ratios twice that than injection, suggesting
that absence of first pass liver metabolism in injection methods results in decreased
active metabolite concentrations (Caccia et al., 1990). However, given that the present
study did not measure dam or offspring levels of fluoxetine or norfluoxetine, we cannot
associate blood/serum levels of the parent drug and metabolites with any measured
offspring parameters. Although this dose and timeline of administration is generally
well accepted in the current literature (Millard et al., 2017), a dose response curve,
varied timeline of administration and accurate blood measures of drug metabolites,
could reveal greater insight into the effects of perinatal SSRI dosages on offspring
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behaviour and neurodevelopment. Accordingly, future investigations could look at ways
to minimise risk associated with perinatal fluoxetine use, by tapering dosages or
administering fluoxetine during less ‘vulnerable’ time periods, whilst still ensuring
optimal antidepressant effects in dams.

The WKY model of depression
Like all preclinical models of MDD, the WKY model of depression is faced with several
limitations that need to be taken into consideration. Firstly, there is evidence suggesting
that the WKY strain displays greater phenotypic and genotypic variability compared to
other inbred strains (Will et al., 2003; Zhang-James et al., 2013). Studies have shown
that WKY strains obtained from different vendors display variability in depressive- and
stress-elicited behaviours (Will et al., 2003), with at least one WKY strain (German
WKY/NCrl) showing large genetic variation compared to others (Zhang-James et al.,
2013). These studies highlight the potential for limitations when the source/origin of the
WKY strain is not considered. If accounted for however, the strains genetic variability
may be of benefit, for example a study has shown that the heterogeneity within the
breed results in substrains with varied responsiveness to antidepressants and
behavioural despair (Will et al., 2003). Accordingly, by investigating this genetic
variability it may provide a novel means for dissecting the neurobiology underpinning
antidepressant response in the clinic.

Secondly, the WKY strain was selectively bred from the same parental line of Wistars as
the SHR, and accordingly, is used extensively as the SHR control strain. The SHR rat
develops hypertension at 12-14 weeks of age (McGuire and Twietmeyer, 1985) and
although the WKY strain does not show any specific hypertensive phenotypes, recent
studies have shown the presence of other cardiac abnormalities. Specifically, the WKY
have shown to exhibit increased myocardial fibrosis compared to Wistar rats,
demonstrating blood pressure independent cardiac hypertrophy in the otherwise
normotensive WKY strain (Aiello et al., 2004). Others have reported larger left
ventricular mass in the WKY compared to the Fischer-344 strain (Sebkhi et al., 1999),
and decreased resting blood perfusion in a number of brain regions (i.e. prelimbic
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cortical and striatal regions) compared to the Wistar strain (Gormley et al., 2016).
Collectively these studies suggest that the WKY strain also displays cardiovascular
related abnormalities independent of hypertension. In the clinic several studies have
reported decreased resting blood perfusion in the cortex of depressed individuals (Ho
et al., 2013; Järnum et al., 2011; Lui et al., 2009) suggesting that cortical hypoperfusion
may contribute to a depressive phenotype. Furthermore, there is a well-known
association between MDD, stress and cardiovascular disease (CVD) (Dhar and Barton,
2016) which may validate the use of the WKY strain as a model of MDD with comorbid
CVD. Indeed, it would be of interest for future studies to investigate the aetiology of the
depressive-like phenotype in the WKY strain in the context of cardiovascular
abnormalities and stress.

Finally, MDD is multifaceted and complex and it must be emphasised that there is no
one preclinical model of MDD that encompasses all aetiological, pathophysiological and
phenotypically aspects of the disorder. Indeed, pursuing such a model would be futile
given how far we are from understanding the exact mechanisms of MDD. Instead, a wide
range of preclinical models are required to investigate the disorder thoroughly and
although the WKY strain provides a tool for modelling endogenous MDD, the strain is
but one of many mediums that should be used in future studies.

6.8 Future directions
In addition to addressing some of the limitations discussed above, there are several
recommendations that could be suggested for future investigations to help provide
greater insight into the effects of perinatal Fluoxetine exposure on offspring.

i)

Whilst this study focused on neurobiological outcomes in the prefrontal
cortex and hippocampus, others have found that perinatal fluoxetine
exposure causes alterations in several other brain regions of exposed
offspring, including the thalamus, somatosensory cortex and amygdala
(Millard et al., 2017). Indeed in the clinic perinatal SSRI exposure has been
associated with an increased risk for neurodevelopmental disorders which
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are characterized by structural changes to these functional areas (Cascio,
2010; Nair et al., 2013; Schumann et al., 2011). Therefore, future
investigations assessing the effects of perinatal FLX exposure on offspring in
relevant models of maternal depression, into other areas of the brain will
help elucidate the full effects of exposure and maternal depressive
phenotypes on offspring neurodevelopment.

ii)

Findings from this thesis and other studies suggest that perinatal fluoxetine
exposure can influence offspring behaviour and neurobiology in a sex specific
manner. Future investigations should consider ways in which these effects
on offspring can be minimized whilst still ensuring effective treatment of
maternal depression, such as the use of alternative or adjunct maternal
antidepressant treatment. For example studies have shown that maternal
omega fatty acid supplementation can improve dam cognition and clinical
neurodevelopmental outcomes in offspring (Dunstan et al., 2008; Kavraal et
al., 2012). It is also well-established that the anti-depressive effects of
fluoxetine are improved by exposure to environmental enrichment, and
conversely worsened when treated in a stressful condition (Alboni et al.,
2017). Thus, future investigations could look at ways to minimize the
influence of perinatal fluoxetine exposure on offspring by tapering maternal
doses of fluoxetine and concomitantly exposing dams to environmental
enrichment to ensure effective antidepressant treatment. Furthermore, a
recent study by Gobinath et al., (2018) found that maternal exercise
increased hippocampal neurogenesis in adult offspring, but this was
prevented by concurrent maternal postpartum fluoxetine treatment. Future
studies could look at ways in which maternal exercise and different timelines
of fluoxetine exposure could influence offspring development whilst still
effectively treating the maternal psychopathology.

iii)

Clinical studies investigating the effects of developmental SSRI exposure on
offspring are conflicting and are confounded by the underlying
psychopathology. Moreover, human studies often omit or report difficulties
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in reporting severity of maternal mood disorders (Millard et al., 2017).
Despite this they are invaluable to clarify risk associated with maternal SSRI
exposure. Furthermore, they provide a method for which the clinical risk
associated with SSRI exposure can be further teased out to identify risk
factors that represent the greatest influence. For example, preclinical studies
have shown that offspring sex, and maternal factors such as exposure to
stress, or exercise can influence the effects of SSRI exposure on offspring.
Future clinical studies could further stratify findings by offspring sex and
additional maternal factors to confirm findings from preclinical work.
iv)

Preliminary work from this thesis has shown that perinatal fluoxetine
exposure can influence early neurodevelopmental processes in a dosedependent manner. More specifically, human derived cortical neurospheres
demonstrated reduced growth and increased apoptotic markers in response
to daily fluoxetine treatment. Whilst this is not the first to assess the effects
of fluoxetine using neurospheres, current studies implementing similar
models are limited. Indeed, the use of in vitro stem cells and human derived
neurospheres provide a medium through which antidepressant mechanisms
in early developmental processes can be investigated and screened.
Furthermore, to determine areas of vulnerability in the brain, future studies
could look at ways in which origin of neurospheres (i.e. cortical or
hippocampal derived), are differentially affected by fluoxetine exposure.

v)

Findings from this thesis suggest that perinatal fluoxetine exposure can
influence the number of NeuN+ cells in the prefrontal cortex and
hippocampus. It must be acknowledged that NeuN+ stains indiscriminately,
therefore we cannot be certain whether deficits in NeUN+ cells caused by
perinatal fluoxetine exposure belong to a specific subpopulation, such as
glutamatergic or GABAergic neurons. To gain a deeper understanding as to
the effects of perinatal fluoxetine exposure on offspring neurodevelopment,
future studies could consider immunohistochemistry/immunofluorescence
techniques such as ‘double-staining’ NeuN+ with specific markers of
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neuronal subtypes including VGLUT (glutamate) and GAD67 (GABA). Using
such techniques will help decipher whether specific subpopulations are most
vulnerable to the effects of exposure.
6.9 Conclusions
In conclusion, this thesis has detailed novel insights in the effects of perinatal Fluoxetine
exposure using a relevant model of maternal depressive disorder. This thesis reveals for
the first time that perinatal Fluoxetine exposure produces sex and strain specific effects
on offspring adolescent behaviour, underlined by dysfunction in glutamatergic signaling
and neuronal mapping. Furthermore, we have shown that perinatal FLX exposure
produces mild alterations in glutamatergic signaling as early as PN14, which is enhanced
later at adolescence. In addition, this thesis has detailed the glutamatergic profile of the
Wistar-Kyoto strain, which in the context of increasing interest in glutamatergic
therapeutics for major depressive disorder, has significant implications for future
investigations. Given that dysfunction of the glutamatergic system and associated
proteins has been linked to several neurodevelopmental disorders including autism,
ADHD and mood disorders, findings from this thesis emphasize the need for more
investigation. Furthermore, to date the majority of preclinical studies investigating the
effects of perinatal SSRI treatment have focused on outcomes in otherwise healthy
offspring. This thesis has highlighted that maternal depressive-like phenotypes such as
that modelled using an endogenous model of depression (WKY strain), can influence the
effects of perinatal FLX exposure on offspring. Accordingly, future investigations should
implement relevant models of maternal depression that closely parallel the clinic.
Ultimately, the incidence of depression is on the rise, and untreated maternal
depression can have severe consequences on the health of the mother and child.
Antidepressants play a critical role in reducing the harm of untreated maternal
depression; however, we are just beginning to understand how exposure to
antidepressants during neurodevelopment can alter behaviour and brain biology of
offspring in later life. Future studies investigating ways to minimize the effects of
maternal SSRI treatment on offspring will be critical to ensuring healthy pregnancies and
offspring outcomes.
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